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Introduction: Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized 
by inflammatory synovitis. The histopathological features include synovial hyperplasia, an 
inflammatory cell infiltration, angiogenesis and an inflammatory exudate into the synovial 
joint with progression to bone and joint destruction. While the exact aetiology of RA is 
unknown, a number of inflammatory cells and mediators have been implicated in the 
pathogenesis. Kinins are vasoactive peptides that have the capacity to induce the cardinal 
features of inflammation and considerable evidence exists for a role for the kallikrein-kinin 
cascade in inflammatory arthritis. The proinflarnmatory cytokines are also important 
mediators in rheumatoid arthritis and there is evidence for a functional relationship 
between the kallikrein-kinin and cytokine cascades in rheumatoid arthritis. 
Methods: Following approval from the Ethics Committee of the University of Natal, 
synovial tissue samples were obtained at arthroscopy from patients with RA and at autopsy 
(for controls). The tissue samples were processed for light microscopy and immunostained 
by the immunoperoxidase method to detect tissue kallikrein and the kinin B 1 and B2 
receptors. The intensity of the immunostaining was quantified by image analysis. 
Blood and synovial fluid samples were obtained from patients with RA and blood from age 
and sex matched healthy volunteers. The RA patients were assessed clinically to 
determine the degree of disease activity and the presence or concomitant diseases. Disease 
activity was determined by the duration of morning stiffuess, the twenty eight tender and 
swollen joint counts, pain on a visual analogue scale, patient's and physician's global 
assessment of disease activity (Likert scale), a local activity index, the modified Health 
Assessment Questionnaire (HAQ), disease activity score (DAS) and the erythrocyte 
sedimentation rate (ESR) and C reactive protein (CRP). 
XXl 
In the synovial fluid (SF) samples, the functional activity of tissue kallikrein (TK) was 
demonstrated using an amidolytic assay and the total amount of TK was measured in a 
sandwich enzyme linked immunosorbent assay (ELISA). The Pearson's correlation co­
efficient was used to correlate the TK levels with measures of disease activity. Further, 
basal and generated kinins were measured in the SF by competitive ELISA, and the levels 
correlated with measures of disease activity. 
In the cytokine study, interleukin lP (IL IP) and tumour necrosis factor p (TNFP) were 
measured in the synovial fluid samples by ELISA, and the relationship between the 
cytokine levels and disease activity as well as TK, basal and generated kinins determined. 
Neutrophils were isolated from the blood and synovial fluid samples from the rheumatoid 
arthritis patients and from the blood samples from healthy volunteers. The circulating and 
synovial fluid neutrophils were immunostained to detect tissue kallkrein, the kinin moiety 
in the kininogen molecule and kinin BI and B2 receptors, and the immunofluorescence 
visualized by confocal microscopy. The images were digitally analysed using the Analysis 
2.1 Pro system. The Kruskal Wallis and one-way ANOVA tests were used to compare the 
mean intensity of imrnunostaining in the control neutrophils with that present on the 
circulating and SF neutrophils harvested from RA patients. The intensity of labeling for 
these antigens was correlated with measures of disease activity. 
Results: 
1. Synovial tissue samples: Labeling for tissue kallikrein was observed in the 
synovial lining and endothelial cells in control and rheumatoid tissue. There was a 
significant increase in the intensity of TK labeling in the endothelial cells of the 
rheumatoid tissue (p < 0.05). The kinin Bl and B2 receptor were visualized in the synovial 
lining cells, endothelial cells and the subintimal fibroblasts and macrophages in the control 
XXll 
and rheumatoid synovial samples, with a significant increase in B 1 receptor labeling in the 
synovial lining cells in rhewnatoid synovial tissue (p < 0.01). 
2. Tissue kallikrein activity and the total TK concentration was measured in the
synovial fluid obtained from 20 patients with RA. There was no direct correlation between 
the between the enzymic and antigenic tissue kallikrein. There was a significant negative 
correlation between the enzymic TK and the twenty eight swollen joint count (r = -0.464; p 
<0.05). 
3. There was a significant negative correlation between the basal kinin and generated
kinin levels (r= -0.454; p < 0.05). In addition, there was a negative correlation between the 
basal kinin levels and the CRP (r = -0.537; p < 0.05) and the disease activity score 
(r = -0.458; p < 0.05). In contrast, there was a positive correlation between the generated 
kinin levels and the twenty-eight tender and swollen joint counts (r = 0.536; p < 0.05 and r 
= 0.509; p < 0.05 respectively), the ESR (r = 0.598; p < 0.01), CRP (r = 0.725; p < 0.01) 
and the disease activity score (r = 0.676; p < 0.01). 
There was a significant correlation between the SF levels of IL IP and pain (r = 0.462; p < 
0.05), physician's global assessment of disease activity (r = 0.549; p < 0.05), 28 tender 
joint count (r = 0.4 72; p < 0.05) and CRP (r = 0.530; p < 0.05). Although there appeared to 
be a correlation between the IL 1 p and disease activity score, this was not significant 
(r = 0.412; p = 0.07). In addition, the levels of synovial fluid lNF a correlated with the 28 
tender joint (r = 0.458; p < 0.05) count and CRP (r = 0.653; p < 0.01). 
4. There appeared to be a trend towards a negative correlation between the SF
amidase TK levels and IL 1 p, however this was not significant. While there was no direct 
relationship between the SF levels of IL 1 P and the generated kinins, there was a positive 
correlation between low to moderate levels of IL 1 p and the generated kinins (r = 0.51, 
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p < 0.05). In contrast, there was a negative correlation with higher levels of IL Ip 
(r = -0.5, p < 0.05). 
5. Immunoreactive TK, kinin moiety and the Bl and B2 receptors were visualized on
the circulating neutrophils from the healthy volunteers and the circulating and SF 
neutrophils from the RA patients. There was no statistically significant difference in the 
mean intensity of TK labeling in the circulating neutrophils from healthy volunteers (n=8) 
and the circulating and synovial fluid neutrophils of the RA patients n=8). However, when 
the intensity of labeling of the SF neutrophils (n=80) from the RA patients was compared to 
the circulating neutrophils (n=80) of healthy volunteers, there was a significant loss of TK 
labeling in the SF neutrophils of the RA patients (1-Way ANOVA, p < 0.01). In the RA 
patients, there was a loss of the kinin moiety from both the SF and circulating neutrophils 
compared to controls (Kruskal-Wallis: p < 0.05 and < 0.01 respectively). Although there 
was a clear increase in the intensity of labeling of the kinin BI receptor on the SF 
neutrophils from RA patients (n=8), when compared to the circulating neutrophils from 
healthy volunteers (n=8), the mean values did not reach significance (Kruskal Wallis; p > 
0.05). However, a significant increase in Bl receptor labeling was observed on both the 
circulating and SF neutrophils of the RA patients (n=80) when compared to circulating 
neutrophils of the healthy volunteers (n=80) (1 Way ANOVA, p < 0.01 and < 0.05 
respectively). In addition, there was a positive correlation between the irnmunoreactivity 
for the BI kinin receptor on the circulating neutrophils from the RA patients and the local 
activity index (r = 0.783; p < 0.05). Although there was a clear increase of the kinin B2 
receptor on the circulating and SF neutrophils from the RA patients compared to circulating 
neutrophils from healthy volunteers, this was only significant for the circulating neutrophils 
from the RA patients (Kruskal-Wallis, p = 0.05). There was no correlation between the 
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intensity of labeling of TK, the kinin moiety and the B2 receptor and measures of disease 
activity. 
Discussion and conclusions 
1. This study provides the first evidence for the localization of TK and the kinin
receptors in control and rheumatoid synovial tissue using antibodies specific for each 
protein and standard immunolabelling techniques. Synovial fibroblasts, macrophages and 
endothelial cells through the release of enzymes and cytokines have the ability to mediate 
the inflammatory changes and cartilage and bone destruction in RA. The presence of TK 
and the kinin receptors in these cells therefore provides evidence for a pathogenetic role for 
the kallikrein-kinin cascade in RA. 
2. In addition, in RA there is an exudation of fluid into the joint space. Tissue
kallikrein has been previously reported in the synovial fluid obtained from RA patients, 
however the correlation of TK levels and disease activity has not been previously studied. 
The negative correlation between enzymic TK and the twenty-eight swollen joint count, an 
indicator of disease activity suggests that there is a consumption of TK in inflammation, 
presumably due to increased kininogenase activity. Similarly, the kinin generating capacity 
of synovial fluid obtained from RA patients has been previously reported, however, this is 
the first study demonstrating a link between kinin generating capacity and validated 
markers of disease activity. The kinin generating capacity is a complex and dynamic 
cascade involving the bioregulation of all the components of the kallikrein-kinin system and 
is therefore more likely to accurately define the role of kinins in inflammatory arthritis than 
are individual components of the kallikrein-kinin cascade. Measurement of tissue kallikrein 
and basal kinins is affected by the presence of natural inhibitors and their short half-life in 
biological fluids. In addition to the synovial fluid study a decrease in the urinary TK 
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activity and an increase in urine kinin generated kinins was demonstrated, suggesting that 
there is a systemic activation of the kallikrein kinin cascade in RA. 
3. Although there is evidence for an interaction between the kallikrein-kinin and
cytokine cascades in inflammation, in this study a direct correlation between the levels of 
interleukin 1 J3 and tumour necrosis factor J3 in the synovial fluid and TK and generated 
kinin levels was not found. This may be due to the wide variations in the levels of 
cytokines, the presence of inhibitors and anti-inflammatory cytokines, or a complex and 
dynamic relationship between the two cascades. However, the correlation of both 
generated kinins and interleukin l J3 and tumour necrosis factor J3 with disease activity 
provides circumstantial evidence for a synergistic role for these mediators in inflammatory 
arthritis. 
4. In the neutrophil study, loss of immunoreactive tissue kallkrein and kinin moiety
from the neutrophils obtained from RA patients was demonstrated. This finding supports 
the hypothesis that kinins are released from the neutrophils by the enzymatic action of 
tissue kallkrein and suggests that the kallkrein-kinin system is activated both locally and 
systemically in patients with RA. Further, there was upregulation of the both the kinin B 1 
and B2 receptors on the neutrophils from the RA patients. While the B2 receptor is 
thought mediate most of the actions of kinins, the correlation of the intensity of B 1 
receptors and the local activity index implies that the B 1 receptor may be important in 
inflammation. 
5. These findings provide convincing evidence for the role of the kallikrein-kinin
cascade in the pathogenesis of inflammation in RA. Further development of kinin receptor 
antagonists may provide a novel therapeutic modality. 
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1.1 THE SYNOVIAL JOINT
Diarthrodial or synovial joints are lined by a soft connective tissue lining or synovium 
composed of a matrix of numerous microfibrils (Edwards, 1987), and abundant 
proteoglycan aggregates within which lie the synovial cells. Normal or healthy synovium 
(Fig. I. I) consists of a superficial cellular layer called the lining layer or intima, 
approximately 20 mm and a deeper subintimal layer of compact tissue carrying a rich 
vascular plexus (Wilkinson and Edwards, 1989). The intimal cells are of two types; one 
resembling the macrophage (Type A) and the other fibroblast like (Type B) which 
produces hyaluronan (Barland et al. 1962). Within the joint spaces is a small amount of 
synovial fluid that is rich in hyaluronan. The contact surfaces of adjoining bone are 
covered by hyaline cartilage, which is mainly comprised of water and proteoglycan 
aggregates restrained in an arching framework of type 11 collagen fibres. The 
proteoglycan is made up of chrondroitin sulfphate and keratin sulphates. 
In an inflamed joint, early changes include endothelial cell damage, synovial oedema, 
fibrin deposition, polymorphonuclear (PMN) leucocyte invasion and mild lining cell 
hyperplasia (Schumacher and J(jtridou, 1972). This is followed by further synovial 
hyperplasia, infiltration of the sublining layer with mononuclear cells, T and B 
lymphocytes, macrophages and plasma cells, overgrowth of a fibrovascular granulation 
tissue known as the pannus and striking proliferation of blood vessels or angiogenesis 
(Fig.1.2). The markedly hyperplastic pannus becomes locally invasive at the synovial 
interface with cartilage and bone with subsequent cartilage and bone destruction. In 
addition, there is an increase in synovial fluid due to exudation and increased vascular 
permeability. The synovial fluid is abundant with neutrophils ranging from <l 000 to > I 00 
000/mm3 • These pathological changes result from the activation and complex interaction 
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of a number of different cells and inflammatory mediators. The aetiology, degree of 
synovitis and joint damage varies in the different arthritides. 
Figure 1.1 Normal synovium 
Photomicrograph of normal synovial tissue showing a 
single layer of synovial lining cells (S). 
Figure 1.2 Inflamed synovium 
Photomicrograph of synovial tissue from a patient with 
rheumatoid arthritis showing hypertrophy of the synovial 
layer (S) and a dense inflammatory cell infiltrate in the 
subintimal layer (I). 
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1.2 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is an immune-mediated systemic disease characterized by 
chronic widespread synovitis resulting in bone and joint damage. It affects about 1 % of 
the world's population and is more common in women (Lawrence, 1961). Initially 
considered benign, RA is now recognized as a severe progressive disease with increased 
morbidity and mortality (Pincus and Callahan, 1989). 
1.2.1 Clinical presentation 
The onset of RA is generally insidious with systemic features such as morning stiffness, 
fatigue and pain followed by joint inflammation. The typical presentation is that of a 
symmetrical polyarthritis. The most commonly involved joints include the wrists, 
metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints. However, the 
large joints are also affected. In active disease, the joints are tender and swollen joints with 
or without effusions. The synovial fluid consists of a large number of neutrophils. 
Persistent inflammation leads to progressive damage of joints with the development of 
deformities and bone and cartilage destruction. In addition, a number of extra-articular 
features may occur. These include nodules, vasculitis, keratoconjunctivitis sicca (KKS), 
Sjogren's syndrome and serositis. Diagnostic criteria have been established by the 
American Rheumatism Association (ARA) (Arnett et al. 1988) (Table 1.1 ). 
The prognosis of RA is determined by the activity and severity of the disease (Wolfe, 
1997). Disease activity refers to the extent of current inflammation and can be measured 
by clinical and laboratory criteria. Clinical measures include duration of morning stiffness, 
extent of joint tenderness and swelling, intensity of pain measured on a visual analogue 
scale, global measures of disease activity using either a categorical or visual analogue scale 
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and functional assessment. Severity of the disease is usually measured by outcome 
measures such as death, disability and radiological progression. 
Table 1.1 The 1987 revised criteria for the classification of rheumatoid arthritis* 
Criterion 
1. Morning sti:ffuess
2. Arthritis of 3 or more joints
3. Arthritis of hand joints
4. Symmetric arthritis
5. Rheumatoid nodules
6. Serum rheumatoid factor
7. Radiographic changes
Definition 
Morning sti:ffuess in and around the joints, lasting at 
least 1 hour before maximal improvement 
At least 3 joint areas simultaneously have had soft 
tissue swelling or fluid (not bony overgrowth alone) 
observed by a physician. The 14 possible areas are 
right or left PIP, MCP, wrist, elbow knee, ankle, and 
MTP joints 
At least 1 area swollen (as defined above) in a wrist, 
MCP, or PIP joints 
Simultaneous involvement of the same joint areas (as 
defined in (2) on both sides of the body (bilateral 
involvement of PIPs, MCPs, or MTPs is acceptable 
without absolute symmetry) 
Subcutaneous nodules, over bony prominences, or 
extensor surfaces, or m juxtaarticular regions, 
observed by a physician 
Demonstration of abnormal amounts of serum 
rheumatoid factor by any method for which the result 
has been positive in <5% of normal control subjects 
Radiographic changes typical of rheumatoid arthritis 
on postero-anterior hand and wrist radiographs, 
which must include erosions or unequivocal bony 
decalci.fication localized in or most marked adjacent 
to the involved joints ( osteoarthritis changes alone do 
not qualifv) 
*For classification purposes, a patient shall be said to have rheumatoid arthritis if he/she
has satisfied at least 4 of these 7 criteria. Criteria I through 4 must have been present for at
least 6 weeks.
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1.2.2 Diagnostic features 
Rheumatoid factors (RF) are antibodies directed against the Fe fragment of 
immunoglobulin G (IgG). While not specific for the disease, RF is present in 75% of 
patients with RA, and a positive RF has been shown to predict prognosis and the later 
development of radiological damage (Richardson and Emery, 1996). 
Acute phase response 
The proinflammatory cytokines, interleukin I, 6 (IL-I, IL-6) and tumor necrosis factor 
(TNF), stimulate the hepatic synthesis of acute phase proteins, namely, C-reactive protein 
(CRP), fibrinogen, haptoglobin and serum amyloid A (SAA). Measurement of the acute 
phase proteins can be used to quantify and monitor disease activity. The two most 
commonly used tests are the CRP and erythrocyte sedimentation rate (ESR). 
The CRP is generally accepted as the most accurate measure of the acute phase response. 
It does not vary with age and sex, and in healthy individuals, basal concentrations are very 
low. In response to active inflammation, there is a rapid and early rise up to l 000 fold. 
The ESR is an indirect measure of the acute phase response. It measures the rate of 
sedimentation of erythrocytes in a vertical tube over a standard period of l hour. The ESR 
is determined by the negative electrical charge on the erythrocyte surface, which prevents 
aggregation. Certain plasma proteins for example fibrinogen decrease the negative charge 
and therefore increase the sedimentation rate. The CRP and ESR are both surrogate 
markers for disease activity, and assist in the monitoring of therapy. Persistent acute phase 
response is associated with an increased rate ofradiological progression. 
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Radiology 
In the early stages of RA, soft tissue swelling may be the only radiological finding. 
However, persistent inflammation results in joint and cartilage damage. The ARA has 
designated 4 anatomical stages to describe the physical deterioration of the joints. In stage 
I, there is osteoporosis, but the joint line is intact. Stage II is characterized by slight 
diminution of the joint line and early subchondral erosions, while obvious cartilage and 
bone lesions are present in stage III and gross destruction in stage V. 
1.2.3 Pathogenesis 
The exact aetiology remains unknown however; it is believed that an unknown antigen 
triggers an exaggerated immune response in a genetically susceptible individual. The 
inflammatory process in RA is multifactorial and may result from a number of different 
mechanisms (Fig. 1.3): 
• antibody mediated complement activation and cytotoxic cellular injury.
• immune complex deposition with activation of the complement system and generation
of pro-inflammatory mediators
• T cell mediated either through direct cytotoxic or via the elaboration of cytokines.
1.2.3.1 Genetic factors 
A higher incidence of RA among famiJies of patients with RA (Spector, 1990), and a 
concordance frequency of 30% in monozygotic twins compared to 5% in dizygotic twins 
(Lipsky, 1991) support a genetic predisposition for RA. A significant association between 
RA and the major histocompatibility complex (MHC), human leucoytes antigen (HLA), 
has been reported. A higher prevalence of HLA DR4 and ORI has been reported in 
various populations. The predisposition to the disease is conferred by a 'shared epitope' 
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present in the third hypervariable region of the DRB 1 gene. This epitope is encoded by 
DR4 and non-DR4 alleles, namely DRI, DRlO and DRw6. In addition, the epitope is also 
associated with more severe disease. However, only 20-30% of the cause of RA can be 
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1.2.3.2 Primary mediators of synovitis 
1.2.3.2.1 The kallikrein -kinin cascade 
The "contact system" consists of a group of four proteins which circulate in plasma in 
inactive forms, and are activated to provide a host defence system (Fig. 1.4). It consists of 
Hageman factor (HF) or coagulation factor Xl 1, prekallikrein, high molecular weight 
kininogen (H-kininogen) and coagulation factor Xl (plasma thromboplastin antecedent). 
Most of the plasma kallikrein exists as a proenzyme complexed to H-kininogen. The 
contact system is activated by contact with negatively charged surfaces found in a variety 
of substances, including monosodium urate and calcium dihydrate crystals, collagen, 
vascular basement membranes, glycosaminoglycans and immune complexes. Activation is 
initiated by the binding of HF to negatively charged surfaces with cleavage of HF to form 
activated HF (HFa). HFa then cleaves the prekallikrein-H-kininogen complex to release 
the active enzyme, plasma kallikrein, which has the ability to cleave bradykinin from H­
kininogen. Bradykinin is a potent mediator of inflammation because of its ability to cause 
vasodilatation, and increased vascular permeability. In addition, it produces pain, causes 
leucocyte margination in blood vessels and has the ability to release cytokines from 
monocytes. Closely related to the kinin system are the clotting and fibrinolytic systems. 
Plasmin, a peptide cleaved from fibrin, is capable of activating HF and cleaving the C3 
component of complement. In addition, plasmin possesses chemotactic activity and 







HF Factor XI 
t/i) 








Plasminogen --------�--.:.Plasmin _. 
Fibrinolysis 
Figure 1.4 Contact activation cascade 
(HF, hageman factor; Hfa, activated Hageman factor; PK, plasma 
kallikrein). 
Overview 
Kinins are potent vasoactive peptides that are thought to be responsible for the cardinal 
signs of inflammation as well as a number of other biological activities. The kinins, 
bradykinin and lys-bradykinin (kallidin) are cleaved from endogenous substrates cal ed 
kininogens by the serine proteases, kallikreins. Two types of kallikreins, tissue and 
plasma, have been identified. Tissue kaUikrein (TK) releases lys-bradykinin from L­
kininogen (low molecular weight kininogen or LK) and plasma kallikrein (PK) releases 
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Figure 1.5 Cleavage sites on kininogen molecule for the release of kin ins 
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Although the half-life of kin.ins in the circulation is considered to be very short (less than 
30 seconds), paracrine formation of kin.ins in extracellular spaces is known to have a 
longer half-life. Kinins once formed, are degraded by kininases. The actions of kinins are 
mediated via G-protein linked kin.in receptors, with subsequent activation of a series of 
second messengers by signal induction. A number of receptor antagonists have been 
developed for clinical use. 
Historical background 
In 1909, Abe lo us and Bardier, reported the presence of a hypo tensive substance in normal 
human urine (Abelous and Bardier, 1909) that they called urohypotensin. This was 
subsequently confirmed by Frey ( 1926). The compound was later isolated and 
demonstrated in blood, pancreas and the salivary glands (Frey et al. 1932, 1950). Since it 
was assumed that this substance originated from the pancreas (kallikreas in Greek), they 
named it kallikrein. Later, it was demonstrated that when urinary kallikrein was incubated 
with serum it enzymatically released a smooth muscle contracting substance from an 
inactive precursor (Werle et al. 1937). This substance was initially called substanz DK 
(darmkontrahierende substanz" or "gut-contracting substance"). This was later renamed 
kallidin and the inactive precursor, kallidinogen (Werle and Berek, 1948). At about the 
same time, Rocha e Silva et al (1949) demonstrated that the incubation of dog plasma with 
snake venom or trypsin produced a substance that was hypotensive and caused slow 
contraction of the guinea pig ileum. This substance was called bradykinin, because of the 
slowly initiated sustained contraction of the guinea-pig ileum. Since kallidin (lys­
bradykinin) and bradykinin were formed under the same conditions and had similar 
pharmacological actions, it was suspected that they were closely related and derived from 
the same substrate. This was later confirmed pharmacologically (Schachter, 1956), and by 
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chemical synthesis (Boissonnas et al. 1960). 
Kallikreins 
The biological effects of the kallikrein-kinin cascade are mediated via the vasoactive 
peptides, bradykinin and lys-bradykinin, liberated from the kininogen substrate by 
kininogenases. Although trypsin, uropepsin and plasmin have kininogenase activity, the 
two most potent endogenous kininogenases are plasma and tissue kallikrein. The 
kallikreins differ from each other with respect to their molecular weights, isoelectric 
points, substrate specificity, immunological profiles and the type of bioactive peptide 
released. Plasma kallikrein acts on HK to produce the nonapeptide bradykinin, and 
tissue/glandular kallikrein releases the decapeptide kallidin (Lys-bradykinin) from LK 
(Fielder, 1979). Kallidin is converted to bradykinin by the action of an arginine 
aminopeptidase (Guimaraes et al. 1973). 
Tissue Kallikrein 
Tissue kallikreins are a group of serine proteases encoded by a multigene family (KLK) in 
several species (Evans et al. 1987). The human KLK locus is situated on chromosome I 9q 
(Evans et al. 1988), and was thought to consist of three genes; KLKJ (tissue kallikrein), 
KLK2 (human glandular kallikrein), and KLK3 (prostate specific antigen), each comprising 
5 exons and 4 introns. The KLKJ gene is expressed predominantly in the salivary glands, 
pancreas and kidney (Mahabeer and Bhoola, 2000), while KLK2 and KLK3 are expressed 
almost exclusively in the prostate (Yousef et al. 1999a). However, recently new genes 
have been mapped in the region of the kallikrein gene family, suggesting that the kallikrein 
gene family consists of 13 genes (Yousef et al. 1999a). These include zyme, normal 
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epithelial cell-specific 1 gene (NESI), stratum corneum chymotryptic enzyme, neuropsin, 
trypsin-like serine protease (TLSP) and five new kallikrein genes (KLK-L l to KLK LS). 
KLK L 1 is expressed in prostate tissue, testis, mammary gland, adrenals, uterus, thyroid, 
and salivary glands and has been demonstrated in the breast carcinoma cell line BT-474 
(Yousef et al 1999b ). KLK-L2 is expressed mainly in breast, brain, and testis and to a 
lesser extent in many other tissues and is upregulated by estrogens and progestins in the 
breast cancer cell line BT-474 (Yousef and Diamandis, 1999). KLK-L4 is expressed in a 
variety of tissues including prostate, salivary gland, breast, and testis and appears to be 
down regulated in breast cancer tissues and breast cancer cell lines (Yousef et al. 2000a). 
Similarly, TLSP is expressed in many tissues including cerebellum, prostate, salivary 
glands, stomach, lung, thymus, small intestine, spleen, liver, and uterus and it's expression 
appears to be regulated by steroid hormones in the breast carcinoma cell line BT-474 
(Yousef et al. 2000b ). 
Tissue kallikreins are acidic glycoproteins with a molecular weight of 25-45 kDa and an 
isoelectric point of 3.5-4.4 (Pisano, 1975). Human urinary TK is synthesized bound to a 
17 amino acid signal peptide, which is cleaved to produce an inactive proenzyme, 
prokallikrein. The further removal of seven amino acids forms the active enzyme. The 
proteolytic enzymes, trypsin and thermolysin (a bacterial metalloproteinase) have been 
shown to activate the proenzyme in vitro (Takada et al. 1985), as has plasmin and plasma 
kallikrein (Yamada and Erdos, 1982). However, the endogenous pathway for the 
activation of the proenzyme is not known. 
Human urinary kallikrein is a single chain polypeptide of 238 amino acids with Ile at the 
amino terminal and Ser at the carboxy-terminal (Takahashi et al. 1988). The number and 
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position of glycosylation sites vary in the different species. Human urinary kallikrein has 
three asparagine linked glycosylation sites (Lu et al. 1989) and three oxygen glycosylation 
sites linked to two serine and one threonine residues (Kellerman et al. 1988). Tissue 
kallikrein immunoreactivity and/or enzyme activity has been demonstrated in numerous 
cells and biological tissues, including the saliva and salivary gland (Bhoola and Dorey, 
1971 ), colon (Chen el al. l 995), endometrium and myometrium of the uterus (Clements et
al. 1994), placenta and amniotic fluid (Malofiejew, 1973), cardiac tissue extracts (Nolly et
al. 1981 ), bronchial lavage from asthmatics (Christiansen el al. 1987) and nasal secretions 
from patients with allergic rhinitis (Baumgarten et al. 1989). Of interest is that increased 
levels of salivary gland TK have been reported in patients with malignant tumours away 
from the oral cavity (Jenzano et al. 1986), and restriction of sodium intake increased both 
salivary and urinary TK levels (Horwitz et al. l 982). Additionally, TK has been identified 
in synovial fluid from arthritic joints (Worthy et al. 1990; Bhoola and Dieppe, 199 l ;  
Rahman et al. 1994), and in the circulating and synovial fluid neutrophils (Figueroa et al. 
1989; Williams el al. 1997). 
The primary function of TK is the cleavage of the kininogen substrate to release the 
decapeptide lys-bradykinin (kallidin). Although LK is the preferred substrate for TK, the 
enzyme releases the kinin molecule from both HK and LK (Carretero and Scicli, 1980). 
Release of kallidin from the kininogen molecule requires the hydrolysis of the Met-Lys 
bond at the amino terminal and the Arg-Ser bond at the carboxy terminal. In addition to its 
kininogenase activity, TK has been implicated in other biological actions such as 
processing of growth and peptide hormones (Mason et al. 1983), pathogenesis of acute 
pancreatitis, the homeostatic control of blood pressure and neutrophil diapedesis (Figueroa 
et al. 1989). In addition, tissue kallikreins are considered to process in vitro a variety of 
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promolecules that may include matrix metalloproproteinases (Tschesche et al. 1989), 
procollagenase (Eeckhout and Vaes, 1977) and progelatinase (Menashi et al. 1994). The 
potential activation of these proproteinases by TK, suggests that TK may play a role in 
endothelial cell migration, leucocyte aggregation and tissue remodeling. 
Plasma kallikrein 
Plasma kallikrein is a serine protease synthesized in the zymogen form, plasma pre­
kallikrein (PPK) predominantly by the liver. However, PPK mRNA has also been detected 
in the kidneys, adrenal gland and placenta (Ciechanowicz et al. 1993) as well as the brain, 
heart, lung, trachea, endothelial cells, leukocytes and a variety of fibroblast and epithelial 
cell lines (Hermann et al. 1999). The PPK is encoded by a single gene of about 22 
kilobases in length (Beaubien et al. 1991) that is located on chromosome 4 q34--q35, and 
structurally similar to the Factor Xl (thromboplastin antecedent factor) gene (Asakai et al.
1987). It consists of 15 exons, the first 2 exons encoding 5'-untranslated regions and the 
signal peptide, the next eight exons encode the heavy chain and the last five exons the light 
chain and protease portion of the molecule. A 75% homology exists between the human, 
rat and mouse plasma kallik.reins. PPK is a single chain glycoprotein synthesized in the 
liver and is secreted into the circulation. In the plasma, it is present in two forms, 85 and 
88 k.Da, (Hojima et al. 1985; Veloso and Colman, 1991). The inactive PPK circulates as a 
heterodimer complex bound with Factor XI to its substrate HK through domain 6 of the 
kininogen molecule (MandJe et al. 1976). Following vascular damage, HK orientates PPK 
and factor XI towards Hageman Factor (HF). Following activation of HF through either 
contact with anionic surfaces, autocatalytically or the negative feedback action of plasma 
kallikrein, activated HF (HFa) converts the inactive PPK to active plasma kallikrein, which 
consists of a 32 k.Da light chain and 52 k.Da heavy chain linked by disulphide bonds 
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(Kaplan et al. 1989). Plasma kallikrein subsequently cleaves bradykinin from HK through 
hydrolysis of the Lys-Arg and Arg-Ser bonds to produce a nonapeptide with arginine at 
both the amino- and carboxy-terminals (Fig. 1.5). This process is amplified in the presence 
of HK, which acts as a cofactor (Griffin and Cochrane, 1976). Although LK is a poor 
substrate for PK, it will form BK in the presence of neutrophil elastase. It is believed that 
neutrophil elastase cleaves a fragment from LK, from which plasma kallikrein releases 
bradykinin (Sato and Nagasawa, 1988). 
Activated HF also converts factor XI (bound to HK) to activated factor XI (Xia) that 
initiates the coagulation cascade (Ratnoff et al. 1961 ). In addition, PK, factor X 1 a and 
HFa convert plasminogen to plasmin, and thereby promote fibrinolysis (Colman, 1969; 
Mandie and Kaplan, 1977). Plasma prekallikrein localizes on the outer surface of the cell 
membrane of non-fixed neutrophils, attached to domain 6 of HK (Henderson et al. I 994 ). 
Plasma kallikrein also participates in the inflammatory process since it is chemotactic for 
PMN leucocytes (Kaplan et al. 1972), and has the ability to cause aggregation of PMN 
leucocytes with a similar potency to that of the chemotactic peptide N-formyl-methionyl­
leucyl-phenyl-alanine (N-fMLP) (Schapira et al. 1982). Purified PK has also been shown 
to cause significant release of elastase from neutrophils pre-treated with cytochalasin B 
(Wachtfogel et al. 1983), and to convert latent collagenase to its active form in vitro 
(Nagase et al. 1982). Activation of the plasma kallikrein/kinin system has also been 
demonstrated on endothelial cells (Rojkjaer and Schmaier, 1999). On endothelial cells, 
prekallikrein appears to be activated by an antipain sensitive protease and is dependent on 
the presence of high molecular weight kininogen and an optimal free Zn2
+ 
concentration. 
The kallikrein formed on endothelial cell membranes is capable of cleaving its receptor and 
HK, thus liberating bradykinin and the HK PK complex from the endothelial cell surface 
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as well as activating pro-urokinase and plasminogen (Lin et al. 1997). 
Kallikrein inhibitors 
The presence of inhibitors of TK was first described in the circulation and in bovine organs 
(Kraut et al. 1930). More recently, kallistatin-binding protein, a specific endogenous 
inhibitor of TK, has been identified, purified and cloned (Chao et al. 1990; 1996). 
Kallistatin also binds to elastase and chymotrypsin, but not to PK, urokinase or 
collagenase. At the gene and protein level, kallistatins are considered members of the 
serpin (serine protease inhibitor) superfamily (Chao and Chao, 1995). Similarly, other 
members of the serpin family that show a high degree of homology to kallistatin, namely, 
protein C inhibitor (Espana et al. 1995), a 1 antitrypsin and a 1 antichymotrypsin also bind 
tissue kallikrein (Clements, 1997). The enzyme and inhibitor form a 1: 1 stoichometric, 
heat stable complex of 92 kDa, which is erniocytosed by hepatocytes and cleared from thr.: 
circulation. Aprotinin (trasylol) is an in vitro inhibitor of both PK and TK, and the 
substitution of an amino acid has resulted in the synthesis of [Val 15] aprotinin, which 
selectively binds PK and neutrophil elastase (Wenzel et al. 1986). Whereas, the actions of 
TK are inhibited by a 1 antitrypsin, PK is inhibited by a2 macroglobulin and C 1 esterase 
inhibitor (Worthy et al. 1990). Fifty percent of PK is trapped within the protease inhibitor, 
a.2 macroglobulin (Suzuki et al. 1987). After the kallikrein-inhibitor complexes are 
formed, they are rapidly cleared from the circulation. 
Kininogens 
Kininogens are single chained glycoproteins synthesized primarily synthesized by 
hepatocytes (Takagaki et al. 1985), and secreted into the circulation. There are three 
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molecular species of kininogens with the HK and LK present in humans, while T­
kininogen is unique to the rat. The kininogen molecule consists of an amino acid terminal 
heavy chain and a carboxy-terminal light chain, with the kinin moiety interleafed between 
the two polypeptides and linked to both terminals by single disulphide bonds (Kellerman et
al. 1987). The heavy chain is common to both HK and LK, but the light chain is unique to 
either HK or LK. 
A single kininogen gene consisting of 11 exons, transcribes a unique mRNA for HK and 
LK by alternative splicing (Kitamura et al. 1985). HK and LK share the coding region of 
the first nine exons, a part of exon 10 containing the bradykinin (BK) sequence and the 
first 12 amino acids after the carboxyterminal BK sequence. Exon 11 codes for the 4 kDa 
light chain of LK. The complete exon IO contains the full coding sequence for the 56 kDa 
light chain of HK. 
The kininogens are multidomain proteins. Although each domain has one or more specific 
functions (Fig. 1.6) the protein as a whole participates in several biological processes. The 
heavy chain consists of 3 domains (DI - D3). Domain 1 has a low affinity Ca2
+ 
binding 
site, the function of which is unknown (lshiguro et al. 1987). Domains 2 and 3 contain the 
amino acid sequence, Glu-Val-Val-Ala-Gly found in cysteine protease inhibitors (Salvesen 
et al. 1986). Both HK and LK are potent cysteine protease inhibitors (Schrnaier, 1997). 
Domain 2 is the calpain inhibitory region (Bradford et al. 1993). When platelets are 
activated, calpain translocates to the external membrane where it may be inhibited by 
plasma or externalised platelet a. granule HK (Schmaier et al. 1986). Domain 3 inhibits 
cysteine proteases except calpains (Salvesen et al. 1986). Domain 4 contains the kinin 
moiety, released from the kininogen molecule by the enzymic action of kininogenases. In 
addition, domain 4 has the ability to inhibit a. - thrombin induced platelet aggregation 
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(Hasan et al. 1996), and serves as a cell-binding site (Hasan el al. 1994 ). The carboxy
terminal portion of BK and the amino terminal portion of the light chain participate as low 
affinity binding sites to endothelial cells. More importantly, the domain 4 cell-binding 
region holds the kininogens in the appropriate conformation for optimal cell binding. The 
light chain of LK is 4 kDa and consists of one domain (D5) of unknown function. The 
light chain of HK is 56 kDa and consists of domains 5 (D5H) and 6 (D6). Domain 5 
contains two histidine and glycine rich regions, one at its carboxy-terminal and the other 
on its amino-terminal. It serves as a cell-binding site on platelets (Meloni et al. 1992), 
neutrophils (Wachtfogel et al. 1993) and endothelial cells, (Reddigari el al. 1993). In 
addition, the histidine and glycine-rich regions have the ability to bind to anionic surfaces 
such as Zn2
+ 
(DeLa Cadena and Colman, 1992) and heparin (Bjork et al. 1989). Domain 6 
of HK has a PPK and factor Xl binding site (Tait and Fujikawa, 1987). The procoagulant 
activity of HK is dependent on its ability to bind to PPK and factor XI, as well as its ability 
to bind to anionic surfaces. Inhibition of either inhibits the procoagulant activity of HK 
(Reddigari and Kaplan, 1989). The binding of PPK to bound HK initiates a sequence of 
events that lead to prekallikrein activation on biological surfaces. LK is a 66 kDa 13-
globulin with a plasma concentration of 160 µg/ml (2.4 µM) and an isoelectric point of 4.7. 
HK is a 120 kDa a - globulin with a plasma concentration of 80 µg/ml (0.67 µM) and an 
isoelectric point of 4.3 (Schmaier, 1997). 
Kininogens are present in extracellular fluids and have been isolated on human platelets 
(Schmaier el al. 1986), the collecting ducts of human kidney (Figueroa et al. 1988), sweat 
glands, endothelial cells (van Iwaarden, 1988), and human neutrophils (Figueroa el al.
1992). Specific, reversible and saturable binding sites for kininogens have been reported 
on human neutrophils, platelets and endothelial cells. On the human neutrophil, the 
kininogen molecule is bound to PPK, and the substrate and enzyme exists as a complex. 
20 
The kininogens present on the human neutrophils probably originate from the plasma pool 
or are co-secreted from the hepatocytes and enter the circulation as a complex. Currently 
there is no evidence as to whether they are synthesized by the neutrophils. 
HEAVY CHAIN I BRADYKININ I LIGHT CHAIN I 
NH,7 D1 D2 D3 D4 D5 1D6 rCOOH 
calcium calpain papain thrombin surface PK, FXI 
binding binding inhibition inhibition binding binding 
celJ cell cell 
binding binding binding 
Figure 1.6 Domain structure of high molecular weight kininogen 
Kinins 
Bradykinin and lys-bradykinin are potent vasoactive peptides released from HK and LK by 
plasma and tissue kallikrein respectively. Kinins in plasma range from 10-5000 pg/ml 
(Carretero and Scicli, 1988), and urinary excretion of kinins is about 24.6 ± 1.0 µg/day. 
They are thought to initiate the cardinal signs of inflammation namely pain, vasodilatation 
and oedema. The kinin peptides are potent pain-producing substances and cause pain 
through two mechanisms. Firstly, via the direct-stimulation of nociceptors (C and AD) 
fibres, and secondly, by inducing sensitisation of sensory fibres to physical and chemical 
stimuli (Rang et al. 1991 ). 
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When compared to 5' hydroxytryptamine (5'HT), BK is at least IO times more potent in 
causing pain on the blister base (Whalley et al. 1987). This algesic effect of BK is 
potentiated by thromboxanes, prostaglandins (Vane, 1978) and 5'-HT. Both bradykinin 
and kallidin cause vasodilatation and increase vascular permeability (Bhoola et al. 1960; 
Carter et al. l 974). It is postulated that the release of kinins could result in opening the 
junctions between the endothelial cells, and thus promote the local diapedesis of 
neutrophils and plasma extravastion, as seen in the inflammatory process (Figueroa et al.
1989) (Fig. 1. 7). In addition, kinins stimulate the release of the pro-inflammatory 
cytokines, IL-I and TNF (Tiffany and Burch, 1989), osteoclastic bone resorption (Lerner 
et al. 1987), and stimulate the release of several second-generation mediators, for example, 
platelet activating factor, leucotrienes, prostaglandins, substance P, acetlycholine and 
noradrenaline (Fig. 1.8). 
Neutrophil collagenase 
Diapedesis 
Figure 1.7 Role of kin ins in neutrophil diapedesis 
Kinins cleaved from HK by the protease PK (both present on neutrophils) are 
thought to result in endothelial cell retraction and neutrophil migration. This is 
enhanced by the simultaneous secretion of collagenase. 
(HK, high molecular weight kininogen; LK, low molecular weight kininogen; PK 
plasma kallikrein; TK, tissue kallikrein) 
22 
Kinin Receptor 
Ca i+ inophore 
Figure 1.8 Kinin receptor coupling and signal transduction 
(PI, phosphotidylinositol second messengers (diacyl glycerol and inositol 
triphosphate); gK
2+
, potassium conductance; GC, guanylate cyclase, AC, 
adenly cyclase) 
Several studies support the hypothesis that bradykinin sensitises primary afferent neurones 
to other chemicals present in inflamed tissues by recruiting additional sensory neurons 
thereby contributing to hyperalgesia. In a study using primary cultures of dorsal root 
ganglion neurons from neonatal rats, pre-treatment with bradykinin increased the 
proportion of "intermediate-size" dorsal root ganglion neurons that responded to capsaicin 
or a low pH ( 6.1) and "small-size" neurons that responded to low pH but not to capsaicin 
(Stucky et al. 1998). In addition B2 bradykinin receptors have been localised in neurones 
of the brain stem, basal nuclei, cerebral cortex, thalamus and hypothalamus, endothelial 
lining of the superior sagittal dural sinus and ependyma of the lateral and third ventricles, 
whereas Bl kinin receptors have been localised on neurones of the thalamus, spinal cord 
and hypothalamus (Raidoo and Bhoola, 1997). Increased expression of B2 and B 1 
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receptor mRNA in the lumbar dorsal root ganglia following chronic constriction injury to a 
rat sciatic nerve has been observed after 48 hours and 14 days respectively (Levy and 
Zochodne, 2000). The increased expression of both receptors coincided with the analgesic 
effects of their antagonists in that HOE-140 (a potent B2 receptor antagonist) was 
analgesic at both 48 hours and 14 days, while the Bl receptor antagonist des-Arg(9), 
[Leu(8)]-BK had an analgesic effect only at 14 days (Levy and Zochodne, 2000). In 
another study, intramuscular infusions of BK and serotonin into the tibialis anterior muscle 
of volunteers produced significantly increased pain as measured by the visual analogue 
scale compared to an infusion of isotonic saline and the duration of pain was significantly 
increased by the combination of BK and serotonin (Babenko et al. 2000). In addition, the 
infusion of the non -peptide BK B2 receptor antagonist, FRI 73657, has been shown to 
reduce the nociceptive behavioural responses following intraplantar injection of BK in 
unanaesthetized rats (Griesbacher et al. 1998). 
Other biological activities of kinins include the ability to lower systemic blood pressure, 
increase capillary permeability and produce natriuresis. Kinins also stimulate the secretion 
of renin from the kidney (Beierwaltes et al. 1985) and the release of vasopressin from the 
neurohypophysis (Baertschi et al. 1981). In the nervous system BK is involved in the 
central regulation of blood pressure, nociception and diuresis and it increases neuronal 
excitability (Nitsch et al. 1998). The cellular actions of kinins are mediated via the 
activation of specific kinin receptors situated on the surface membrane of many cells. 
Kininases 
Kinins are inactivated by peptidases called kininases (Bhoola et al. 1992). The kininase 
family comprises the kininase 1 carboxypeptidases; kininase 1 carboxypeptidase N (Kl-
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CPN) and kininase caboxypeptidase M (Kl-CPM) and the kininase II peptidyl- peptidases, 
kininase II-angiotensin coverting enzyme (K.11-ACE) and kininase II neutral 
endopeptidases (Kl 1-KEP). In addition, the prolidase, aminopeptidase B and two 
endogenous kininases (kininase A and B) also hydrolyse, and thus inactive kinin. 
Kininase I carboxypeptidases N (KI-CPN) is an arginine carboxypeptidase synthesised by 
the liver and secreted into the circulation where it accounts for 90% the bradykinin­
hydrolysing activity (Zacest et al. 1974). The enzyme is a tetrameric molecule and 
comprises two heterodimers, each consisting of a 83 kDa non-catalytic unit and a 50 kDa 
catalytic unit (Levin et al. 1982). KI-CPN acts on the carboxy-terminal of the bradykinin 
molecule, and removes the Arg9 residue to produce des(Arg9]-BK that is a B 1 receptor 
agonist. Similarly, hydrolysis of the C-terminal arginine of kallidin results in the 
formation of the Rl receptor agonist, des(Arg 10]-kallidin. Levels ofKI-CPN are decreased
in cirrhosis of the liver and increased in pregnancy (Erdos and Skidge� 1997). Elevated 
levels have also been reported in the blood and synovial fluid of patients with arthritis 
(Chercuiffe et al. 1987). 
Kininase I Carboxypeptidase M (KI-CPM) is a membrane bound 62 kDa single chain 
glycoprotein (Skidgel et al. 1989), and is found in a wide variety of cells and tissues. High 
levels of CPM mRNA have been shown in human placenta, lung and kidney. The enzyme 
cleaves the C-terminal arginine of BK and Lys-BK to form des[Arg9] BK and des[Arg
10
] 
kallidin respectively. Since it is localised to the plasma membranes of a wide variety of 
cells and tissues, where kinin receptors are located, KI-CPM is likely to regulate the local 
actions of kinins (Erdos and Skidgel, 1997). Des[Arg9]BK and des[Arg 10] kallidin are
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agonists for the B 1 receptors, therefore KI-CPM may play a role at sites of inflammation 
where B1 receptors may be upregulated (Bhoola et al. 1992). 
Kininase 11-Angiotensin I-converting enzyme (Kll-ACE) is a single chain glycoprotein of 
about 140 to 170 kDa, and is present in vascular beds bound to the plasma membrane of 
endothelial cells as well as in a soluble form (Erdos and Skidgel, 1997). High levels are 
found in the pulmonary vascular beds, kidney , myocardial vascular endothelium small 
intestine choroid plexus and placenta (Erdos and Skidgel, 1997). Soluble ACE is found in 
urine, lung oedema, amniotic, seminal and cerebrospinal fluid and in homogenates of 
prostate and epididymis (Erdos and Skidgel, 1997). KIi-ACE inactivates circulating kinins 
mainly during their passage through the lung (Bhoola et al. 1992) by hydrolysis of two 
separate bonds on the C-terminal end of the kinin molecule. First, it removes the dipeptide 
Phe-Arg and next splits the Ser-Pro bond (Zacest et al. 1974). In addition, KII-ACE 
hydrolyses enkephalins, neurotensin, substance P and lutenising hormone-releasing 
hormone (Erdos and Skidgel, 1997). Several inhibitors of ACE have been developed. 
Kininase II-Neutral Endopeptidase 24.11 (KII-NEP 24.11) is a single chain protein 
consisting of 742 amino acids, and has a molecular weight of 88 k.Da (Malfroy et al. 1988). 
After synthesis, the enzyme migrates to plasma membrane where it becomes translocated 
to be anchored on the outer surface of the :fibroblast from which it may be secreted into the 
body fluids (Lorkowski et al. 1987). It inactivates kinins by removing the C-terminal Phe­
Arg dipeptide (Gafford et al. 1983). In addition, it cleaves several other peptides including 
substance P, enkephalins, atrial natiuretic factor and neurotensin (Erdos and Skidgel, 
1997). KII-NEP is present in high concentrations in the brush border of proximal tubules 
of the kidney, microvilli of the intestine, :fibroblasts of the lung and brain placenta and 
male genital tract (Erdos and Skidgel, 1997). In addition, KII-NEP, has been reported on 
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the cell membrane of human neutrophils (Connelly et al. 1985). KII-NEP hydrolyses N­
fMLP, a peptide that stimulates chemotaxis. Activation of neutrophil or antigen-antibody 
reactions triggers the internalisation of KII-NEP, with a rapid loss of its enzymic activity. 
This could have marked effect on the migration of neutrophils to sites of inflammation. It 
could also have a regulatory effect on the biological activity of kinins formed on the 
external surface of the neutrophil membrane on which HK, LK and plasma prekallikrein 
have been localised (Figueroa et al. 1992; Henderson et al. 1992). 
Additional kinin peptidases: Aminopeptidase B which cleaves the Arg
1 -Pro
2 bond of the 
BK molecule has been described in erythrocytes, kidney and lung tissue (Erdos and 
Skidgel, 1997). Two additional endopeptidases, kininase A and B, have been purified 
from the rat brain (Oliviera et al. 1976). Kininase A cleaves the Phe6-Ser8 bond and 
kininase B the Pro7-Phe8 bond ofbradykinin. 
Kinin Receptors 
The pharmacological activity of the carboxypeptidase metabolites, desArg
9 -BK and 
desArg 10 - kallidin, was initially demonstrated in isolated preparations of rabbit vascular 
smooth muscle (Regoli et al. 1977), and the receptor mediating these responses was 
classified as a B 1 receptor. Subsequently two major types of receptors were identified, B 1 
and B2 (Regoli and Barabe, 1980), and their classification confirmed with selective 
agonists, gene cloning and receptor expression studies. Both these receptors belong to a 
superfamily of G-protein coupled rhodopsin-like receptors, and consist of a seven 
transmembrane spanning regions with three extracellular and four intracellular loops 
(Burch and Axelrod, 1987) (Fig. 1.9). 
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Figure 1.9 Structure of the kin in receptors 
(NH2, amino terminal; COOH, carboxy terminal) 
The cDNA clone encoding a human BI kinin receptor has been isolated from a human 
embryonic lung fibroblast cDNA library by expression cloning (Menke et al. 1994). The 
mRNA encoding for the B 1 receptor is approximately 2 kb shorter than that of the B2 
receptor (Webb et al. 1994). The B 1 receptor is composed of 353 amino acids, and has a 
36% homology to the amino acid sequence of the B2 receptor. The potency order of of 
kinin receptor agonists for the Bl receptor in isolated tissues is desArg9-BK > Tyr-(Me)8-
BK > BK. Des-Arg9 -BK was the first described selective agonist for Bl receptors (Regoli 
et al. 1977). Subsequent studies have reported that desArg9 -kallidin is a potent agonist 
(Menke et al. I 994), in contrast to BK, which is essentially inactive at the Bl receptor. 
The BI receptors are apparently not present constitutively, but appear to be inducible by 
inflammatory mediators such as bacterial lipopolysaccharide and interleukins (Pesquero et 
al. 2000) in smooth muscle cells and fibroblasts in experimental inflammation or after 
exposure to noxious stimuli. Mice with a targeted deletion of the gene for the B 1 receptor 
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are healthy, fertile, and normotensive and show a blunted hypotensive response to bacterial 
lipopolysaccharide and a reduced accumulation of PMN leukocytes in inflamed tissue. 
Under normal non-inflamed conditions, these animals are analgesic in behavioral tests of 
chemical and thermal nociception. Using whole-cell patch-clamp recordings it has been 
shown that the Bl receptor was not necessary for regulating the noxious heat sensitivity of 
isolated nociceptors. However, functional B 1 receptors are present in the spinal cord, and 
their activation can facilitate a nociceptive reflex (Pesquero et al. 2000). Induction of B 1 
receptors was observed in the cardiovascular responses of rabbits injected with Kl I-ACE 
inhibitors (Nwator and Whalley, 1989), on the isolated rabbit aorta as a selective time­
dependent response to in vitro incubation ( deBlois et al. 1991 ), inflamed porcine vascular 
tissues as compared to healthy tissue (Schremmer-Danniger et al. 1996), and in the porcine 
aortic smooth muscle layer in LPS induced inflammation (Schremmer-Danniger et al.
1998). Moreover, while B2 receptor blockade has been shown to attenuate LPS- induced 
porcine end toxin shock; B 1 receptor blockade appeared to counteract the beneficial effects 
of B2 blockade (Siebeck et al. 1996). These findings suggest that the upregulation of the 
BI receptors may be a mechanism of host defence. B 1 receptor upregulation has also been 
reported in an in vivo model of myocardial infarction (Tschope et al. 2000), in endotoxin­
induced renal inflammation in the rat (Marin-Castano et al. 1998), as well as in the 
peripheral T cells from patients with multiple sclerosis (Prat et al. 1999). In addition, 
cytokines, notably IL-1 f3, released during the inflammatory response, have been shown to 
induce the expression of B 1 receptors (Perk.ins and Kelly, 1994 ). TNF a and IL-I f3 have 
been shown to increase the expression of both B 1 and B2 receptor expression in a human 
embryonic lung fibroblasts and this upregulation was inhibited by dexamethasone (Haddad 
et al. 2000). IL-8 has also been shown to increase BI receptor expression and mRNAs in 
human lung fibroblasts (Bastian et al. 1998). In the nai"ve rat, infusions of IL-I f3 or TNF a 
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increased the paw oedema induced by a B 1 agonist (Campos et al. 1998). In addition, the 
paw oedema was inhibited by a B 1 antagonist and not by the B2 antagonist. The induction 
of B 1 receptors by the pro-inflammatory cytokines is thought to be due to the release of 
other cytokines, activation of protein kinase C and tyrosine kinase pathways, co-ordinated 
with the activation of MAP-kinase and nuclear factor kappa B (Campos et al. 1999). 
Conversely, stimulation of the B l  receptor on macrophages has been reported to release 
IL-1 and TNF (Tiffany and Burch, 1989). This led to the hypothesis that B 1 receptors 
essentially mediate kinin responses in inflamed and injured tissues (Marceau, 1995). 
B 1 receptor expression or activity has also been demonstrated in cardiovascular system 
(Pruneau et al. 1996), urinary (Butt et al. 1995), intestinal (Rhaleb and Carretero, I 994) 
and lung tissues (Nadar et al. 1996), as well as cultured vascular cells (Tropea et al. 1993), 
embryonic calvarium bones (Ljunggren and Lerner, 1990), tracheal smooth muscle (Marsh 
and Hill, 1994) and fibroblasts (Marceau and Tremblay, 1986). 
B 1 receptors stimulate phosphatidylinositol hydrolysis in smooth muscle leading to 
mobilization of intracellular Ca2
+ 
(Butt et al. 1995), phospholipase C or phospholipase A 
(Burch and Axelrod, 1987), and appear to cause biosynthesis and release of prostaglandins 
(Schneck et al. I 994 ). In in vivo studies, B 1 receptors have been implicated in kinin 
induced persistent hyperalgesia (Perkins et al. 1993), and plasma extravasation (Cruwys et 
al. 1994). 
B2 Receptors 
The human B2 receptor gene is localised on chromosome 14 (14q32 band), comprising 
more than 28 kb, and organised in 3 exons and 2 introns. The B2 receptor protein consists 
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of 364 amino acids, is highly glycosylated, and exists in multiple isoforms at 69 kDa with 
an isoelectric point of pH 6.8 - 7.1. The BK binding site is located at the amino-terminal 
part of the third extracellular loop (Abd Alla et al. 1996). Most of the actions of BK and 
kallidin are mediated through B2 receptors (Regoli and Barabe, 1980; Marceau, 1995). 
The potency order ofkinin receptor agonists for the B2 receptor is Tyr-(Me)8-BK >BK> 
desArg9-BK. B2 receptors are ubiquitous and are expressed in most tissues. Their effects 
have been demonstrated in the gastro-intestinal and respiratory (Field et al. 1992), 
genitourinary (Butt et al. 1995), cardio -vascular (Gaudreau et al. 1981) and neuronal 
tissues (Babbedge et al. 1995), as well as the eye (Everett et al. 1992), the plasma 
membrane of neutrophils (Haasemann et al. 1994) and synovial tissue (Bathon et al.
1992a; Uhl et al. 1992) and a higher density of B2 receptors have been reported in RA 
compared to osteoarthritis (OA). In the normal human kidney B2 receptors are present in 
the entire nephron and are thought to be responsible for most of the physiological effects of 
BK (Naicker et al. 1999). However, in the diseased kidney B2 receptors appear to be 
reduced. These receptors have also been identified in normal skin (Schremmer-Danninger 
et al. 1999) myometrium and endometrium of the uterus (Murone et al. 1999), human 
embryonic lung fibroblasts (Haddad et al. 2000), retina (Takeda et al. 1999) and human 
deciduas derived cells (Buchinger and Rehbock 1999). Upregulation of the B2 receptors 
has been reported following myocardial infarction {Tschope et al. 2000) and in response to 
cytokines. TNF-a and IL-IP both induced a rapid and transient increase in Bl and B2 
receptor mRNA expression in human embryonic lung fibroblasts (Haddad et al. 2000) and 
IL-1 p has been shown to increase the expression of B2 receptors in human deciduas 
derived cells (Rehbock et al. 1999). In addition immunolabeling for B2 has been observed 
on the astrocytic cells in patients with astrocytomas (Raidoo et al. 1999) and oesophageal 
carcinoma (Dlamini et al. 1999). 
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Like the B 1 receptors, B2 receptors are coupled to G-proteins, and promote several signal 
transduction events at the cellular level (Bhoola et al. 1992). These include calcium 
mobilisation, chloride transport, activation of phosphotidylinositol-specific phospholipase 
C, formation of nitric oxide, activation of phospholipase A2 and stimulation of adenyl 
cyclase. Thus, the acute nociceptive and inflammatory responses as well as the vasoactive 
properties elicited by BK appear to be mediated via B2 receptors. In vivo, the B2 receptors 
have been implicated in hypotension (Benetos et al. 1986), acute bronchoconstriction and 
oedema formation (Sakomoto et al. 1994). 
Receptor Antagonists 
The understanding of the critical role the kinin receptor plays in health and disease has 
been greatly enhanced by the development of several antagonists. The first selective 
antagonist of the 81 receptor was desArg9 [leu8] BK (Regoli et al. 1977). Other
antagonists such as desArg 10[Ieu9] kallidin, with higher affinity and a longer duration of
action have been reported (Regoli et al. 1990). The "first generation" competitive 
antagonists of B2 receptors were bradykinin analogues, in which the proline at position 7 
was replaced with D-phenylalanine (D Phe) and the two phenylalanine residues at position 
5 and 8 were replaced with thienyalanine. 
The prototype [D Phe7] BK was moderately potent as an antagonist.
The "second generation" antagonists introduced two new unnatural amino acids into the 
first generation structure; D tetrahydroisoquinolone-3-carboxylic acid (Tic) at position 7 
and octrahydroindole-2-carboxylic acid (Oic) at position 8 (Wirth et al. 1991). DArg­
[Hyp3, T
h
i5, Dtic7, Oic8]-BK (Hoe 140 or icatibant) proved more potent than the first
generation antagonists with a longer in vitro lifetime and has been efficacious in clinical 
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trials for allergic asthma and rhinitis. 
The "third generation" single chain BK antagonists (B-9224, B-9430 and B-9668) were 
introduced with the new amino acid, a-2-indanyl-glycine (Igl) at positions 5 (L-isomer) 
and 7 (D-isomer) of the HOE 140 structure (Stewart et al. 1999). The antagonist B 9430 is 
effective at both B2 and B 1 receptors and is not degraded by lung and kidney 
homogenates. The next important advance is the introduction of the 
pentafluorophenylalanine (5f) residue at position 7. These "fourth generation antagonists" 
have the highest potency compared to the previous antagonists and show combined B2-B 1 
antagonist activity. 
Non-peptide BK antagonists 
Non-peptide antagonists have been developed for several substances, including substance 
P, angiotensin II and vasopressin. The first non-peptide antagonist for the B2 kinin 
receptor, WIN64338, had muscarinic cholinergic activity. Subsequently several orally 
available non-peptide antagonists for the kinin receptors have been developed. Three non­
peptide antagonists, FR 173657, 165649 and 167344 have been developed. These have 
been found to be potent against B2 binding, with no effect on B 1 binding. In vivo, they 
blocked human B2 receptor mediated phosphatidylinositol hydrolysis, BK induced 
bronchoconstriction in guinea pigs and carrageenin-induced paw oedema in rats (Asano et 
al. 1999). In addition, a non-peptide antagonist for the B 1 receptor (PS020990) has also 
been developed (Horlick et al. 1999). 
The effects of B 1 and B2 antagonists have been studied in several animal models. The B2 
antagonists have been shown to reduce BK-induced effects on vascular tone and oedema 
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formation in the rabbit hind limbs (Breil et al. 1995) and LPS-induced hyperalgesia 
(Walker et al. 1996). Indomethacin also reduced the LPS-induced hyperalgesia supporting 
the hypothesis that kinins mediate hyperalgesia via the stimulation of B2 receptors and the 
formation of prostanoids. Similarly, the non peptide B2 antagonist (FRI 73657) has also 
been shown to abolish BK stimulated release of prostaglandins in the isolated rabbit ear 
(Griesbacher et al. 1997) and HOE 140 to inhibit BK induced release of arachidonic acid, 
interleukin-6 (IL-6), and interleukin-8 (IL-8) in cultured decidua-derived cells (Buchinger 
and Rehbock, 1999). BI and B2 receptor antagonists have also been shown to inhibit 
PMN elastase release and the resultant increase in permeability of endothelial cells (Carl et
al. 1996) and HOE 140 to reduce the LPS induced increase in vascular permeability (Ueno 
et al. 1996) and to suppress growth of solid tumours (Wu et al. 1998). Further, B2 receptor 
antagonists inhibited the allergic like inflammatory pleurisy triggered by BK, which is 
characterized by acute mast cell degranulation, protein leakage and pleural eosinophil 
infiltration (Bandeira-Melo et al. 1999). In addition blockade of the B 1, B2 and IL-I p 
receptors have been shown to substantially modulate capsaicin and substance P induced 
hyperalgesia (Davis and Perkins, 1996) and both B2 and B 1 receptor antagonists had an 
analgesic effect following peripheral nerve injury (Levy and Zochodne, 2000) and 
zymosan-induced hyperalgesia (Belichard et al. 2000). Bradyzide, a rodent-selective non­
peptide B (2) bradykinin antagonists inhibited BK-induced inositol trisphosphate (IP3) 
formation, blocked BK-induced hypotension and plasma extravasation and reversed 
Freund's complete adjuvant-induced mechanical hyperalgesia in the rat knee joint to the 
same degree as morphine and diclofenac, but was more potent than paracetamol (Burgess 
et al. 2000). 
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1.2.3.2.2 Cytokines 
Cytokines are a family of low molecular weight soluble molecules that are responsible for 
direct cell-to-cell communication in a non-antigenic, but specific manner. They are 
important for both physiological responses and the pathophysiology of a range of diseases, 
including the initiation and perpetuation of inflammation and share the following common 
characteristics: 
• Low molecular weight
• Involvement in immunity and inflammation where they regulate the amplitude and
duration of response
• Produced transiently and locally, acting in a paracrine or autocrine manner
• Extremely potent, acting at picomolar concentrations
• Interaction with high affinity celJ surface receptors specific for each cytokine
• Their cell surface binding ultimately leads to a change in the pattern of cellular RNA
and protein synthesis and altered cell behaviour
• Individual cytokines have multiple overlapping cell regulatory actions
• Cytokines interact in a network by inducing each other, transmodulating celJ surface
receptors and by synergistic, additive or antagonistic interactions on cell functions.
A variety of cells, macrophages, lymphocytes, fibroblasts and endothelial celJs secrete 
cytokines. The cytokines may be either pro-inflammatory or anti-inflam atory. 
Interleukin (IL-1), IL-6, IL-8 and TNFa are considered to be the most potent pro-
inflammatory cytokines and interact in a network with TNFa stimulating the production of 
IL-1, IL-6 and IL-8 and IL-1 stimulating the production of IL-6 and IL-8 in the 
pathogenesis of synovitis (Brennan et al. 1992a) (Fig. 1.10). The major targets for these 
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cytokines in joint inflammation are the vessels, symposium, cartilage and bone (Table 1.2). 
The net result of activation of the cytokine system results in new blood vessel formation 
and infiltration of the symposium by inflammatory cells that contribute to the development 





Figure 1.10 Interaction of the pro-inflammatory cytokines 
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fibroblasts, T and B cells 
endothelial cells 
neutrophils, fibroblasts, 
hepatocytes, epithelial and 
endothelial cells 
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endothelial cells and activated 
lymphocytes 
Actions 
• recruits cells to site of inflammation
• stimulates production ofIL-6 & TNFcx::
• augments T cell proliferation & B cell
activation
• induces hepatic production of acute
phase proteins
• activates neutrophils to synthesise and
release PGs
• increases binding of lymphocytes and
monocytes to endothelial cells
• induces endothelial cell proliferation
• stimulates production of IL-1,6 and 8
• enhances PG-dependent bone resorption
• inhibits collagen synthesis
• increases PGE2 and collagenase
production
• increases plasminogen activity
• increases release ofFGF
• modulates PMN function such as the
release of oxygen metabolites, phagocytosis,
adhesion to endothelium and the ability to
degrade cartilage
• stimulates the release of hepatic acute
phase
• induces activated B cells to differentiate
into plasma cells
• stimulates and attracts neutrophils
• stimulates secretion ofIL-1, TNFcx:: &
PGE2
• amplifies cartilage destruction by IL- I &
TNFcx::
• activates chemotaxis, phagocytosis,
antibody cytotoxicity and oxidative
metabolism in granulocytes
• induces HLA-DR ex2ression on monocytes
ABBREVIATIONS: IL: interleukin; TNF: tumour necrosis factor; PG: prostaglandin; 




The IL-I family consists ofIL-la, IL-IP and IL-I receptor antagonist (IL-IRA), which are 
structurally related to each other and have similar affinity for IL-I receptors on cells 
(Dinarello, 1994). IL-I a and IL-Ip are potent agonists that elicit various biological 
responses, whereas IL-IRA blocks the effects of the agonists by competing for binding 
sites on the cell surface receptors (Arend, 1993). 
IL-la, IL-IP and IL-IRA are encoded by separate genes; designated as ILIA, !LIB, and
ILIRN respectively. The three genes are clustered on the long arm of human chromosome 
2 in a region (ql3-q21) that spans more than 430 kilobases (Nicklin et al. 1994). The 
human ILIA and ILIB genes are approximately 10.2 and 7.5 kb in size respectively, and 
have 7 exons each that encode similar regions on the respective proteins. The IL/RN gene 
contains 8 exons, spanning approximately 17 kb, and gives rise to both secretory IL-IRA 
(sIL-IRA) and intracellular (icIL-lRA) (Eisenberg et al. 1991). Transcription is induced 
rapidly in response to various stimuli, including bacterial cell wall components, cytokines, 
BK, immune stimuli and inflammatory mediators, and does not require de novo protein 
synthesis. The mRNAs for IL- I oc and IL-1 p are translated into 31 kDa polypeptides on 
free polysomes (Fenton, 1992), 
IL-I a has an isoelectric point of 5 and is functional in the propeptide state, whereas IL-1 p 
has an isoelectric point of 7 and has to be processed to an active 17 kDa protein by the 
specific proteinase interleukin converting enzyme (ICE) (Kostura et al. 1989). These 
molecules share 50% homology at the gene level and 26% homology at the protein level. 
Three related cell surface proteins are involved in IL-I binding and signalling; type 1 IL-
38 
IR (receptor), type 2 IL-IR and the IL-IR associated protein (Sims and Dower, 1994). 
The IL-lR genes are members of the large immunoglobulin supergene family, and are 
located in the same region of human chromosome 2 as their ligands. Type 1 IL-1 R is an 
85 kDa glycoprotein consisting of 552 amino acids and is divided into a 319 residue 
extracellular ligand-binding domain, a 20-residue transmembrane ligand-binding domain, a 
20-residue transmembrane-spanning region, and a 213-residue cytoplasmic tail (Tocci and
Schmidt, 1997) (Fig. 1.11). The type 1 IL-IR binds all three members of the IL-I family, 
but has the greatest affinity for IL-IRA (Sims and Dower, 1994). The type 2 IL-IR is a 68 
kDa glycoprotein consisting of 386 amino acids, a 332-residue extracellular domain, a 20-
residue transmembrane region and a short 29-residue cytoplasmic tail. Type 2 receptors do 
not transduce a signal upon IL-I binding, instead the type 2 IL-IR is shed from the cell 
surface as a soluble form. The soluble IL-IR ( sIL-1 R) type 2 is found circulating in the 
blood of healthy individuals, and its cell surface expression is increased by a variety of 
inflammatory mediators, and is thought to function as a constitutive natural antagonist 
(Colotta et al. 1993). The IL-IR-associated protein (IL-IRAP) has not been shown to bind 
IL-1 directly, but increases the affinity of the type l receptor for IL-I a, and IL-IP 
approximately three fold. 
IL-I is produced during antigen presentation and is secreted by macrophages, fibroblasts, 
endothelial cells, synovial lining cells and T and B lymphocytes (Lorenzo, 1991 ). It has a 
wide range of biological actions and acts via modulating gene expression in target cells. 
Both IL-I a, and IL-Ip possess co-mitogenic properties, recruit cells to the site of 
inflammation, and stimulate the production of pro-inflammatory mediators, including IL-6 
and TNF. IL-I has been shown to augment T-cell proliferation and B-cell activation in 
response to antigenic challenge (Dinarello et al. 1986), induce hepatic production of acute 
39 
phase proteins (Dinarello, 1984), and activate neutrophils to synthesize and release 
prostaglandins (Rossi et al. 1985). It also increases binding of lymphocytes and 
monocytes to endothelial cells, induces endothelial cell proliferation and 
neovascularization. IL-1 has been shown to be arthritogenic in animals (Chandrasekhar et
al. 1990), and causes a transient synovitis when injected directly into the joints. In man, 
high levels of IL-1 are present in serum and synovial fluid of patients with RA (Arend and 
Dayer, 1995), and immunoreactive IL-1 has been identified in the synovial lining cells and 
subintirnal mononuclear cells (Brennan et al. 1991). On exposure to IL-I cultured 
fibroblast-like synoviocytes proliferate, produce metalloproteinases (such as collagenase 
and stromelysin), and secrete cytokines such as GM- CSF (Alvaro-Gracia et al. 1989). In 
addition IL-1 dramatically increases prostaglandin production (Dayer et al. 1986). 
Interleukin 1 is a potent inducer of bone resorption (Boyce el al. 1989). This effect may be 
mediated through PGE2, which is known to resorb bone (Klein and Raisz, 1970) or other 
mechanisms such as the inhibition of collagen synthesis, and the stimulation of 
plasminogen activator (Boyce el al. 1989). In addition, IL-1 is responsible for cartilage 
destruction (Dinarello, 1994 ). The increase in secretion of plasminogen activator 
stimulated by IL-1 converts plasminogen to plasmin, a neutral protease that causes 
cartilage destruction (Campbell et al. 1988). Interleukin-I also has chemo-attractant 
properties and increases neutrophil accumulation in joints (Pettipher et al. 1986), and has 
the capacity to increase the lifespan of neutrophils in vitro and in vivo (Barrett, 1994). 
Interleukin-I interacts with cells through its receptor. The specific inhibitor, IL-1 receptor 
antagonist, inhibits IL-1 related processes in vitro and in vivo (Dinarello et al. 1991 ). It is 
thought that lower levels of IL-1 receptor antagonists relative to that of the total production 
ofIL-1 may be responsible for the IL-1 induced effects in RA (Firestein et al. 1994a). 
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lg -Domain- I 
lg-Domain-2 
Hinge region 
Figure 1.11 Structure of the IL-1 receptor 
NH2 
Cytoplasmic tail 
(COOH, carboxy; lg, immunoglobulin;IL-1 RA, interkeukin I receptor antagonist 
NH2, amino) 
Tumour necrosis factor (I'NF) 
The human TNF gene is located on the short arm of chromosome 6 close to the HLA locus. 
The coding region spans approximately 3 kb and includes 4 exons (Nedwin et al. 1985). 
The TNF gene family also includes lymphotoxin-a, which was previously known as TNF 
�- Human TNF is initially translated as a pro hormone consisting of 233 amino acids and is 
subsequently modified by acylation with myristic acid for insertion into membranes 
(Stevenson et al. 1992). The membrane bound portion of 26 kDa retains biological 
activity. During activation and induction of TNF secretion, the membrane form is cleaved 
by a serine protease, to a 17 kDa monomer composed of 157 amino acids and three 
secreted monomers associate into a biologically active trimer (Smith and Baglioni, 1987). 
TNF is produced principally by macrophages and monocytes. The production of TNF is 
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stimulated by several factors, including LPS, IL-1, GM-CSF and TNF-itself, hypoxia, 
oxygen radicals and complement activation. TNF mediates its effects by interaction with 
two related membrane receptors, TNF-Rl and TNF-R2 (or type 1 and type 11) with 
molecular masses of approximately 55 and 75 kDa (Brockhaus et al. 1990) (Fig. 1.12). 
Signaling occurs when two or three receptors mingle around a single TNF trimer and 
results in activation of secondary signal cascades involving prostaglandins, leukotrienes, 
calcium, ceramides, and tyrosine kinases. The cell surface receptors are cleaved by 
proteolytic enzymes. T
h
is results in the down-regulation of the membrane receptors and 
the formation of soluble receptors (sTNFR), which, by competing for TNF, block its 
function. 
TNFa is thought to be the controlling element in the 'cytokine network' and is responsible 
for the production of other cytokines for example IL-I, JL-6 and IL-8 (Brennan et al.
1992a). The cellular actions of TNFa include a PG-dependent stimulation of bone 
resorption (Lorenzo el al. I 991 ), inhibition of collagen synthesis (Canalis, 1987), increase 
in PGE2 and collagenase production (Dayer et al. 1985), increase in plasminogen activity 
and increased release of fibroblast growth factor from synovial and endothelial cells 
(Takahashi et al. 1991). Several studies have shown that TNFa modulates PMN function 
such as degranulation, release of oxygen metabolites, phagocytosis, adhesion to the 
endothelium and the ability of neutrophils to degrade cartilage in vitro (Kowanko et al.
1990). The TNFa molecule binds with both the p55 and p75 receptors, both of which are 
upregulated in RA synovial tissue (Brennan et al. 1992b). TNFa -containing cells have 
been localised to the cartilage-pannus junction (Chu et al. 1991 ), suggesting production 
near the site of tissue destruction. In addition, increased levels of soluble TNF receptors in 
synovial fluid compared to serum have been reported in RA patients (Cope el al. 1992), 
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supporting local production of these molecules. High concentrations of TNF are present in 
serwn and synoviwn of patients with RA (Tetta et al. 1990, Manicourt et al. 1993) and RA 
patients with detectable levels of TNFa have a higher erythrocyte sedimentation rate and 
synovial fluid leucocyte count (Saxne et al. 1988) suggesting that high TNFa activity is 
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Figure 1.12 Schematic representation of the tumour necrosis factor 
receptors 
IL-6 is a glycoprotein produced by most nucleated cells, including macrophages, 
monocytes, fibroblasts, T and B cells, and endothelial cells (Mizel, 1989). The human IL-
6 gene, located on chromosome 7p21 (Bowcock et al. 1988), is approximately 5 kb in 
length and consists of 5 exons and 4 introns (Y asukawa et al. 1987). The gene encodes for 
a 212 amino acid protein that is cleaved to a mature protein of 183-185 amino acids and a 
molecular weight of 21 kDa (Van Snick, 1990). Gene expression is upregulated by IL-1, 
TNF, platelet derived growth factor (PDGF), fibroblast growth factor (FGF) and 
lipopolysaccharide (Akira et al. 1990; Northemann et al. 1989). Treatment with 
corticosteroids, on the other hand, inhibits the expression of the IL-6 gene (Tobler et al.
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1992). The effects of IL-6 are mediated via the IL-6 receptor, which is a 80 kDa 
glycoprotein with structural homology to immunoglobulin supergene family, is specific for 
IL-6 and is present on monocytes, hepatocytes and T and B lymphocytes. This can be shed 
from the cell surface and can be found in a soluble form in biological fluids and cell 
supematants. IL-6 binds to either the soluble or membrane bound receptors to form a 
complex which is then associated with a transmembrane 130 kDa glycoprotein required for 
signal transduction (Cox and Gauldie, 1997). 
IL-6 is produced by monocytes, T lymphocytes and fibroblasts, and the synthesis of this 
cytokine is induced by ILI and 1NFa (Wong and Clark, 1988). IL-6 stimulates the release 
of acute phase proteins from the liver (Gauldie et al. 1987), and induces activated B cells 
to differentiate into plasma cells which produce immunoglobulins (Arend and Dayer, 
1990). This mechanism may account for the production of rheumatoid factor. High levels 
of IL-6 have been detected in the synovial fluid of patients with RA (Van Leeuwen et al.
1995) and the level oflL-6 has been shown to correlate with disease activity (Waage et al.
1989). In addition, synovial cells in culture have been shown to spontaneously produce IL-
6. Further, this production is augmented by IL-1 and 1NF (Gueme et al. 1989). In
contrast, IL-4 suppresses IL-6 production (Suzuki et al. 1993). 
Interleukin 8 
IL-8 is a member of the chemokine supergene family. The chemokines belong to two 
related polypeptide families, C-X-C and CC chemokines, as defined by the location of the 
two cysteine residues at the amino terminus. In the C-X-C family, the cysteine residues 
are separated by a non-conserved amino acid and, in the CC family the cysteine residues 
are in juxtaposition (Baggiolini et al. 1994). The C-X-C chemokines are clustered on 
44 
human chromosome 4. IL-8 is an 8 kDa peptide of the C-X-C chemokine family. It is a 
potent neutrophil attractant and stimulator, and is produced by neutrophils, fibroblasts, 
hepatocytes, epithelial and endothelial cells (Baggiolini et al. 1989). Interleukin-I, TNF, 
and LPS stimulated neutrophils exhibit increased expression of IL-8 mRNA and IL-8 
production (Strieter et al. 1992). Other chemotactic factors such as, NfMLP, C5a, and 
platelet activating factor also increase IL-8 production by neutrophils and together these 
factors account for the influx of large numbers PMN leucocytes into the synovial cavity in 
an autocrine manner. The activity of IL-8 is mediated by its binding to high affinity 
receptors present on neutrophils. These are G-protein coupled receptors with 7 
transmembrane regions (Baggiolini et al. 1994). The expression of the receptors is down 
regulated by IL-8, GM-CSF and TNFa (DeMarco and Zurier, 1997). High levels of IL-8 
have been demonstrated in the synovial fluid of patients with RA (Brennan et al. 1990) and 
gout (Terkletaub et al. 1991). Human synovial cells stimulated by IL-1 have also been 
shown to express IL-8 in RNA (DeMarco et al. I 991) and immunoreactive IL-8 has been 
localised in the sublining macrophages and in scattered lining cells (Koch et al. 1991 ). 
Granulocyte-macrophage colony stimulating factor (GM CSF) 
GM-CSF is a predominant growth factor that may be synthesized by macrophages, 
fibroblasts, endothelial cells and activated lymphocytes (Groopamn et al. 1989). The gene 
for GM-CSF is located on the long arm of chromosome 5 (Wong et al. 1985), and encodes 
for a glycoprotein consisting of 174 amino acids with a molecular weight of 18.6 kDa. 
Although it was first characterized based on promotion of growth and differentiation 
granulocytes and macrophages, it also has several pro-inflammatory properties and may be
involved in the pathogenesis of RA. GM-CSF stimulates the secretion of IL-1 and 
enhances the secretion of TNFa and prostaglandin E2 (PGE2) from macrophages (Fischer 
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et al. 1988; Heidenreich et al. 1989), and amplifies cartilage destruction by IL-I and TNF 
(Alvaro-Gracia et al. 1989). In addition, GM-CSF activates chemotaxis, phagocytosis, 
antibody dependent cytotoxicity and oxidative metabolism in granulocytes (Firestein, 
1994), and induces HLA-DR expression on monocytes (Xu et al. 1989). Furthermore, IL­
I and TNFa have been shown to induce GM-CSF production in the synovium and 
antibodies to TNFa to decrease its production (Haworth et al. 1991). Significant levels 
have been demonstrated in rheumatoid synovial fluid and rheumatoid synovial explants 
have been shown to produce GM-CSF in vitro (Xu et al. 1989). 
1.2.3.2.3 Role of immune and inflammation signalling cells 
As the initiating event antigen is engulfed by the macrophage or antigen presenting cell, 
processed and then expressed on the surface of the cell in the groove of Class II major 
histocompatibility complex (MI-IC) molecules, where it interacts with specific receptors on 
the T cells (Panayi, 1992). The macrophage releases a number of cytokines, IL- I, TNFa, 
IL-6, colony stimulating factors, coagulation factors, lysozomal enzymes, plasminogen 
activator, collagenases, leucotriene B4 (LTB4), prostaglandin £2 (PGE2), and oxygen free 
radicals which are necessary for the activation of T cells. The activated T cells then 
proliferate as helper cells, generate cytotoxic T cells and induce B cells to proliferate and 
differentiate to antibody producing plasma cells. In addition, the activated T cells 
stimulate the production of a variety of cytokines and other inflammatory mediators, which 
are responsible for the synovial proliferation and joint damage. While the T cells are 
implicated in the initiation of the inflammatory process a number of other cells such as the 
macrophages, neutrophils, fibroblasts, endothelial cells and chondrocytes participate in the 
chronic disease process, and may be responsible for the perpetuation of the synovitis (Figs. 
1.13 and 1.14). 
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Lymphocytes 
Following recognition of foreign antigen, T cells proliferate into either CD4 or CD8 cells. 
The CD4 cells stimulate B cell proliferation via the secretion ofIL2, IL-4 and IL5, enhance 
cytotoxic T cells, and induce the expression ofMHC antigens, IL-3 and GM-CSF. A large 
number of lymphocytes are found in the synovium. Following the release of B cell growth 
factor and B cell differentiating factor by activated T cells, B cell proliferate and 
differentiate into plasma cells which produce immunoglobulins and rheumatoid factors. 
Synovial plasma cells have been shown to produce RF (Milgrom, 1988), and deposits of 
lgM and IgG RF are found in the cartilage matrix from patients with RA, but not in normal 
or osteoarthritic cartilage (Jasin, 1985). Rheumatoid factors play a role in perpetuating and 
amplifying the immune response by their ability to activate the complement cascade, 
initiate local damage and act as antigen presenting cells. 
Neutrophils 
Neutrophils infiltrate the diseased joints in huge numbers and can exceed 100,000/mm3 , 
and have the potential to cause tissue damage. This may result either from the release of 
granule contents and or by the generation of reactive oxygen species involving 
nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH) oxidase, present 
on their surface. The neutrophil granules contain several potent proteolytic enzymes and 
hydrolases that may induce tissue damage (Spitznagel, 1984). These include elastase, 
cathepsin G, collagenase, gelatinase, glucuronidase, N-acetyl glucosarninidase, acid 
phosphatase, phospholipase A2 and tissue kallikrein. Other constituents include 
myeloperoxidase, lysozome, CS cleaving enzyme, plasminogen activator, cationic proteins 
and lactoferrins. A second mechanism by which neutrophils are capable of tissue injury is 
through the generation of reactive oxygen metabolites such as hydrogen peroxide and 
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hydrochlorous acid (Eisbach and Weiss, 1988). 
Normally, neutrophils circulate in a non-activated state and do not attach to endothelial 
cells, whereas activated neutrophils have an increased adhesiveness, motility, chemotaxis, 
phagocytosis, degranulation and activation of surface NADPH oxidase. The neutrophil 
surface contains a variety of receptors including those for complement chemotactic peptide 
(C5a), leucotriene B4 (LTB4) (Sherman et al. 1988), platelet activating factor (PAF) (Ng 
and Wong, 1986) and kallikreins and kininogens (Haasemann et al. 1994). Following 
receptor binding there is activation through, a guanine-nucleotide-binding (G) protein of 
phospholipase A2 that cleaves phosphoinositide to generate inositol triphosphate (IP3) and 
diacyglycerol (DAG), both of which function as intracellular second messengers. DAG 
activates protein kinase C and IP3 increases intracellular calcium through release from 
stores. These actions facilitate phosphorylation of several intracellular proteins and 
subsequent alteration in cell shape and function. In addition, neutrophils can be activated 
by several other factors including IL-8, GM-CSF, immune complexes and plasma 
kallikrein. Activated neutrophils have the ability to degrade cartilage in vitro (Kowanko et
al. 1989) and this ability is increased by TNFa (Kowanko et al. 1990). TNFa also 
modulates other neutrophil function such as degranulation, release of oxygen metabolites 
(Shalaby et al. 1987), phagocytosis and adhesion to the endothelium (Gamble et al. 1986). 
Activated neutropbils attach firmly to and damage the endothelial cells following oxidant 
generation. The activated neutrophils induce phospholipase A2 to release arachidonic acid 
metabolites from membrane phospholipids to produce prostaglandins and leucotrienes 
(Fig. 1.14). Kinins, by activating phospholipase A augment this process (Sharma, 1988). 
Prostaglandin E2 (PGE2) and PGF2 induce oedema, vasodilatation and increase 
sensitisation of pain in response to bradykinin. Leucotrine B is a chemo-attractant, and 
48 
attracts quiescent neutrophils to the site of activation (Pillinger and Abramson, 1995). In 
addition, neutrophils secrete a number of cytokines including IL-8, which may play an 
autocrine role in attracting further neutrophils to the synovial fluid, thus perpetuating the 
inflammatory process. Similarly, the endothelial cell can also be activated to facilitate 
interactions with neutrophils and other lymphocytes. 
Macrophages and mast cells 
Macrophages are thought to play an important role both in the initiation of RA, as antigen 
presenting cells, and in chronic inflammation (Burmester et al. 1997). A large number of 
activated macrophages are found in rheumatoid synovium and within the destructive 
pannus tissue. The macrophage infiltration in the synovium correlates with both disease 
activity (Soden et al. 1991 ), and radiological progression.(Mulherin et al. 1996). 
Macrophages produce large amounts of prostaglandins (Seitz and Hunstein, 1985), 
proinflammatory cytokines (Hahn et al. 1993; Firestein et al. 1990), and the proteolytic 
enzymes stromelysin, gelatinase B and elastase (Burmester et al. 1997). 
A small number of mast cells are present in the normal synovium. However, in the 
inflamed synovium, there is an increase in the number of mast cells in the synovial fluid as 
well as at the cartilage-pannus junction (Tetlow and Woolley, 1995a; 1995b). An increase 
in mast cells has been reported with flares in disease activity. In contrast, corticosteroid 
therapy and clinical improvement is associated with a decrease (Malone et al. 1987). Mast 
cell granules contain a number of mediators, including tryptase, chymase and histamine. 
Tryptase has been detected in the synovial fluid of patients with arthritis (Buckley et al.
1997). In addition, mast cells have the ability to generate L TB4 from membrane 
phospholipids and secrete a number of cytokines such as IL-1, TNFa, GM-CSF, IL-8 and 
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IL-6. Tryptase has also been shown to induce the release of bradykinin either through the 
activation of prekallikrein or direct release from kininogen (Imamura et al. 1996). This 
process is enhanced by neutrophil elastase (Kozik et al. 1998). Thus the mast cells are 
thought to play a role in angiogenesis, fibroblast proliferation and neutrophil chemotaxis 
(Austen KF, 1994). 
Endothelial cells 
One of the earliest changes in the inflamed synoviurn is endothelial cell damage (Koch, 
1998). While the primary cause of the endothelial cell damage is not known, it is believed 
to result from the activity of cytokines, complement activation components, arachidonic 
acid metabolites, histamine, serotonin and other inflammatory mediators. In inflammation, 
the rnicrovasculature undergoes two distinct morphological changes. Firstly, there is an 
increase in high endothelial venule (HEY) formation that facilitates lymphocyte trafficking 
to the synovium and T cells accumulate in a perivascular distribution. Secondly, there is 
new blood vessel formation or angiogenesis that may contribute to cartilage destruction 
(Koch, 1998). Angiogenesis is stimulated by a variety of cells, such as macrophages, 
lymphocytes, PMN leucocytes, mast cells and fibroblasts as well as by various soluble 
molecules, including transforming growth factor a, TNF-a, heparin, PGE2 and platelet 
activating factor. Kinin receptors have been identified on the endothelial cells of elastic 
arteries and veins, as well on the endothelial cells of muscular arteries and arterioles 
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• differentiates into plasma cells
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• activates complement
Figure 1.14 Cellular interactions in the pathogenesis of rheumatoid arthritis 
(DF, differentiation factor; GF, growth factor; GM CSF, granulocyte macrophage colony 
stimulating factor; IL, interleukin; LTB4, leucotriene B4; PGE 2 , prostaglandin E 2 ; TNF, tumour 
necrosis factor) 
1.2.3.3 Secondary mediators of synovitis 
Complement proteins 
Complement proteins may cause direct damage to the cell membrane or cytokine-like 
effects, for example C5a is a neutrophil chemotactic factor. Complement proteins are 
mainly produced in the liver, but may also be produced locally by the synovial 
macrophages and/or fibroblasts (Littman et al. 1989; Katz and Strunk, 1988) and induced 
by cytokines such as IL-I and TNF (Perlmutter et al. 1986). Activation of the complement 
pathway is initiated when immune complexes activate C 1 with subsequent cleavage of C4 
and C2 culminating in the activation of C3 that binds to the cell surface and facilitates 
phagocytosis. Alternatively, activated C3 may activate the remainder of the complement 
pathway by cleavage of C5 leading to the formation of the membrane attack complex by 
sequential addition of C6, C7, C8 and C9 (Fig. 1.15). This complex is inserted into cell 
membranes, and produces cell lysis. C3a is a potent vasodilator, whereas C5a is 
chemotactic for neutrophils and triggers neutrophil oxidative burst, promotes endothelial 
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membrane attack complex 
Figure: 1.15 Complement pathways 
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Arachidonic acid metabolites 
Activation of phospholipase A2 cleaves arachidonic acid from membrane phospholipids. 
Further metabolism via the cyclo-oxygenase pathway results in the production of 
prostaglandins or leucotrienes via the lipo-oxygenase pathways (Fig. 1.16). Prostaglandins 
are potent vasodilators that act synergistically with other mediators including, complement 
:fragments, histamine and kinins to increase vascular permeability. In addition, PGE2 and 
PGh stimulate osteoclastic bone resorption. Leucotriene B4 (LTB4) is a chemo-attractant 
for leucocytes and promotes the adherence of leucocytes to endothelial cells. It also 
activates the secretion of reactive oxygen species and degradative enzymes from 
neutrophils. Interleukin- I and TNFcx. increase the production of PG from synoviocytes in
vitro (Rossi et al. 1985; Dayer et al. 1985). 
kinins 
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• leucoctyte adherence to endothelial cells
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degradative enzymes from neutrophils
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Neuropeptides 
Peptide mediators produced by neurons (neuropeptides) such as substance P and met­
enkephalin also play a role in the pathogenesis of RA. 
Substance P, an 11 amino-acid peptide, is a member of a structurally related family of 
peptides called tachyk.inins. Mammalian tachykinins are encoded by two distinct genes; 
the pre-protachy-kinin (PPT)-A and PPT-B genes. Substance P is encoded by mRNAs 
arising from the PPT-A gene (Schaffer et al. 1998) and is synthesised in the cell bodies of 
the dorsal root ganglion. It is thereafter distributed to central and peripheral nerve 
terminals by a fast axonal transport system. The tachykinins mediate their actions by 
activating the neurokinin (NK) receptors, NK.1, NK2 and NK3. All three receptors are G­
protein coupled receptors that, on stimulation activate phospholipase C and thus lead to the 
generation of inositol triphosphate and diacyl-glycerol. Substance P is able to induce 
vasodilatation because of direct action on vascular smooth muscle and enhanced 
production of nitric oxide by the endothelium (Schaffer el al. 1998). In addition it increases 
histamine release from mast cells, and causes activation of macrophages and neutrophils by 
stimulating the release of PG and lysozomal enzymes. Substance P plays an important role 
in synovitis because of its ability to increase monocyte production of cytokines such as IL-
I and IL-6 and to stimulate fibroblasts-like synoviocytes to proliferate and produce 
collagenase (Lotz et al. 1987). 
Met-enkephalin is a pentapeptide that binds to opiate receptors. It is synthesized in the 
adrenal gland as a large precursor molecule, proenkephalin. In addition, human T cells and 
macrophages have also been shown to produce met-enkephalin (Plotnik.off et al. 1997). 
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Three opiod receptors have been identified, µ, K, and 8. Met-enkephalin binds with high 
affinity to 8 receptor. Receptors for met-enkephalin have been reported on human T 
lymphocytes and phagocytic leukocytes. Met-enkephalin enhances B cell antibody 
production and macrophage oxygen radical generation. It is also a macrophage and 
lymphocyte chemotactic factor. lmmunoreactive met-enkephalin has been detected in 
synovial fluid. 
Vasoactive amines and nucleotides: Histamine, serotonin and adenosine are low molecular 
amines, which are important inflammatory mediators. Histamine, a decarbox:ylation 
product of histidine, is stored in mast cells and released on mast cell activation. Its 
biological effects include vasodilatation and enhanced permeability of postcapillary 
venules. Serotonin, stored in the dense bodies of platelets, enhances microvascular 
permeability and fibrosis by promoting collagen synthesis by :fibroblasts. Adenosine, a 
nucleotide generate during mast cell activation, enhances the phagocytosis of immune 
complexes and superoxide formation by neutrophils at low concentrations. 
Effector molecules: enzymes causing cellular damage: Effector molecules differ from 
cytokines and growth factors in that they have the ability to alter the environment directly 
without the need to bind to cell surface receptors. Of these metalloproteinases (MMPS) are 
matrix degrading enzymes, which participate in acute inflammation, and include 
collagenase, stromelysin and gelatinase (Woessner, 1991 ). They are proenzymes that 
require proteolytic cleavage for activation. In vitro this proteolysis has been shown to be 
accomplished by many enzymes, including trypsin, plasmin, tryptase and other proteases. 
Collagenase degrades proteoglycan when in a triple helical structure, whereas gelatinase 
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degrades denatured collagen and stromelysin degrades proteoglycan and is able to cleave 
and activate collagenase. Collagenase and stromelysin are both produced by synovial 
lining cells, and their production is induced by IL-1 and 1NFa (Walakovits et al; 1992, 
Dayer et al. 1986). High levels of MMPS have been noted in the serum and synovial fluid 
of patients with RA (Clark et al. 1993; Manicourt et al. 1995). The activity of MMPs is 
inhibited by tissue inhibitors of metalloproteinases (TIMP); natural inhibitors produced 
locally by chondrocytes and fibroblasts (Vincent et al. 1994). 1NFa significantly inhibits 
TIMP production in endothelial cells, synoviocytes and chondrocytes (Shingu et al. 1993.) 
1.2.4 Therapeutic management of RA 
The exact aetiology of RA remains elusive thus curative treatment has not been discovered. 
The goals of treatment have been to relieve pain and decrease joint inflammation, prevent 
joint destruction, restore function uf disabled joints, correct deformities and maintain 
quality of life. To achieve this a multidisciplinary approach is required. 
Medical management: 
Three main classes of drugs have been used to treat RA: 
1) Non steroidal anti-inflammatory drugs (NSAIDs)
2) Corticosteroids
3) Disease-modifying anti-rheumatic drugs (DMARDs)
NSA/Ds reduce pain and inflammation by inhibiting the action of cyclo-oxygenase (COX) 
and therefore decrease the production of the vasoactive prostaglandins and leucotrienes. 
However, NSAIDs do not significantly alter the course of disease. Recently more specific 
NSAIDs, the COX2 inhibitors have been developed. This class may have less 
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gastrointestinal toxicity. 
Corticosteroids have immunosuppressive and anti-inflammatory effects. Their main effect 
is through the increased synthesis of lipocortin, which inhibits the enzyme phospholipase 
A2, thereby reducing the production of PGs and LTs. (Fig. 1.16). Corticosteroids also 
inhibit pro-inflammatory cytokine production, including that of IL-1 and TNF and the 
synthesis of a variety of pro-inflammatory enzymes, including collagenase, elastase and 
plasminogen activator (Kirwan, 1994). Although systemic steroids provide effective 
symptomatic relief, substantial toxicity with long-term use precludes the use of high dose 
oral steroids on a long-term basis (Saag, I 997). However, recent studies have suggested 
that the early use of low steroids may significantly retard bone and joint damage (Kirwan, 
1995). The local use of corticosteroid preparations, normally intra-articular injections of 
long-acting steroids is well established. 
Disease modifying anti rheumatic drugs or "remittive" therapy are thought to retard the 
progression of the disease. These include gold, sulphasalazine, penicillamine, 
hydroxychloroquine, methotrexate (MTX) and other cytotoxics. These drugs provide 
symptomatic and clinical improvement and have been shown to retard radiological 
progression (Sharp et al. 2000), however there is insufficient evidence that they alter long­
term outcome. Their onset of action is usually delayed for weeks to months. The 
mechanism of action of this class of drugs is not entirely known, and their effect is 
variable. Several studies have suggested that these drugs may extend their benefit via their 
effects on cytokines. Methotrexate inhibits IL-I activity and production (Chang et al. 
1992), and has been shown to decrease the concentrations of TNFa receptors with an 
associated clinical improvement (Barrera et al. 1993), to decrease synovial TNFa 
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production (Firestein et al. 1994b) and to suppress the synthesis ofIL-6 and the subsequent 
generation of reactive oxygen species in synoviocytes (Sung et al. 2000). In addition, 
MTX has also been shown to decrease the number of synovial fluid neutrophils by 
inhibiting neutrophil migration (Kraan et al. 2000). Sulphasalazine treatment has been 
associated with a fall in serum IL-I levels (Danis et al. 1992). Cyclosporin A suppresses 
IL-1 secretion (Cranney and Tugwell, 1998) and significantly reduces serum IL-6 levels in 
RA patients (Crilly et al. 1995). Most of these drugs have serious potential side effects and 
require long-term monitoring. Recently, a new class of drug, leflunomide, has been 
developed as a DMARD in the treatment of RA. Leflunomide acts by inhibiting de novo 
pyridimidine synthesis and is thought to be superior to placebo and comparable to MTX 
and sulphasalazine in efficacy (Sharp et al. 2000). Like MTX, Leflunomide has also been 
shown to decrease neutrophil migration (Kraan et al. 2000). 
Jmmunotherapy: With the advances in the understanding of the pathogenesis of RA, 
several newer therapeutic agents have been developed. These include agents that target 
cell surface receptors and cytokine function, such as recombinant IL-1 receptor antagonist 
(IL-IRA) and monoclonal antibodies directed against TNFa.. Recombinant IL-1 RA has 
been shown to decrease the number of tender joints and serological indices of 
inflammation, m clinical trials in RA patients (Bresnihan and Cunnane, 1998). The 
monoclonal antibodies against TNFa. appear to be the most promising in view of their 
integral role in the pathogenesis of RA. Treatment with both a recombinant TNF receptor 
(p75)-Fc fusion protein and a chimeric TNF monoclonal antibody (CA2) has been 
associated with significant clinical and laboratory improvement (Keystone, 1999). The 
addition of anti-TNFa. monoclonal antibody to MTX in patients with persistent activity has 
been found to be safe and effective in reducing the inflammation (Kavanaugh et al. 2000). 
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1.3 THE ROLE OF KININ PEPTIDES IN INFLAMMATORY JOINT DISEASE 
Kinins are potent vasoactive peptides, with the cellular actions of stimulation of 
nociceptive C fibres, extravasation of vascular fluid, release of neurotransmitters and 
stimulation of the release of second messengers including cytokines, prostaglandins and 
leucotrienes. Kinins are potent pain producing substances when applied to a blister base 
(Bhoola et al. 1961) or when injected intradermally (Ferreira, 1972). In addition, they 
increase capillary permeability (Bhoola et al. 1960, Imamura et al. 1984). Various 
components of the kinin system have been identified in synovial fluid and synovium, 
thereby supporting their role in inflammatory joint disease. The first isolation of a pain 
producing substance, resembling BK was reported in synovial fluid of patients with RA 
(Armstrong et al. 1957). Subsequently elevated kinin levels were reported in acute gouty 
arthritis (Eisen, 1966; Melmon et al. 1967). In a later study, Hargreaves et al ( 1988) 
compared circulating levels of immunoreactive BK in patients with RA with volunteer 
subjects. Higher levels of immunoreactive BK were found to be present in the patients 
with RA. In the same study the addition of soybean trypsin inhibitor (a serine protease 
inhibitor of PK) blocked the formation of BK in vitro in a rat model, and produced 
analgesia. In addition, both BK and kallidin appear to enhance bone resorption via 
prostaglandin formation (Lerner et al. 1987; Gustafson et al. 1998). These studies support 
the role of kinins as mediators of the inflammatory response and joint damage in 
inflammatory arthritis. Additionally, in patients with RA, elevated KI-CPN levels have 
been reported in the blood and synovial fluid (Chercuiffe et al. 1987). Increased 
expression of KII-NEP 24.11 has been reported on the cell membranes of circulating 
neutrophils (Connelly et al. 1985). Activation of the neutrophils or antigen-antibody 
reactions triggers the intemafuation of KII-NEP 24.11, with a rapid loss of its enzymic 
activity. Since KII-NEP 24.11, hydrolyses N-fMLP (a chemotactic factor), this could have 
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a marked effect on neutrophil migration to sites of inflammation. KII-NEP 24.11 has also 
been identified on human synovial :fibroblasts suggesting that it may play a role in 
regulating peptide levels in the joint (Bathon et al. 1992b ). 
Plasma kallikrein was first implicated in gout (Kellerrneyer and Beckenridge, 1965) and 
later in RA (Jasani et al. 1969). PK has been identified in the synovial fluid from patients 
with RA (Rahman et al. 1995). Higher activity has been reported in synovial fluid from 
patients with RA compared to OA (Suzuki et al. 1987), and in the synovial fluid compared 
to plasma of patients with RA (Volpe-Junior et al. 1996). In addition, PK has been shown 
to be chemotactic for PMN leucocytes (Kaplan et al. 1972), and to induce aggregation of 
PMN leucocytes (Schapira et al. 1982). It also, primes neutrophils for superoxide 
production in the joint and converts latent collagenase to its active form in vitro (Nagase et
al. 1982). These findings suggest that PK plays a role in neutrophil mediated tissue 
damage in arthritis. This is further supported by studies of the effects of PK inhibitors on 
synovitis. The intra-peritoneal injection of PKS-527, a new selective PK inhibitor, 
suppressed collagen-induced arthritis in mice and reduced levels of PK (Fujimori et al.
1993). In another study, pretreatment with a specific PK inhibitor modulated 
peptidoglycan polysaccharide induced synovitis and joint erosions in the genetically 
susceptible Lewis rats (Colman et al. 1997). 
Tissue kallikrein has also been described in inflammatory exudates, and in human and 
animal synovial biopsy specimens (Thomas and Zietlin; 1983, Al- Haboubi, 1986; Selwyn 
et al. 1989). Active enzyme levels were reported to be higher in patients with RA 
compared to OA (Selwyn et al. 1989). Additionally, TK has been identified in synovial 
fluid from arthritic joints (Worthy et al. 1990; Bhoola and Dieppe, 1991) and in circulating 
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and synovial fluid neutrophils (Figueroa et al; 1989, Rahman et al. 1994). In a study 
comparing PMNs leucocytes from synovial fluid of patients with RA to blood PMN 
leucocytes from healthy volunteers, there was reduced TK immunoreactivity on the SF 
neutrophils (Williams et al. 1997). This suggests that TK is released from the granules of 
RA synovial fluid PMNs and cleaves the kinin moiety from the k.ininogen molecule on the 
surface of the PMNs. TK also processes a variety of substrates in vivo, including the 
matrix pro-proteinases, procollagenase and progelatinase, which degrade collagen 
(Eeckhout and Vaes, 1977; Tschesche et al. 1989; Menashi et al. 1994). In addition, saliva 
of patients with connective tissue diseases including RA has been shown to contain 
increased levels of immunoreactive TK (Greaves et al. 1989). 
Both HK and LK have been reported in synovial fluid (Jasani et al. 1969). The presence of 
HK, LK, and specific high affinity reversible binding sites for HK on neutrophils (Figueroa 
et al. 1992; Gustafson, 1989), together with the accumulation of large numbers of 
neutrophils in the synovial fluid and synovial membranes (Dularay et al. 1990) provides 
strong circumstantial evidence for the role of kininogens as a substrate for kininogenases in 
arthritis. 
Kinin B2 receptors have been identified on synovial tissue by autoradiography (Bathon et 
al. 1992a) and Scatchard analysis (Uhl et al. 1992). A higher density of receptors was seen 
in RA compared to OA (Bathon et al. 1992a), and treatment with IL-I enhanced the 
number of binding sites. The B2 receptor antagonist, HOE 140, has been shown to reduce 
BK induced plasma extravasation in rat arthritic joints (Cruwys et al. 1994), and to 
suppress knee swelling in adjuvant induced arthritis in rats (Sharma and Wirth, 1996). The 
BI agonist, desArg9 BK induced slight but significant plasma extravasation, which was 
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inhibited by desArg9 (Leu8) BK, the Bl receptor antagonist (Cruwys et al. 1994). The
authors suggest that while most of the inflammatory responses are mediated by B2 
receptors; a small number of BI receptors may be present in normal joints. 
1.4 INTER-RELATIONSHIP BETWEEN THE CYTOKINE AND KININ 
CASCADES 
Both the cytokines and kinins are potent pro-inflammatory molecules, and evidence exists 
that cytokines may potentiate bradykinin activity and vice versa. Des Arg9-BK is a potent 
stimulator of IL-1 and TNF release from macrophages (Tiffany and Burch, 1989). 
Conversely, cytokines for example, IL-I and TNF have been shown to induce 
responsiveness of cells to BK to evoke release of PGE2 (Burch and Tiffany, 1989; Bathon 
et al. 1989). Synovial cells from patients with RA pretreated with IL-1 and TNF showed 
increased responsiveness to BK by release of prostanoids (Bathon et al. 1989). ln a study 
to determine the ability of IL-I, TNF and BK to release PGE2 from human synovial cells, 
lL-1 was most potent and BK weakest. However, pretreatment of cells with IL-I, 
potentiated the BK and TNF and induced PGE2 release (O'Neill, 1989). Additionally, pre­
treatment with IL-I enhanced the number of BK binding sites on human synovial 
:fibroblasts (Bathon et al. 1992a). Similarly, a relationship between cytokines and kinins 
has been noted in other conditions. In human decidua cells cultured with and without BK, 
IL-6 and IL-8 secretion was enhanced by BK (Rehbock et al. 1997). Cultured human 
bronchial smooth muscle cells treated with IL-I, elicited a rapid and transient increase in 
the density of B2 receptors through an increase in B2 receptor MRNA level (Schmidlin, 
1998). 
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These studies support an inter-relationship between the cytokine and kinin systems. In the 
pathogenesis of inflammatory joint disease there exists a possibility of a positive loop 
where BK stimulates IL-I and TNFa. release from the macrophages and IL-I in turn 
stimulates the induction of BK receptors (Fig. 1.17). This may account for the intensity 

















































































































































































Rheumatoid arthritis is a chronic multisystem disease of unknown aetiology. The current 
hypothesis is that an unknown antigen triggers an autoimmune response in a genetically 
susceptible individual. The predominant pathological change is that of an inflammatory 
synovitis, characterized by a cellular infiltration and angiogenesis with subsequent bone 
and cartilage destruction. These pathological changes occur as a result of the activation of 
a variety of cells, inflammatory mediators and effector molecules. The pro-inflammatory 
cytokines appear to play a central role in the pathogenesis of RA. Sufficient evidence also 
exists for a key role for the kallikrein-kinin system. In addition, there appears to be an 
inter-relationship between cytokines and kinins in the inflammatory process. Kinins 
induce the release of cytokines and cytokines have been shown to augment the effects of 
kinins. This may lead to an enhancement and perpetuation of the inflammatory process. 
Clinically, RA presents with an insidious onset of symmetrical polyarthritis affecting both 
the small and large joints. Active disease is manifest by swollen, tender joints clinically, 
elevation in acute phase proteins and functional disability. The extent of joint 
involvement, levels of laboratory indices of inflammation and degree of radiological 
damage may be used to assess the severity of the disease. These markers are also used to 
initiate and monitor therapy. 
Due to the lack of an exact aetiology, curative treatment for RA is not available. Treatment 
is therefore aimed to reduce joint inflammation and pain and to prevent further joint 
damage. Despite significant symptomatic effects, current treatments do not appear to alter 
the bone and cartilage changes. Recent advances in the understanding of the pathogenetic 
mechanisms, has led to the development of biological agents that are promising. 
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Further advances in the understanding of the pathogenesis are necessary and may lead to 
alternative and perhaps more effective treatment options. Several previous studies have a 
suggested a role for the kallikrein-kinin system in the inflammatory process and joint 
damage in rheumatoid arthritis. In addition, the inter-relationship between the cytokine 
and kinin systems and other effector molecules has been studied in vitro. However, the 
correlation of the markers of disease activity in rheumatoid arthritis ( clinical, biochemical 




Kinins and cytokines influence the disease activity in rheumatoid arthritis and there is an 
inter-relationship between cytokines and kinins. 
1.6.2 AIMS OF THE STUDY 
1. To visualize the presence of tissue kallikrein and bradykinin receptors on synovial
tissue samples.
2. To correlate tissue kallikrein activity in the synovial fluid and urine with measures
of disease activity in patients with rheumatoid arthritis.
3. To demonstrate evidence of kinin generation by demonstrating kinin activity in
synovial fluid and to correlate the kinin generating capacity with disease activity.
4. To demonstrate the presence of cytokines (IL-1 J3 and TNFa.) in the synovial fluid
and to correlate the cytokine levels with tissue kallikrein activity and kinin
generation.
5. To visualize the presence of tissue kallikrein, kinin moiety and bradykinin receptors
on circulating and synovial fluid neutrophils from patients with rheumatoid arthritis






2.1 SAMPLE COLLECTION 
2.1.1 Ethical approval and Patient/Guardian Consent 
Ethical permission for this study was obtained from the Ethics Committee of the Medical 
School, University of Natal Permission for the collection of post-mortem tissue samples 
was obtained from Professor M A Dad� Head - Department of Forensic Medicine, 
University of Natal. Informed consent was obtained from all subjects (Appendix 2.1 ). 
Control samples (blood) were obtained from age and sex matched healthy subjects. Control 
synovial tissue was collected at autopsy with the co-operation of the attending forensic 
surgeon. 
2.2 PATIENT SELECTION 
Patients attending the arthritis clinic with a diagnosis of rheumatoid arthritis were enrolled in 
the study. The following inclusion and exclusion criteria were applied. 
Inclusion criteria: 
Patients who fulfilled the revised 1987 American College of Rheumatology criteria for RA 
(Appendix 2.2), and who had active synovitis of at least one knee joint as judged by the 
presence of pain and a palpable warm effusion. 
Exclusion criteria: 
Intra-articular steroid injection within the last three months. 
Change in disease modifying antirheumatic drug therapy within the last three months. 
Oral steroids therapy in a dose of more than 10 mg daily. 
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2.3 ASSESSMENT OF DISEASE ACTIVITY 
At the time of entry into the study a full history and clinical assessment was undertaken. 
Demographic <lat� including age, sex, duration of disease and age at onset of disease were 
recorded. The presence or absence of extra-articular manifestations of RA as well as the 
duration and treatment regimen was noted. In addition, the following parameters were 
assessed to determine the degree of disease activity and or disability: 
• Duration of morning stiffness
• Swollen and tender joint counts
• Pain
• Physician's global assessment of disease activity
• Patient's global assessment of disease activity
• Local activity index
• Modified health assessment questionnaire (HAQ)
• Erythrocyte sedimentation rate
• Disease activity score
2.4 SAMPLE COLLECTION 
2.4.1 Blood 
Whole venous blood (10 ml) was obtained by venipuncture from the RA patients and 
volunteer subjects. Each sample was drawn into a vacutest tube containing 0.5 ml of 3.8 % 
(w/v) sodium citrate. For CRP measurements, blood was centrifuged at 4°C at 1000 g for 
IO min and the serum stored at -70° C. 
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2.4.2 Synovial fluid 
Synovial fluid (SF) was collected from the knee joint of the RA patients requiring 
therapeutic arthrocenthesis. Approximately 10- 15 ml of synovial fluid was aspirated 
using a sterile technique. All samples were centrifuged at 4°C, 1000 g for 10 min, within 3 
h of collection. For measurement of basal kinin and cytokine levels, the SF was mixed 
immediately with an equal volume of the cocktail that prevented both the formation and 
destruction of the peptides, and the kinin generating cocktail for measuring the capacity of 
the synovial fluid to form kinins (Appendix 2.3). Thereafter samples were aliquotted into 
eppendorf tubes and stored at -20°C until assayed. 
2.4.3 Synovial tissue 
Synovial tissue obtained from patients with acute synovitis attending the early Arthritis 
Clinic at St Vincent's Hospital, Dublin were kindly supplied by Dr D Kane and Professor 
B Bresnihan. Ethical approval was obtained from the local ethics committee. Synovial 
tissue was obtained from the knee by needle biopsy under local analgesia, thoroughly 
washed in cold sterile saline (physiological saline; 0.9 % NaCl, Sabax, Adcock Ingram, 
SA) at 4°C to remove excess blood, and thereafter suspended in 5 % formal saline (41 % 
formaldeyde/0.9 % NaCl, I: 8 v/v) for 48 h at room temperature (RT). 
Control synovial tissue was obtained at post-mortem, performed within 24 h of death, from 
individuals who had died because of trauma not involving the joints or sudden unexplained 
death. The corpses had been refrigerated immediately, and had been maintained at 4°C in the 
state morgue, prior to removal of tissue. Histologically undiagnosed, visually normal
synovial tissue was removed and washed in cold sterile normal saline (physiological saline; 
0.9 % NaCl, Sabax) at 4°C to remove excess blood, before being divided into approximately 
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1 cm3 wedges. This divided tissue was then suspended in 5 % fonnal saline ( 41 % 
fonnaldehyde/ 0.9 % Naci 1:8 v/v) for 48 h at RT. 
2.5 SAMPLE PROCESSING AND STORAGE 
2.5.1 Neutrophil isolation 
The SF and anticoagulated blood (3.8 % sodium citrate) samples were mixed with an equal 
volume of phosphate buffered saline (PBS: 150 mM sodium chloride, 200 mM sodium 
dihydrogen, pH 7.2). Neutrophils were isolated by careful layering of blood on 3.5 ml 
histopaque 1119/1077 (Sigma, UK), and centrifugation at 1000 g for 30 min at 20°C. 
Neutrophils were harvested with a pasteur pipette from the band formed on centrifugation, 
mixed with an equal volume of PBS, centrifuged and washed twice with PBS. The cell 
pellet was resuspended in PBS and spotted onto glass slides, air-dried overnight, fixed in 4 
% paraformaldehyde for 5 min at RT and stored at 4° C. 
2.5.2 Tissue processing: fixation and wax embedding for light microscopy 
Formalin-fixed synovial tissue samples were orientated and set in plastic tissue cassettes. The 
tissue samples were then processed by routine fixation and embedding techniques. Briefly, 
the tissue samples were dehydrated using absolute ethanol and xylene, and then embedded 
in paraffin wax under sterile conditions, in an automatic tissue processor (Shandon, UK). 
These wax-embedded samples were used for both light and fluorescent microscopy. The 
automated :fixation, dehydration, clearing, infiltration and embedding was carried out by the 
Department of Histopathology, University of Nat� SA (Appendix 2.4). The wax-embedded 
tissue samples were stored at RT for future microscopic and immunohistochemical analysis. 
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2.5.3 Histology 
2.5.3.1 Haematoxylin and Eosin (H&E) staining of wax-embedded tissue 
Ultra-thin (3 µm) sections of the wax-embedded tissue were cut on a rotary microtome (Jung 
RM2035, Leica, Germany) and floated onto poly-L-lysine (10 % in distilled water v/v; 
Sigma, St. Louis) coated glass slides (LASEC, SA). The slides were allowed to air-dry and 
then stained with haematoxylin and eosin (H&E) (Appendix 2.5) to confirm the 
presence/absence of disease in post-mortem synovium, to determine the histological diagnosis 
in arthroscopic samples, and to ensure that tissue processing was optimal. The following 
staining method was performed at RT. 
2.6 IMMUNOCYTOCHEMISTRY 
2.6.1 Neutrophils 
The SF and circulating neutrophils from RA patients and circulating neutrophils from control 
subjects (section 2.5.1) were immunostained to detect the presence or absence of tissue 
kallikrein, the kin.in moiety in the kininogen molecule and BI and B2 receptors. The specific 
antibody being studied was the primary antibody, and the secondary antibody was a 
conjugated antibody labelled with fluorescein isothiocyanate (F1TC, 525 nm emission; Sigma, 
St Louis) visualised by confocal microscopy. 
Primary and secondary anJibodies. 
The primary and secondary antibodies used for the immunolocalisation of the kin.in moiety in 
the kininogen molecule, TK, B 1 and B2 receptors are detailed below: 
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Kinin moiety: Primary antibody: monoclonal mouse antibradykinin antibody [ ( diluted 
TK: 
1 :200 with 0.01 M phosphate buffer (pH 7.2)/1 % 
BSA)] (donated by M. Webb, Sandoz, UK) 
Secondary antibody: FITC labelled anti-mouse IgG (Sigma, St Louis) 
[(diluted I :32 with 0.01 M phosphate buffer (pH 
7.2)/1 % BSA)] 
Primary antibody: polyclonal goat anti-human recombinant TK IgG 
[( diluted I: 1000 with 0.01 M phosphate buffer (pH 
7.2)/1 % BSA)] (Raidoo et al., I 996) 
Secondary antibody: FITC labelled sheep anti-goat IgG (Sigma, St 
Louis) [(diluted 1 :32 with 0.01 M phosphate buffer 
(pH 7.2)/1 % BSA)] 
B 1 receptors: Primary antibody: rabbit anti-human B 1 receptor IgG 
(donated byF. Hess) [(diluted l:200with 0.0I M 
phosphate buffer (pH 7.2)/1 % BSA)] 
Secondary antibody: FITC labelled anti-rabbit IgG (Sigma, St Louis). 
B2 receptors: Primary antibody: 
[(diluted 1:32 with 0.01 M phosphate buffer (pH 
7.2)/1 % BSA)] 
rabbit anti-human B2 receptor IgG ( donated by W. 
Mtiller-Esterl and K.Jarnagin) [(diluted l :200 with 
0.01 M phosphate buffer (pH 7.2)/1% BSA)] 
Secondary antibody: FITC labelled sheep anti rabbit IgG ((diluted 
1 :200 with 0.01 M phosphate buffer (pH 7.2)/1 % 
BSA)] 
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Anti -TK antibody: The polyclonal anti-TK antibody was raised in rabbit and goat host 
animals (Raidoo et al., 1996). Antibody generation was directed against recombinant tissue 
kallikrein (rTK) generated in E.coli transfected with human TK cDNA. Dr. Michael Kemme 
kindly supplied this rTK (Institute for Biochemistry, Technical University of Darmstadt, 
Darmstadt, Gennany). The lyophilised rTK protein was reconstituted in sterile 
physiological saline (0.9 % NaCl) at a concentration of 1 µg/ul, frozen in 50 ul aliquots, 
and maintained at -20°C. 
Anti B2 receptor antibodies: Of the eight polyclonal antibodies, fully characterised for 
specificity, raised to synthetic peptides of the amino-terminal and loop regions encoded by 
the rat B2 receptor cDNA, and based on the homogeneity between these regions with the 
human receptor, only four were shown to react strongly with human epithelial cells and 
neutrophils (Haaseman et al. 1994). Of these, a combination of antibodies directed to 
intracellular domain one (ID 1, LHK, 280), intracellular domain two (ID2, DRY, 277) and 
the fourth extracellular domain (ED4, DTL, 283) were used in this study as the match 
between the peptide sequences of these regions in the rat and human receptors was 80 %, 
I 00 % and 75 % respectively. Werner Miiller-Esterl and Kurt Jarnagin (Germany) kindly 
provided the anti-peptide antibodies and the corresponding peptides. 
Anti-Bl antibodies: A polyclonal antibody directed at the following C-terminus synthetic 
peptide of the kinin Bl receptor (Ile-Ser-Ser-His-Arg-Lys-Glu-Ile-Phe-Gln-Leu-Phe-Trp­
Arg-Asn) (I-S-S-S-H-R-K-E-I-F-Q-L-F-W-R-N) was raised in rabbit. It was kindly supplied 
by Fred Hess (Merck Research Laboratories, R80M-213, Rahway), USA having been fu]ly 
characterised for specificity. 
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Confocal microscopy 
Protocol for immunolabelling-neutrophils: Fe receptors in the neutrophil preparations and 
other non-specific sites were blocked with 1 % human IgG (Sigma, St. Louis) for 10 min at 
RT. The slides were then incubated with the specific goat or rabbit primary antibody 
diluted with 0.0lM phosphate buffer (pH 7.2)/ 1 % BSA, at 4°C, under humid conditions, for 
I 8 h. Finally, the bound primary-antibody-complex was conjugated to a FITC labelled 
secondary antibody for 30 min at RT. The labelled slides were then mounted onto glass 
coverslips with an aqueous mountant (90 % glycerol/IO % PBS, v/v), and the edges of the 
coverslips sealed with commercial fingernail varnish. All washing steps, after each 
incubation, were carried out in 0.01 M phosphate buffered saline (pH 7.2) (Sigma, St. 
Louis). Fluorescent emission was analysed using the Leica TD4 confocal microscopy 
system (Leica, Germany). Between incubations the sections were washed thoroughly by 
submerging the slides in PBS (0.01 M phosphate buffer (pH 7.2) containing 0,0027 M 
potassium chloride, 0. 137 M sodium chloride; Sigma, St. Louis] for 5 min. In the method 
controls the primary antibody was replaced with buffer. All dilutions were made up in 0.0 I 
M PBS/I % BSA (Appendix 2.6). The cell preparations were not allowed to dry out at any 
stage and labelled slides were stored in the dark. 
Image analysis 
Images were generated with immunolabelled neutrophils, using the Leitz DM IRB confocal 
microscope (Leica, Germany) attached to Diamond Pro 17 (Mitsubishi) and Diamond PRO 
21T (Mitsubishi) monitors. The pixel density for these 8 bit false colour images was 225 x 
225. The grey scale ranged from Oto 256, and was divided into 8 equal phases (POLI Look­
Up-Table), with each phase having a lower and upper threshold value on the grey scale (Fig 
2.1 ). Pixels with a grey scale value between 156 and 256 were considered to indicate specific 
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immunofluorescence intensity. 
Grey values for the Representative immuoolabelling 
8 grey scale phases intensity 
(8) 221 - 253
(7) 188 - 220 I-UGH 
(6) 155 -187
(5) 122 - 154
MEDnJM 
(4) 89-121
(3) 56 -88 LOW 
(2) 33 -55
(1) 0-32 ZERO 
Figure 2.1 Grey scales for immunolabelling intensity 
The amount of antigen was estimated by analysis of the computer-generated images. 
Using the Analysis 2.1 Pro system (Soft-Imaging Software GmbH, 1996, Germany) the 
regions of interest (ROI) in each image were encircled. Within these areas the number of 
pixels falling within each phase, as well as the area analysed, was established. This data, 
was exported to Microsoft Excel to give an indication of the relative intensity of 
immunolabelling in (n) number of cells, by calculating the mean value of the grey scale in 
the range 155 - 256, and expressing the values as pixels x 102/µm2• 
2.6.2 Protocol for immunolabelling : synovial tissue 
Three-micron sections of the wax-embedded tissue were adhered onto adhesive coated (poly­
L-lysine; Sigma, St. Louis) slides. Detection of immunoreactive TK, BI and B2 receptors 
was performed by standard histochemistry techniques using the relevant specific primary 
antibody (see section 2.6.1.), and the appropriate anti-species secondary antibody conjugated 
with peroxidase-antiperoxidase (PAP) immuno-enzyme complex. The final reaction involved 
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the hydrolysis of diaminobenzidine (DAB), the chromogen substrate, and the product 
precipitate ( dark brown) was visualised by light microscopy. 
The PAP method as modified by Figueroa et al. (1988) was used for the irnmunolabelling of 
TK and the kinin receptors. The three-micron thin sections of the wax-embedded tissue 
sections on glass slides were heated on a heating block (Clifton, UK) at 60°C (to melt the 
wax) for 5 min. The peroxidase-anti-peroxidase (PAP) method required dewaxing the 
tissue sections in analytical grade xylene (analytical grade; Saarchem, SA) twice for 10 min 
each, rehydration with graded ethanolic solutions (100 %, 90 %, 70 % and 50 % in distilled 
water, v/v) and distilled water as the final rehydrant. When the tissue was approximately 
50 % rehydrated, it was immersed in absolute methanol (analytical grade, Saarchem, SA) 
for 20 min to quench endogenous tissue-peroxidase activity. Following rehydration, the 
tissue was boiled in a metal-salt solution, 0.lM sodium citrate, pH 6.0 (analytical grade, 
Saarchem, SA) at 80°C for 10 min (antigen retrieval) (Shi et al. 1999) in a conventional 
microwave oven (R-4A52; Sharp Corp., Japan). The tissue in the boiling solution was 
allowed to cool down to RT (approximately 20 - 25 min). The tissue-sections were then 
further blocked with 10 % H202 (analytical grade, Saarchem, SA)/90 % absolute methanol 
(v/v) for 20 min to quench endogenous peroxidases. Incubation with the primary antibody 
was performed at 4°C for 18 h in a humidified chamber. Then, the tissue was treated with a 
peroxidase-anti-peroxidase (PAP) streptavidin-biotin conjugating system (LSAB K0690; 
Dako, USA) for 20 min. each. This entailed incubating the tissue with a universal (goat, 
rabbit, mouse) IgG-biotin link for 20 min at RT in a humidified chamber. Next, the tissue 
sections were covered with a strepavidin-peroxidase conjugate for 20 min at RT in a 
humidified chamber. The labelled antibody bound to the PAP immuno-enzyrne complex 
was visualised by incubating the sections, in the dark, for 5 to 7 min with liquid 
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diarninobenzidine (DAB) precipitant (DAB K3465; Dako, USA). The sections were 
counterstained with Mayers Haematoxylin (Sigma, St. Louis,) for 3 min and intensified under 
running tap water for 5 min. Sections were then dehydrated by a reversal of the dehydration 
process from distilled water, through the increasingly concentrated ethanolic solutions into 
xylene, and finally mounted with a permanent medium (Entellen, Merck) (Appendix 2. 7). 
Results were viewed by conventional light microscopy under a Nikon photo-microscope 
(Nikon Optiphot; Nikon, Japan). All incubations were carried out in a humidifying chamber. 
Between incubations the sections were washed thoroughly by submerging the slides in PBS 
[0.01 M phosphate buffer (pH 7.2) containing 0,0027 M potassium chloride, 0.137 M sodium 
chloride; Sigma, St. Louis] for 5 min. Tissue sections were not allowed to dry out at any 
time during the labelling process. The labelled slides were stored in the dark. 
Positive tissue and method controls/or immunocytochemistry (ICC) 
As the kinin moiety within the kininogen molecule has been previously localised on control 
circulating neutrophils, these cells were used for the positive and method controls. 
For the TK studies control human salivary gland tissue was used a positive control tissue to 
demonstrate localisation, upon previous evidence of abundant labelling for TK in such 
tissue (Schachter et al. 1980). Samples of fresh control human salivary gland were collected 
at post-mortem, fixed in 5 % formalin and embedded in paraffin wax. During each 
immunolabelling run, this tissue, demonstrating the presence of TK in the ducts of the 
human salivary gland, served as an appropriate method control for the labelling procedure. 
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Sections of fresh control human kidney collected at post-mortem, served as positive 
controls for B2 receptors. During each labelling run, this appropriate positive control 
tissue demonstrated the presence of B2 receptors in tubules and connecting ducts (Naidoo 
et al. 1996a). Human spinal cord was used as positive control tissue for Bl  receptor 
immunolocalisation. During each labelling run, the presence of immunoreactive BI 
receptors was demonstrated in the neurons in the substantia gelatinosa of the spinal cord 
(Raidoo and Bhoola, 1997). All labelled slides were stored in the dark to minimise 
bleaching of fluorescence and fading of precipitant immunolabels. 
Negative method controls for ICC 
The absence of positive specific immuno-labelling following pre-adsorption of the primary 
antibody with an excess of the specific antigen demonstrated the specificity of the antibody 
utilised. The primary antibody was diluted I :500 with 0.01 M phosphate buffer (pH 7.2) 
and added to a 2 mg/ml stock solution of antigen to yield a final concentration of 1 mg/ml 
antigen. This antibody-antigen conjugate was incubated overnight at 4°C to allow
maxnnum formation of antigen-antibody complexes. Following removal of the 
preadsorbed antigen by centrifugation (2200 x g, 4°C, Heraeus Biofuge 1.3 R, Germany)
the supernatant was used for the immunolabelling experiments instead of the primary 
antibody. 
For the immunolabelling of controls for the synovial tissue the primary antibody was 
replaced with goat non-immune serum diluted in 0.0 I M phosphate buffer (pH 7.2)/1 % 
BSA. In the method controls the primary antibody was replaced with buffer. All dilutions 
made up in 0.01 M PBS/I% BSA (pH 7.2). 
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2.7 MEASUREMENT OF TISSUE KALLIKREIN IN SYNOVIAL FLUID 
Assays for tissue kallikrein 
In the synovial fluid samples, the presence of enzymatically active TK was determined by an 
amidolytic assay, while the enzyme linked imrnunosorbant assay (ELISA) measured immuno­
reactive TK. Commercially purified human urinary tissue kallikrein (HUI(, Calbiochem, 
USA) was used to validate both the amidolytic assay and the ELISA. These results were 
used to calculate both the intra- and inter-assay coefficients of variation for both assays. 
Synovial fluid 
Before TK measurement of synovial fluid was possible, it was necessary to reduce the 
viscosity of the fluid by incubation with hyaluronidase. Next, a,2 macroglobulin and 
rheumatoid factor were removed. 
Hyaluronidase digestion: For measurement of basal kinin levels, frozen synovial fluid (to 
which both kinin generating and kininase cocktails had been added at the time of aspiration) 
was thawed and digested with hyaluronidase (Sigma, 22.5 U per ml synovial fluid) at 37°C 
for 30 min. The treated synovial fluid was centrifuged (7,000 g, 4°C, 10 min), and the kinins 
in the supernatant extracted with acid-alcohol (section 2.8. l ). For the kinin generation 
studies, frozen synovial fluid (collected without the addition of i:nlubitors) was thawed and 
centrifuged (7,000 g, 4°C, 10 min). The supernatant was incubated with an equal volume of 
kininase inhibitors (10 µm phosphoramidon, 10 µm captopril, 6 mm 1,10 µM 
phenoanthroline and 60 mm EDTA in phosphate-buffered saline, pH 8) and hyaluronidase 
(22.5 U/ml synovial fluid), at 37°C. 
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Removal of a2 macroglobulin: a.2 macro globulin ( a.2 M) was removed from SF by 
adsorption with anti-a.2 macroglobulin lgG (Dakopatts, Dako, UK) coupled to CnBr 
Sepharose. SF was incubated with an equal volume of anti a.2-M Sepharose and 0.2 vol of 
0.1 M Tris/0.5M NaCl pH 8.5 for 30 min at RT. The mixture was centrifuged and 
supernatant removed. 
Removal of rheumatoid factor: SF was incubated with 0.3 vol of heat aggregated rabbit IgG 
coupled to CnBr Sepharose (Sigma, UK) and 0.2 of vol 0.1 M Tris/0.5 M NaCl pH 8.5 for 30 
min at RT. 
2.7.1 Eozymic assay (amidolytic micro-assay) 
This end-point chromogenic assay was used to measure functionally active TK in the 
synovial fluid samples using a rnicrotitre plate. The amount of functionally active TK was 
measured by assessing the arnidolytic activity of the enzyme TK on a selective, synthetic 
substrate, H-D-Val-Leu-Arg-pNA (S2266; Kabivitrwn, Sweden) (Amundsen et al. 1979) 
in the presence of SBTI (Sigma, St. Louis), and ethylenediarninetetraacetic acid (EDTA; 
Sigma, St.Louis) as modified by Selwyn et al. (1989), and further developed as an end­
point assay in a rnicrotitre plate by Rahman et al. (l 994). In this amidase assay, the 
enzyrnic activity of TK on H-D-Val-LeuArg-pNA releases para-nitroaniline (pNA), which 
has a peak absorbance at 405 nm. A standard curve was set up using commercially available 
purified human urinary kallikrein, HUK (Calbiochem, USA) from which the concentration of 
TK in the sample extracts were calculated using Biorad Microplate Manager software 
(Biorad, UK). Following the measurement of total protein in an aliquot of the extract, using 
the Bradford Protein Determination method (Bradford 1976) (Appendix 2.8), the enzyrnic 
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activity of TK was expressed as ng TK/ug protein. Control urine was included in each assay 
run to determine inter-assay coefficients of variation. During each assay, 2 sets of plates were 
processed simultaneously, one being the measure of basal activity of TK at zero time, and the 
other measuring the enzymic activity of TK after a 3 h substrate incubation. The method was 
as follows. 
Protocol: For the standard curve 600 ul of 400 ng/ml HUK standard, stored at -20°C as 
1200 ng/ml aliquots, was prepared in arnidase buffer (0.2 M Tris-Cl, pH 8.2). 300 µl of this 
standard was serially diluted to 6.25 ng/ml in arnidase buffer. 50 µl (in triplicate) of each 
standard dilution was added to two 96-well tissue culture plates (Corning Cell Wells™, 
Coming, USA) designated blank and substrate plates. For the control curve, pooled urine 
was serially diluted down to 1/64 in amidase buffer (0.2 M Tris-Cl, pH 8.2) and 50 µl of 
each dilution (in triplicate) was added to both plates. 50 µl of each sample was loaded (in 
triplicate) onto each plate. Next, 50 µI of assay buffer (60 mg/ml SBTI, 75 mg/ml EDTA in 
amidase buffer) was added to each well in both plates. To the blank plate 50 µl of dH20 was 
added to each well, and the absorbance of this plate read at 405 run on a Biorad Microplate 
Reader 3550 at RT. To the substrate plate 50 µI of substrate S2266 (1.5 mM in deionised 
distilled water, as per manufacturer's instructions) was added to each well, and the plate 
incubated for 3 h at 37°C. The absorbance of this substrate plate was then read at 405 nm 
on a Biorad Microplate Reader 3550 at RT (Appendix 2.9). To determine the arnidolytic 
activity of TK, the blank absorbance values were subtracted from the standards, controls and 
samples, on each plate. Then, the values of each standard, control and sample from the blank
plate (zero activity) were subtracted from the substrate plate (enzymic activity). The net 
enzymic activity of the HUK standards was used to set up a plot of absorbance versus HUK 
concentration using Biorad Microplate Manager software (Biorad, UK). 
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2.7.2 Enzyme linked immunosorbant assay (ELISA). 
An aliquot of the synovial fluid samples was used to measure the total TK by a basic 
sandwich ELISA using goat anti-human rTK IgG and rabbit anti-human rTK IgG. The anti­
species antibody, anti-rabbit IgG (Sigma, St. Louis), conjugated to the enzyme alkaline 
phosphatase, interacts with the rabbit anti-human rTK IgG. The conjugated alkaline 
phosphatase then cleaves the chromogenic substrate disodium p-nitrophenyl phosphate 
(pNPP) to produce a yellow colour that has peak absorbance at 405 nm 
Protocol: A 96 well, flat-bottomed polystyrene ELISA plate (Corning, USA) was 
loaded 100 µI/well with primary antibody, goat anti-human rTK lgG (30 ng/ml goat anti­
human rTK lgG in coating buffer) and incubated at 4°C overnight. The wells were then 
washed with 200 µl 0.01 M PBS/0.5 %Tween three times for three min each at RT. The 
wells were incubated with 200 ul 5 % milk blocker twice for 30 min each at RT, with a 0.01 
M PBS/0.5 %Tween wash in-between. Next, a 1200 ng/ ml aliquot of HUK (Calbiochem, 
USA), stored at -20°C, was thawed at 4°C and then serially diluted from 40 ng/ml to 0.625 
ng/ ml in 0.01 M PBS (pH 7.2), and 100 µI of each standard (in triplicate) added to the 
wells. Blank wells (in triplicate) were filled with l 00 µI of 0.0 lM PBS (pH 7.2) and control 
wells were filled (in triplicate) with 100 µI/well pool urine (see section 2.4.4.5) diluted 1/8 
to 1/512 in 0.01 M PBS (pH 7.2). In addition, 100 µI of sample (in triplicate) was loaded 
onto the plate. The plate was then incubated at 37°C for 1 h in a shaking water bath 
(Tecator, UK). The wells were then washed with 200 µl 0.01 M PBS/0.5% Tween three 
times for three min each at RT. Next, 100 µI of 25 ng/ml secondary antibody rabbit anti­
human rTK IgG (in 0.01 M PBS, pH 7.2) was loaded into every well and the plate incubated 
at 37°C for 1 h in a shaking water bath (Tecator, UK). The wells were then washed with 200 
µl 0.01 M PBS/0.5 % Tween three times for three min each at RT. Next, all the wells were 
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loaded with 1/250 anti-rabbit phosphate conjugate (diluted in 0.01 M PBS, pH 7.2) and 
incubated for 1 h at 37° C in a shaking water bath. The plate was washed with 200 µI 0.01 
M PBS/0.5 % Tween for 3 min each at RT. Finally, the wells were all loaded with 100 µI of 
a 1 mg/ml chromogenic pNPP substrate (Sigma, St. Louis, 1 tablet in 5 ml of MgCh/10 % 
diethanolamine, pH 9.6 substrate buffer) and the colour was allowed to develop until the 
highest absorbances peaked at 1 to 1.5 absorbance units (Appendix 2.10). Readings were 
taken at RT with a Biorad Microplate Reader 3550 (Biorad, UK) using Biorad Microplate 
Manager software. The mean blank absorbance was subtracted from the standards, controls 
and samples, and a curve of absorbance versus HUK concentration was plotted, values 
expressed as ng/ml. 
2.8 KININ GENERATION ASSAYS 
The capacity to form kinins from the kininogen content of SF was determined. Initially, 
endogenous TK was activated by incubating the SF samples with an equal volume of the 
generating cocktail for 60 min at 3 7° C, in the presence of kininase inhibitors to limit the 
degradation of the generated kinins. The kinins generated were thereafter extracted with 
acid-alcohol and measured by a competitive ELISA. 
Before kinin measurement of synovial fluid was possible, it was necessary to reduce the 
viscosity of the fluid by incubation with hyaluronidase. Next, a2 macro globulin and 
rheumatoid factor were removed (section 2.7). Thereafter, kinins were extracted by the 
acid-alcohol extraction procedure, modified from that of Albano et al. (1976), and measured 
by a competitive ELISA. 
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Acid-alcohol extraction The synovial fluid was mixed with an equal volume of 0.003 % 
HCI in absolute ethanol, vortexed and then incubated at - 20°C for 90 min. This was then 
centrifuged (7,000 g, 4°C, 10 min) and the supernatant decanted. The precipitate was 
washed with one volume of acid alcohol (diluted 1:1 in distilled water) and after 
recentrifugation, the corresponding supernatants pooled, evaporated to dryness at 55°C and 
the dry residue was reconstituted in the required volume of assay buffer, centrifuged and 
the clear supernatant used for measurement. 
Kinin ELISA 
To optimise binding of bradykinin (BK) to the plate it was necessary to first conjugate BK 
to a large protein. Cytochrome C was used for this purpose. 
Conjugation of bradykinin to cytochrome C: Bradykinin (Sigma, UK) was conjugated to 
cytochrome C via a linker molecule, N-succinimidyl 3-(2-pyridyldithio) propionate 
(SPDP) (Sigma, UK), according to a method modified from that of Carlsson et al. (1978). 
SPDP (13 µM in 0.1 M phosphate buffer pH 8.6, containing 20 % ethanol) was mixed with 
an equal volume of cytochrome C (type IIS from Saccharomyces cerevisiae, Sigma, UK, 
IO µM in phosphate buffer pH 8.6) and incubated at 22°C for 60 min. The mixture was 
then filtered through ultra-free filters, (Millipore, UK) with 10,000 nominal molecular 
weight cut off, to remove any unconjugated SPDP. The cytochrome C-SPDP conjugate 
was resuspended in the two volumes of 0.3 M phosphate buffer pH 6. One volume of 
bradykinin (1 rnM) was then added and this was incubated at 22°C for 60 min. Before use 
in the ELISA, each new batch of conjugate was tested to determine the optimum 
concentration for coating of the ELISA plate. 
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ELISA procedure: The acid-alcohol extracts were reconstituted to the original volume of 
the synovial fluid in PBS, and kinin concentration measured by an ELISA method as 
follows. Nunc Immulon Maxisorp (Nunc, UK) microtitre plates were coated overnight at 
4 °C with 100 µI/well of 3 to 4 µg/rnl bradykinin-cytochrome C conjugate in sodium 
carbonate buffer, pH 9.6. Also overnight at 4°C, the sample or standard was preincubated 
with an equal volume of anti-rabbit anti-bradykinin monoclonal antibody (kindly donated 
by M. Webb, Sandoz, London) (Phillips and Webb, 1989) at 9.4 µg/rnl. The next day, 
empty sites on the plate were blocked with I % bovine serum albumin (BSA< Roche, 
Germany) for 30 min at RT. The preincubated samples or standards (100 µI/well) were 
then incubated on the plates for 3 h at 37°C. In the next step, alkaline phosphatase labelled 
anti-mouse lgG (Sigma, UK) was added (diluted 1:250 in 0.01 M PBS, pH 7.2)) and then 
incubated for 2 h at 37°C. Finally, the substrate, disodium p-nitrophenyl substrate (Sigma, 
UK) was added, incubated at RT for approximately one hour until sufficient colour 
developed (i.e. maximum absorbance at 405 nm). Incubations were carried out in a humid 
box. Between each step the wells were washed three times for 3 min with PBS containing 
0.05 % Tween (Sigma, UK). All dilutions were carried out in PBS containing 0. I % BSA, 
unless stated otherwise. Nonspecific binding to the plate was determined for each plate by 
incubation of anti-bradykinin antibody (preincubated with buffer only) in wells that had 
been coated with coating buffer containing no bradykinin conjugate, and subtracted from 
all absorbance values. The absorbance values obtained for the standard BK was used to 
plot a standard curve of absorbance versus log concentration from which the basal and 
generated kinin contents of the SF samples were determined (Bio Rad microplate manager 
software). The basal and generated kinin contents of control urine were also measured 
during each run to determine the inter- and intra-assay coefficients of variation. 
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An important aspect of this assay is the use of two kininase/protease inhibitor cocktails. 
Firstly, aliquots of all samples and control urine were stored in inhibitor cocktail. This 
contained proteins that inhibited the enzymic activities of TK, PK and other trypsin-like 
proteases ((IO µM aprotonin and 10 µM SBTI), thereby preventing the release of kinin 
from endogenous k.ininogen. It also contained 10 µM captopril, an inhibitor of the KIi 
family of kininases, and phosphoramidon, another kininase inhibitor, to ensure that the 
basal kinins present in the samples were not destroyed. 
A second aliquot of each sample and control urine was stored in kinin generating cocktail, 
which was similar to the inhibitor cocktail except that it lacked aprotonin and SBTI. The 
absence of these protease inhibitors ensured that kinin could be released from endogenous 
kininogen and once formed, was protected by inhibitors of the peptidases. The detailed 
stepwise method for the competitive ELISA is tabulated in appendix 2.11. 
2.9 CYTOKINE MEASUREMENTS 
An aliquot of the synovial fluid samples was used to measure interleukin- I J3 (IL-I f3) and 
tumour necrosis factor a (
T
NF) levels by a quantitative sandwich enzyme immunoassay 
technique using a commercial ELISA kit (Quantikine HS, R&D Systems). 
Tumour necrosis factor a: A monoclonal antibody specific for TNF a is precoated onto a 
microplate. Standards and samples are pipetted into the wells and any TNFa present is 
bound by the immobilised antibody. Thereafter, an enzyme-I.inked (alkaline phosphatase) 
polyclonal antibody specific for TNFa is added. Following a wash to remove any 
unbound antibody-enzyme reagent, a substrate solution is added to the wells. After an 
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incubation period, an amplifier solution is added and colour develops in proportion to the 
amount ofTNFa. bound in the initial step. 
Protocol: A 96 well, flat bottomed polystyrene ELISA plate had been precoated with 
a murine monoclonal antibody against TNFa.. 50 µl of assay diluent HD 1-11 was added to 
each well. The standard solution was reconstituted to produce a stock solution of 32 pg/ml 
and thereafter serially diluted from 32 pg/ml to 0.5 pg/ml. 200 µl of standard or sample 
was added to the wells. The plate was then incubated for 14-20 h at 2°-8° C. The wells 
were then washed using an automated AWi Anthos washer. Next, 200 µI of TNFa. 
conjugate was added to each well. The plate was then incubated for 3 h at RT. The wells 
were washed as before. Next, 50 µl of substrate solution (NADPH) was added to each 
well. The plate was covered and incubated for 3 h at RT. 50 µl of amplifier solution was 
added to each well. The plate was covered and incubated for 30 min at RT. Next, 50 µI of 
stop solution was added to each well. The optical density of each well was determined 
within 30 min using rnicroplate reader set at 490 run with correction to 650 run (Appendix 
2. I 2). A standard curve was plotted using the absorbance of the standards versus the
concentration of the standards. 
Interleukin-I /3: A monoclonal antibody specific for IL- Ip is precoated onto a microplate. 
Standards and samples are pipetted into the wells and any IL- I P present is bound by the 
immobilised antibody. Thereafter, an enzyme-linked (alkaline phosphatase) polyclonal 
antibody specific for IL-Ip is added. Following a wash to remove any unbound antibody­
enzyme reagent, a substrate solution is added to the wells. After an incubation period, an 
amplifier solution is added and colour develops in proportion to the amount of IL-1 P 
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bound in the initial step. 
Protocol: A 96 well, flat bottomed polystyrene ELISA plate had been precoated with 
a murine monoclonal antibody against IL-1 p. 100 µl of assay diluent HD 1-11 was added 
to each well. The standard solution was reconstituted to produce a stock solution of 8 
pg/ml and thereafter serially diluted from 8 pg/ml to 0.125 pg/ml. 150 µI of standard or 
sample was added to the wells. The plate was then incubated for 14-20 h at RT. The wells 
were then washed using an automated A WI Anthos washer. Next, 200 µl of IL-1 p 
conjugate was added to each well. The plate was then incubated for 3 h at RT. The wells 
were washed as before. Next, 50 µI of substrate solution (NADPH) was added to each 
well. The plate was covered and incubated for 45 min at RT. 50 µI of amplifier solution 
was added to each well. The plate was covered and incubated for 45 min at RT. Next, 50 
µI of stop solution was added to each well. The optical density of each well was 
determined within 30 min using rnicroplate reader set at 490 nm with correction to 650 nm 
(Appendix 2.13). 
2.10 STATISTICAL ANALYSIS 
Results are presented as the mean and standard deviation of mean. A two-tailed, paired 
Student's t-test, unpaired for unequal variance, the Kruskal Wallis and one way analysis of 
variance (ANOVA) tests calculated significance. Levels of significance were determined 
using a 95% confidence interval; a p-value < 0.05 was taken to be statistically significant. 
All correlations were performed using the Pearson's correlation co-efficient. 
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Appendix 2.1 Patient information/consent form 
As you know, you are suffering from arthritis, which has resulted in the accumulation of 
fluid in your knee. To allow us to understand why patients develop arthritis we would like 
to take blood, urine and fluid from your knee joint for testing in the laboratory. Blood will 
be taken from a vein in your arm and the fluid will be aspirated from your knee. You may 
feel slight pain. In addition you may be given an injection in of cortisone plus local 
anaesthetic into your knee to reduce the inflammation and pain. After the injection we will 
like to remove fluid again to determine the effect of the injection. You are free to refuse to 
any of these procedures and your refusal will not alter your future treatment. 
Njengoba wazi, unesifo samathambo esesibangela ukwanda kometshezi edolweni. 
Ekukusizeni ukuba siqondisise ukuthi kwenziwa yini iziguli ziphathwe isifo samthambo, 
sithanda ukutha igazi, umchamo kanye noketshei olusedolweni kuhlolisiswe endlini 
yokucwaninga. lgazi lizothathwa emthanjeni wegalo, bese kuthi uketshezi lukhitshwe 
edolweni. Kungenzeka kube khona ubuhlungwana. Ngaphezu kwaloku uyonikezwa 
umjovu we cortisone kanye nondikindiki edolweni kwenzelwe ukuhlisa ukuvuvuka kanye 
nobuhlungu. Emuveni komujovo siyophinda sikhiphe uketshezi edolweni kona sizbona 
ukusebenza komjovo. Unenkululeko yokwenqaba ukuba kwenziwe lolucwaningo futhi 
ukwenqaba kwakho ngeke kuthikameze inqubo yokulashwa kwakho. 
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2. Arthritis of 3 or more joints
3. Arthritis of hand joints
4. Symmetric arthritis
5. Rheumatoid nodules
6. Serum rheumatoid factor
7. Radiographic changes
Definition 
Morning stiffness in and around the joints, 
lasting at least I hour before maximal 
improvement 
At least 3 joint areas simultaneously have had 
soft tissue swelling or fluid (not bony 
overgrowth alone) observed by a physician. 
The 14 possible areas are right or left PIP, 
MCP, wrist, elbow knee, ankle, and MTP joints 
At least 1 area swollen (as defined above) in a 
wrist, MCP, or PIP joints 
Simultaneous involvement of the same joint 
areas (as defined in (2) on both sides of the 
body (bilateral involvement of PIPs, MCPs, or 
MTPs is acceptable without absolute 
symmetry) 
Subcutaneous nodules, over bony 
prominences, or extensor surfaces, or in 
juxtaartieular regions, observed by a 
physician 
Demonstration of abnormal amounts of serum 
rheumatoid factor by any method for which 
the result has been positive in <5% of normal 
control subjects 
Radiographic changes typical ofrheumatoid 
arthritis on postero-anterior hand and wrist 
radiographs, which must include erosions or 
unequivocal bony decalcification localized in 
or most marked adjacent to the involved joints 
(osteoarthritis changes alone do not qualify) 
*For classification purposes a patient shall be said to have rheumatoid arthritis if
he/she has satisfied at least 4 of these 7 criteria. Criteria 1 through 4 must have
been present for at least 6 weeks
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Appendix 2.3 Composition of inhibitor and buffer solutions 
a) Measurement of kinin generation: inhibitor solutions
10 µM phosphoramidon, 10 µM captopril, 6 mM I, 10 µM phenanthroline (Sigma,
UK) and 60 mM EDT A in phosphate-buffered saline, pH 8 
b) Measurement of basal kin in and cytokine levels: inhibitor solutions:
40 mg/ml aprotinin, 4 mg/ml SBTI, IO µM phosphoramidon, IO µM captopril, 6
mMl, IO µM phenanthroline (all Sigma, UK) and 60 mM EDTA in phosphate­
buffered saline, pH 8
c) Measurement of tissue kal/ikrein
200 µI bacitracin/SBTI
d) ELISA coating buffer: Na2HCO3/NaHCO3 pH 9.6
1.59 g Na2HCO3/2.93 g NaHCO3 per L dH2O
e) Amidase buffer: 0.2 M Tris- HCI pH 8.2
24.22 g Trizina base per L dH2O
f) Assay buffer
300 mg SBTI, 375 mg EDT A/ml amidase buffer
g) Substrate buffer: 5 mM MgCh/10 % diethanolamine pH 9.6
0.1016 g MgCl/10 ml Diethanolamine per I dH2O
h) 0.1 M Sodium citrate pH 6.0
29.4 g Tri-sodium citrate/I dH2O
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Appendix 2.4 Fixation, Dehydration and Embedding schedule for light 
microscopy 
STEP PROCEDURE TEMP TIME 
1. Fixation - 5 % formal saline 24°C 1 h 
2. Fixation - 5 % formal saline 24°c 1 h 
3. Dehydration - absolute ethanol 24
°
C 1 h 
4. Dehydration - absolute ethanol 24
°C I h 
5. Dehydration - absolute ethanol 24
°C I h 
6. Dehydration - absolute ethanol 3s
0c 1 h 
7. Dehydration - absolute ethanol 3s
0c I h 
8. Dehydration - absolute ethanol 3s
0
c 1 h 
9. Dehydration - absolute ethanol 3s
0c 1 h 
10. Clearing - xylene 35
°c I h 
11. Clearing - xylene 35
°c 1 h 
12. Vacuum infiltration 1 - paraffin wax 60
°C 1 h 
13. Vacuum infiltration 2 - paraffin wax 60
°C 1 h 
14. Embedding - paraffin wax 20
°c 20min 
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Appendix 2.5 H&E Staining of wax-embedded tissue 
STEP PROCEDURE 
1. Dewax- Xylene
2. Rehydrate -Absolute ethanol
3. Rehydrate - 90 % ethano I
4. Rehydrate- 70 % ethanol
5. Rehydrate - water
6. Haematoxylin- immerse slides in Mayer's Haemotoxylin (Sigma, St.
Louis)
7. Blue - rinse slides in running tap water
8. Eosin- immerse slides in Eosin (Sigma, St. Louis)
9. Rinse - by quickly immersing slides in 95 % ethanol
10. Dehydrate - Absolute ethanol
11. Dehydrate - Xylene














Appendix 2.6 Immunocytochemical localisation by immuno-fluorescence 
STEP PROCEDURE TEMP TIME 
I. Dewax - Xylene (analytical grade; Saarchem, SA) RT 2x10min 
2. Rehydrate - 100 % EtOH ( analytical grade; Saarchem, SA) RT 2x5min 
3. Rehydrate-90 % EtOH ( in distilled water, v/v) RT 2x4 min 
4. Rehydrate - 70 % EtOH ( in distilled water, v/v) RT l x3 min
5. Rehydrate - distilled water RT I x5min 
6. Antigen retrieval - 0.1 M Sodium Citrate (pH 6.0) in Boil at 3 min high 
microwave. Then allow to cool to RT for± 20min 80
°C & 5 min low 
7. Wash- 0.01 M PBS pH 7.2 RT 
8. Block non-specific binding sites - 1 % Human IgG RT 2 min 
9. Wash - 0.01 M PBS (pH 7.2) RT 5 min 
10. Primary antibody diluted with 0.01 M Phosphate buffer 4°c 18 h 
(pH 7.2) [0.1 M PBS/I %BSA]
11. Wash - 0.01 M PBS (pH 7.2) RT 5 min 
12. F1TC conjugated secondary antibody- (1/32 dilution in RT 30 min 
0.01 M PBS/I %BSA)
13. Wash - 0.01 M PBS (pH 7.2) RT 5 min 
14. Mount - I 0% PBS/90 % glycerol
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Appendix 2. 7 Immunocytochemical localisation by immunoprecipitation 
STEP PROCEDURE TEMP TIME 
1. Dewax -Xylene (analytical grade; Saarchem, SA) RT 2x 10 min 
2. Rehydrate-100 % EtOH (analytical grade; Saarchem, SA) RT 2x5 min 
3. Quench endogenous peroxidase- 100 % MeOH (analytical RT lx20 min 
grade; Saarchem, SA)
4. Rehydrate - 90 % EtOH (in distilled water, v/v; analytical RT 2x4 min 
grade; Saarchem, SA)
5. Rehydrate - 70 % EtOH (in distilled water, v/v analytical RT lx3 min 
grade; Saarchem, SA)
6 .  Rehydrate - distilled water RT lx5 min 
7. Antigen retrieval - 0. 1 M Sodium-Citrate (pH 6 .0) in Boil at 3 min high & 
microwave . Then allow to cool to RT for± 20 min 80
°C 5 min low 
8 .  Wash - 0.01 M PBS (pH 7.2) RT 
9. Block endogenous peroxidase - IO % H2O2/ 90% MeOH RT 20min 
10. Wash - 0.01 M PBS (pH 7 .2) RT 5 min 
1 1. Block non-specific binding sites-1 % non-immune goat 20min 
serum in buffered physiological saline
12 . Wash - 0.01 M PBS (pH 7.2) RT 5 min 
13 . Primary antibody diluted with 0.01 M Phosphate buffer 4°c 18 h 
(pH 7.2) [0. 1 M PBS/I %BSA]
14. Wash - 0.01 M PBS (pH 7.2) RT 5 min 
15. Incubate with anti-goat IgG Biotin link (Dako K0690) RT 20min 
1 6. Wash - 0.0IM PBS (pH 7 .2) RT 
17. Secondary antibody- Strepavidin-peroxidase (Dako K0690) RT 20min 
18. Wash - 0.01M PBS (pH 7.2) RT 5 min 
19. Chromogen - liquid DAB (Dako, K3465) RT 2-5 min
20. Counterstain - Mayers' Heamatoxylin (Sigma, St. Louis) RT 3-5 min 
2 1. Intensify- Wash in tap H2O 5 min 
22 . Dehydrate- 70 % EtOH (in distilled water, v/v) RT 1 min 
23. Dehydrate - 90 % EtOH (in distilled water, v/v) RT l min
24. Dehydrate-100 % EtOH (analytical grade; Saarchem, SA) RT 1 min 
25. Dehydrate -Xylene (analytical grade; Saarchem, SA) RT I min 
2 6 .  Mount - Entellen (Merck)
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Appendix 2.8 Measurement of total protein (Bradford 1976) 
STEP PROCEDURE TEMP. TIME 
l. Protein standard - 100 ml of I mg/ml Bovine Serum Albumin RT 
(BSA, Fraction V, Boehringer) was prepared and stored in 1 mJ
aliquots at -20C. A single 1 ml aliquot ofthis standard was
serially diluted with distilled water from 1000 µg/ml to 16 µg/ml.
30 µl of each dilution was added to a microassay plate, in
triplicate.
2. Blank- 30 µl distilled water was added to 3 wells of the plate RT 
3. Samples - were added in triplicate to the plate RT 
4. Biorad Protein Assay Reagent (Biorad, UK) - was diluted l /5 in RT 
distilled water and 300 µl was added to each well of the plate
5. Read absorbance at 595 nm. RT 
6. Calculation- subtract the absorbance of the blanks from the RT 
absorbance of the standards and samples.
Plot absorbance versus concentration of BSA standards.
Read protein concentration of samples from this graph.
7. TK enzymic activity is expressed as ng TK/µg protein RT 
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Appendix 2.9 Enzymic / amidolytic micro-assay for Tissue Kallikrein 
STEP PROCEDURE TEMP. TIME 
1. HUK standards - prepare 600 ul of 400 ng/ml HUK from a 1200 RT 
ng/ml aliquot stored at - 20°C using amidase buffer (0.2 M Tris-
Cl (pH 8.2)]. Use 300 µI ofthis and double diluted down to 6.25
ng/ml in amidase buffer . Add 50 ul of each dilution in triplicate
to two 96-well tissue culture plates (Coming Cell Wells™
25860, Coming, New York)
2. Blank- add 50 µl amidase buffer (triplicate) to the two microtitre RT 
plates
3. Controls -add 50 µl control urine, from section 2.4.4.5 serially RT 
diluted to 1 :64 (with amidase buffer), in triplicate to both plates
4. Samples - add 50 µl synovial fluid samples in triplicate to the RT 
remaining wells
5. Assay buf er- add 50 µI assay buffer ( 60 mg/ml SBTI, 75 mg/ml RT 
EDTA in arnidase buffer) to each well of both plates
6. Incubate 37°C 30min 
7. Zero activity-add 50 µl distilled water to each of the wells of RT 
one plate and read absorbance at 405 nm on the Biorad
Microplate Reader 3550.
8. Enzymic activity- add 50 µI S-2266 (1.5 mM in deionised 37°C 3h 
distilled water) to each well of the second plate and incubate
9. Read absorbance at 405 nm after 3 h RT 
10. Calculation - for each plate subtract the absorbance of the blanks
from the absorbance of the standards , controls and samples. Then
subtract the z.ero activity absorbance from the enzymic activity
and use this value to plot absorbance versus concentration of
HUK standards . Read concentration of samples from this graph.
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Appendix 2.10 Tissue KaUikrein ELISA 
STEP PROCEDURE TEMP TIME 
1. Primary antibody - Coat the ELISA plate (Corning) with I 00 ul of 4°c ON 
30 ng/ml Goat a-human rTK lgG in coating buffer
2. Wash the plate with 0.0IM PBS/0.5 %Tween RT 3x3min 
3. Block 1 - add 200 µI of 5 % milk blocker to each well RT 30 min 
4. Wash the plate with 0.0lM PBS/0.5 %Tween RT 3x3min 
5. Block 2 - add 200 µI of 5 % milk blocker to each well RT 30 min 
6. Wash the plate with 0.01 M PBS/0.5 %Tween RT 3x3min 
7. Standards - a 1200 ng/ml aliquot ofHUK standard stored at -20°C
was double diluted 40 ng/ml to 0.625 ng/ml, and I 00 µI of each
dilution was added in triplicate
8. Blanks - 100 µI 0.01 M PBS (pH 7.2) was added to 3 wells
9. Controls -control urine from section 2.4.4.5 was serially diluted
from 1/8 to 1/512 in 0.0IM PBS (pH7.2), and 100 µI of each
dilution added in triplicate. Also, known samples are rerun to test
for inter-assay variation
10. Sample - I 00 µI of sample was loaded onto the remaining wells of
the plate in triplicate
11. Incubate 37°c 60 min 
12. Wash the plate with 0.01 M PBS/0.5 %Tween RT 3x3min 
13. Secondary antibody - add I 00 µI of 25 ng/ml rabbit anti- human 37
°c 60 min 
rTK to each well and incubate
14. Wash the plate with 0.0 I M PBS/0.5 %Tween RT 3x3min 
15. I 00 µI of anti-rabbit IgG (Sigma, St. Louis) diluted I :250 with 0.0 I 37
°c 60 min 
M PBS was added to each well and incubated
16. Wash the plate with 0.01 M PBS/0.5 %Tween RT 3x3min 
17. Chromogen - I 00 µI of I mg/ml pNPP substrate was added to each 37
°c 0-60 min
well ( 1 tablet in 5 ml of substrate buffer) and allow colour to
develop
18. Calculation - subtract the absorbance of the blanks from the
absorbance of the standards, controls and samples.
Plot absorbance versus concentration of HUK standards.
Read TK concentration of samples and controls from this graph.
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Appendix 2.11 Kinin generation ELISA 
STEP PROCEDURE 











µg/ml bradykinin-cytochrome c conjugate in sodium
carbonate buffer, pH 9.6
Primary antibody: pre-incubate sample or standard with equal
volume ofbradykinin monoclonal antibody at 9.4 µg/ml
Wash the plate with 0.0IM PBS/0.5 %Tween
Block with: bovine serum saline
Wash the plate with 0.0lM PBS/0.5%Tween
Incubate standards and samples
Wash the plate with 0.0lM PBS/0.5 %Tween
Secondary antibody: add alkaline phosphatase labelled anti
mouse lgG ( diluted I :250) and incubate
Wash the plate with 0.0 lM PBS/0.5 %Tween
Chromogen: add disodium p-nitrophenyl substrate (Sigma,
UK) and allow colour to develop
Calculation - subtract the absorbance of the blanks from the
absorbance of the standards, controls and samples.
Plot absorbance versus basal and generated kinin contents of
urine and synovial fluid samples











RT 3X3 min 
37° c 2h 
RT 3X3 min 
37° c 0-60 min
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Appendix 2.12 Tumour necrosis factor a ELISA 
STEP PROCEDURE TEMP. TIME 
l. Standard solution - reconstitute standard solution to produce a RT 
stock solution of32 pg/ml and serially dilute from 32 pg/ml to 0.5
pg/ml
2. Add 50 µl of assay diluent HD 1-11 to each well of a 96 well, flat RT 
bottomed polystyrene ELISA plate precoated with a murine
antibody against TNF a
3. Add 200 µl of standard or sample to each well RT 
4. Incubate 2o_goc 14-24 h
5. Wash wells using an automated A WI Anthos washer
6. Add 200 µl of TNF a conjugate to each well
7. Incubate RT 3h 
8. Wash wells using an automated A Wl Anthos washer 
9. Add 50 µl of substrate solution (NADPH) to each well
10. Incubate RT 3h 
11. Add 50 µl of amplifier solution to each well
12. Incubate RT 30 min 
13. Add 50 µl of stop solution to each well
14. Read absorbance at 490 run with a correction to 650 run within
30 min
15. Plot a standard curve using the absorbance of the standards versus
the concentration of the standards.
Read the concentration of the samples from this graph
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Appendix 2.13 Interleukin 1 13 ELISA 
STEP PROCEDURE TEMP. TIME 
1. Standard solution- reconstitute standard solution to produce a RT 
stock solution of 8 pg/ml and serially dilute from 8 pg/ml to 0.125
pg/ml
2. Add 100 µl of assay diluent HD 1-1 1 to each well of a 96 well, RT 
flat bottomed polystyrene ELISA plate precoated with a murine
antibody against IL -113
3. Add 150 µl of standard or sample to each well RT 
4. Incubate RT 14-20 h
5. Wash wells using an automated AWl Anthos washer
6. Add 200 µl of IL-113 conjugate to each well
7. Incubate RT 3h 
8. Wash wells using an automated A Wl Anthos washer
9. Add 50 µI of substrate solution (NADPH) to each well
10. Incubate RT 45 min 
11. Add 50 µl of amplifier solution to each well
12. Incubate RT 45 min 
13. Add 50 µl of stop solution to each well
14. Read absorbance at 490 nm with a correction to 650 nm within
30 min
15. Plot a standard curve using the absorbance of the standards versus
the concentration of the standards.






3.1.1 Patients with rheumatoid arthritis 
For the synovial fluid and neutrophil studies, 50 patients with rheumatoid arthritis who 
fuJfilled the inclusion criteria were included in the study (refer 2.2). There were 42 
females and 8 males. The mean age was 49.5 ± 9.8 years with a range from 21 to 72 years. 
The mean duration of arthritis was 9.1 ± 7.2 years with a range from 0.8 to 36 years. All 
the patients fuJfilled the ARA criteria for RA. Rheumatoid nodules were present in 4 
patients (8 %) and the rheumatoid factor was positive in 37 patients (66%). Thirty patients 
(60 %) were receiving disease modifying anti-rheumatic therapy, while 20 (40 %) patients 
were on low dose oral prednisone (5 IO mg per day). Hypertension was the commonest 
co-morbid condition and was present in 13 patients (26 % ). In addition, 4 patients (8%) 
were on treatment for diabetes and 3 patients (6 %) had hypothyroidism (Table 3.1). Full 
details appear in Appendix 3 .1. 
3.1.2 Controls: Blood and urine 
Blood samples were obtained from 50 healthy volunteers who did not have any known 
illness, and were on not regular medication. They were matched with the RA patients for 
age and sex. There were 42 females and 8 males. The mean age was 49.5 ± 9.8 years with 
a range from 21 to 74 years (Table 3.1 and Appendix 3.2.) 
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Table 3.1 Demographics: Patients and Healthy volunteers. 
RA patients Healthy volunteers 
Number 50 50 
Female: Male 42: 8 42: 8 
Mean age 49.5 ± 9.8 yrs 49.5 ± 9.8 years 
(range: 21 - 72 yrs) (range: 21 - 74 years) 
Mean duration of RA 9.1 ± 7.2 yrs 
(range: 0.8 - 36 yrs) 
Rheumatoid nodules 4 patients (8%) 
Positive RF 3 7 patients ( 66%) 
No. of ARA criteria 
7 3 (6%) 
6 24 (48%) 
5 19 (38%) 
4 4 (8%) 
DMARD therapy 36 (60%) 
Low dose corticosteroid 20 (40%) 
therapy 
Co-morbid diseases 
Hypertension 13 (26%) 
Diabetes 4 (8%) 
Hypothyroidism 3 (6%) 
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3.1.3 Synovial tissue: patients with inflammatory arthritis 
For the synovial tissue study, samples were obtained at arthroscopy from 6 patients with 
rheumatoid arthritis. These samples were kindly provided by Dr D Kane and Professor B 
Bresnihan, (St. Vincent's Hospital, Dublin). The mean age was 45.5 years, range 27 - 63 
years (Appendix 3.3). 
3.1.4 Synovial tissue: controls 
Control synovial tissue was obtained from l O patients in whom an autopsy was performed 
within 24 h of sudden death. There were 9 males and one female; with a mean age of 36 
years, range 18 to 48 years. The causes of death were stab wounds (n = 4), gun shot 
injuries (n = 2), suicide by hanging (n = 2), blunt injury and acute myocardial infarction. 
These patients had no evidence of joint disease or trauma or surgery to the joints 
(Appendix 3.4). 
3.2 SYNOVIAL TISSUE IMMUNOCYTOCHEMISTRY 
The control (autopsy) and inflamed synovial tissue samples were initially stained with 
haematoxylin and eosin to verify the tissue morphology. The control synovial tissue 
demonstrated a single layer of synoviocytes and an absence of inflammatory cells in the 
subintimal layer (Fig. 3 .1 ). In the inflamed synovium, there was hypertrophy of the lining 
layer and infiltration of the sublining layer with inflammatory cells, including 
lymphocytes, macrophages and plasma cells (Fig. 3.2). 
Tissue kallikrein activity has been reported in the synovial fluid from arthritic joints 
(Worthy et al. 1990) and the salivary glands of patients with Sjogren's syndrome 
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secondary to RA (Hernandez et al. 1998). In addition, TK has been implicated in 
neutrophil diapedesis (Figueroa et al. 1989) and in the processing of promolecules that are 
involved in the pathogenesis of inflammatory arthritis (Tschesche et al. 1989; Menashi et
al. 1994). The kinin B2 receptor has been identified on human synovial tissue by 
autoradiography (Bathon et al. 1992a) and Scatchard analysis (Uhl et al. 1992). 
Administration of kinin B 1 antagonists and the B2 receptor antagonists, HOE 140, has 
been shown to reduce BK induced plasma extravasation in rat arthritic joints (Cruwys et al.
1994). This study was therefore undertaken to determine the expression ofTK, Bl and B2 
receptors on normal and inflamed synovial tissue. 
Both the control and inflamed synovial tissue samples were thereafter immunostained to 
detect the presence or absence of (i) TK and the (ii) kinin B 1 and B2 receptors. The slides 
were viewed and the intensity of the immunolabelJing was quantified by image analysis in 
pixels x 102/µm2 (see Methods). 
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Figure 3.1 Photomicrograph of control synovial tissue 
Haematoxylin and eosin stain demonstrating a single layer of synovial cells 
(S) and the absence of inflammatory cells in the sublining layer.
Magnification x 400. 
Figure 3.2 Photomicrograph of rheumatoid synovium 
Haematoxylin and eosin stain demonstrating hypertrophy of the synovial 
lining layer (S) and a dense inflammatory infiltrate in the sublining layer (I) 
and increased vascularity (V). Magnification x 200. 
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3.2.1 Immunolocalisation of tissue kallikrein 
The localization of immunoreactive TK in the cells of the apical region of the duct cells of 
the human sub-mandibular salivary glands (Schachter et al. 1980) was used as a positive 
control (Fig.3.3A). The loss of immunolabelling following the preabsorption of the 
antibody with an excess of rTK and replacement of the primary antibody with PBS served as 
the negative method control at each labeling run (Fig 3 .3B). 
Figure 3.3 Photomicrographs of control human salivary gland 
Positive labeling for TK (P) is present in the duct cells (A). There is an absence 
of labeling (N) in the method control (B). Immunoperoxidase stain. 
Magnification x 400. 
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The TK labeling in both the control and rheumatoid synovial tissue is shown in Fig. 3 .4. 
Intense labeling was observed in the synovial lining cells, endothelial cells, and the subintimal 
macrophages. The intensity of labeling was quantified by image analysis. There was a 
significant increase in labeling in the endothelial cells of the RA patients compared to controls 
(p < 0.05) (Table 3.2 and Fig. 3.5). 
Figure 3.4 Immunovisualisation of tissue kallikrein in control and 
rheumatoid synovial tissue 
Intense labeling for TK is seen in the synovial lining (S) and endothelial cells 
(E) in the normal (A) and rheumatoid synovium (B&C). Immunoperoxidase




Figure 3.5 Histogram of tissue kallikrein labeling on synovial tissue 
Table 3.2 Intensity of labeling for tissue kallikrein in synovial tissue 
Synovial lining Endothelial cells 
cells 
Control RA Control RA 
n 65 89 57 37 
Mean 77 76 71 75 
SD 12 11 8 10 
*t-test p > 0.05 p = <0.05 
RA; rheumatoid arthritis, SD; standard deviation. 






p > 0.05 
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3.2.2 Immunolocalisation of the kin in Bl receptor 
The kinin BI receptors have been demonstrated in the neurons of the substantia gelatinosa 
in the spinal cord (Raidoo and Bhoola, 1997). Sections of the human spinal cord were 
therefore used as positive control tissue during the labeling runs (Fig. 3 .6). 
Figure 3.6 Photomicrograph of normal human spinal cord 
Showing positive labeling for kinin B 1 receptors in the neurones (N) of the 
substantia gelatinosa (A) and absence of labeling in the method control (B). 
lmmunoperoxidase stain. Magnification x 400. 
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The labeling for the kinin B 1 receptors in normal and rheumatoid synovium is shown in 
Fig. 3. 7). Although visually there appeared to be an absence of labeling for the kinin B 1 
receptor on the normal synovial tissue, immunolabelling was quantified using image 
analysis. In both the normal and rheumatoid synovial tissue, labeling was demonstrated in 
the synovial lining cells, endothelial cells and subintimal fibroblasts and macrophages. 
There was a significant increase in the intensity of labeling in the synovial lining cells in 
the rheumatoid tissue compared to the control synovial tissue (p < 0.01) (Table 3.3 and Fig. 
3.8). 
Figure 3.7 Immunovisualisation ofkinin Bl receptors in control and 
rheumatoid synovial tissue 
Intense labeling for the kinin B 1 receptor is seen in the synovial lining cells 
(S) and endothelial cells (E) in the rheumatoid synovial tissue (B and C)
compared to control (A) synovium. lmmunoperoxidase stain. Magnification : 




Figure 3.8 Histogram of kin in Bl receptor labeling on synovial tissue 
Table 3.3 Intensity of labeling for kinin Bl receptor in synovial tissue 
(pixels x 102/µm2)
Synovial lining Endothelial cells Fibroblasts Macrophages 
cells 
Control RA Control RA 
n 115 78 14 37 
Mean 62 68 54 54 
SD 15 15 16 15 
*t-test p< 0.01 p > 0.05 
RA; rheumatoid arthritis, SD; standard deviation. 
* students t-test for unequal variance
Control RA Control RA 
41 28 21 28 
49 54 57 68 
13 14 23 12 
p > 0.05 p = 0.07 
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3.2.3. Immunolocalisation of the kinin B2 receptor 
Kinin B2 receptors have been localized on the collecting ducts and tubules of normal 
kidneys (Naidoo et al. 1996a). During each labeling experiment, normal human kidney 
tissue was used as the positive controls. For the method control, loss of labeling following 
preadsorption with an excess of the rabbit anti-human B2 receptor antibody and 
replacement of the primary antibody with PBS was demonstrated (Fig. 3.9) 
Figure. 3.9 Photomicrographs of control human kidney 
Positive labeling for the kinin B2 receptor is seen on the collecting 
ducts and tubules ( + A) and absence of labeling in the method 
control (B). Immunoperoxidase stain. Magnification x 400. 
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Intense labeling for the kinin B2 receptor was observed in the synovial lining layer, the 
endothelial cells and in the subintimal fibroblasts and macrophages in both the rheumatoid 
and control tissue. There were no significant differences (Fig. 3.10). (Table 3.4 and Fig. 
3 .11 ). 
Figure 3.10 lmmunovisualisation of kinin B2 receptors in control 
and rheumatoid synovial tissue 
Intense labeling for the kinin B2 receptor is seen in the synovial lining cells 
(S), endothelial cells (E) and fibroblasts (F) in control (A) and rheumatoid 




Figure 3.11 Histogram of kin in B2 receptor labeling on synovial tissue 
Table 3.4 Intensity of labeling for kin in B2 receptor in synovial tissue 
Synovial lining Endothelial cells Fibroblasts Macrophages 
cells 
Control RA Control RA 
N 115 78 14 37 
Mean 71 72 66 60 
SD 13 14 12 14 
*t-test p > 0.05ns p > 0.05 
RA; rheumatoid arthritis, SD; standard deviation. 
* students t-test for unequal variance
Control RA Control RA 
41 28 21 28 
63 64 68 73 
12 12 8 11 
p > 0.05 p = 0.08 
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3.3 TISSUE KALLIKREIN ACTMTY: SYNOVIAL FLUID 
Tissue kallikrein has been localized in the granules of neutrophils. Since neutrophils 
degranulate in inflammation, it may be expected that TK would be released from the SF 
neutrophils in RA. This is supported by the loss of immunoreactivity of TK in SF 
neutrophils obtained from RA patients (Williams et al. 1997). TK has been previously 
identified in the synovial fluid from patients with arthritis (Worthy et al. 1990), and the 
levels were reported to be higher in RA compared to OA (Selwyn et al. 1989), suggesting 
that there is an increase in the concentration of TK in inflammatory synovitis. However, 
the correlation of TK levels in SF and disease activity has not been previously reported. In 
this study the TK activity and the concentration of TK were measured in synovial fluid 
obtained from 20 patients with RA and the levels correlated with measures of disease 
activity. 
3.3.1 Measurements of TK 
An enzymic (amidase) assay was used to measure TK activity. The TK activity was 
extrapolated from the standard curve obtained in 2. 7.1 (Fig. 3.12). 
An ELISA was used to determine the concentration of TK in the SF from 20 patients with 
RA. A standard curve of absorbance versus HUK concentration was plotted with the 
values expressed as ng/ml (Fig. 3.13). The concentrations of TK in the synovial fluid 
samples were extrapolated from this graph. 
The mean enzymic activity of TK was 1. 77 ± 0.85 ng/µg protein (range: 1.37 - 3.03 ng/µg 
protein), and the mean immunoreactive TK (ELISA) was 20.1 ± 36.5 ng/ml (range: 0.13 -
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Figure 3.13 Tissue kallikrein ELISA Standard curve 
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3.3.2 Measurements of disease activity 
In the RA patients, disease activity was determined using the following measures: 
• Duration of morning stiffness: defined as the difference in the time of awakening and
the time of maximum mobility during the day.
• Swollen and tender joint counts: a twenty-eight joint count (Fuchs et al. 1989) was
used to determine the number of tender and swollen joints. A binary score of0/1 was
applied. Where there was no pain or tenderness, a score ofO was given and a score of
1 was given for either a tender or swollen joint count (Appendix 3.5).
• Pain on a visual analogue scale. A IO cm horizontal line was used to score pain from 0
(no pain) to 10 (worst possible pain).
• Physician's global assessment of disease activity. This is an objective evaluation of the
patient's overall condition at the time of the assessment, and is based on the patient's
disease, signs, functional capacity and the physical examination and is independent of
the patient's global assessment. A 5- point scale was used (l=very good; 2 = good; 3 =
fair; 4 = poor; 5 = very poor).
• Patient's global assessment of disease activity. The patient was asked the following
question: "Considering all the ways your arthritis affects you, how are you feeling
today?" The response was recorded using the 5-point scale as above.
• Local activity index. For the affected knee joint a local activity index was calculated
using the following parameters
increased temperature over the joint 
pain on palpation or passive movement 
presence of effusion 
articular crepitus 
decreased range of movement 
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muscle atrophy 
Each parameter was scored to be either absent (0); mild (1) or severe (2); with a total score 
ranging from 0 -14. 
• The modified health assessment questionnaire (HAQ) (Kirwan and Reeback, 1986)
was scored to provide an overall disability index from 0 (no disability) to 3 (complete
dependence on others) {Appendix 3.6).
• The erythrocyte sedimentation rate (ESR, Westergren method) and C reactive protein
were performed as biochemical indices of disease activity.
• A disease activity score (DAS) that includes the 28 joint count for tender and swollen
joints and the ESR was calculated (Prevoo et al. 1995).
3.3.3. Correlation between synovial fluid TK and disease activity 
The levels of enzymic activity and concentrations of antigenic TK were correlated with 
measures of disease activity. There was a significant negative correlation between the SF 
levels of enzymic TK and the 28 swollen joint count (r = -0.464; p < 0.05) (Fig. 3.14). 
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Figure 3.14 Correlation between the SF levels of enzymic TK 
and the 28 swollen joint count in RA patients. 
3.4 KININ GENERATION: SYNOVIAL FLUID 
Armstrong et al (1957) first reported the presence of a kinin-like substance in SF obtained 
from RA patients. However, it was only recently that specific and precise techniques for 
the measurement of kinins were developed. While, the capacity of synovial fluid to 
generate kinins has been previously demonstrated (Bond et al. 1997), kinin levels have not 
been correlated with clinical and biochemical measures of inflammation. In this study, the 
basal kinin levels and the capacity to generate kinins in the synovial fluid were measured 
in the 20 patients with RA. The levels of basal kinins were correlated with levels of 
generated kinins. Further, the levels of generated kinin were correlated with measures of 
disease activity (see section 3.3.2). All correlations were performed using Pearson's 
correlation co-efficient. 
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3.4.1 Measurement of basal and generated kinins 
A competitive ELISA was used to measure basal kinin levels and the capacity to generate 
kinins in the synovial fluid (see section 2.8). The absorbance values obtained for the 
standard BK was used to plot a standard curve of absorbance versus log concentration (Fig. 
3 .15) from which the basal and generated kinin contents of the synovial fluid were 
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0+------.-----,---------,------r--------, 
0 0.5 1.5 
Log [Bradykinin] (ng/ml) 
Figure 3.15 Kinin ELISA standard curve 
2 2.5 
The mean basal kinin level was 5.7 ± 6.1 ng/ml with a range of0.43 to 26.17 ng/ml. The 
mean level of generated kinin was 80.6 ± 56.3 ng/ml with a range of 12.5 to 216.02 ng/ml 
(Table 3.5). There was a significant negative correlation between the basal kinin and 
generated kinin levels (r= -0.454; p < 0.05) (Fig 3.16). 
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Table 3.5 Basal and generated kinin levels in 
synovial fluid from patients with RA 
Basal kinin Generated kinins 
ng/ml ng/ml 
n 20 20 
Mean 5.7±6.1 80.6 ± 56.3 
Range 0.43 to 26.17 12.5 to 216.02 
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Figure 3.16 Correlation between levels of basal and generated 
kinins in the SF in RA patients. 
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3.4.2 Measurement of disease activity 
The mean values for the measures of disease activity in the 20 patients in whom basal and 
generated kinins were measured in the SF, are presented in Table 3.6. 
Table 3.6 Measures of disease activity 
Index Mean±SD Range 
Duration of morning stiffitess (min) 97.5 ± 122 0-480
Disease activity (VAS) (mm) 48.6 ± 28.6 0-98
Pain (VAS) (mm) 54.5 ± 25.4 9-90
Physician's global assessment 2.8 ± 0.7 1 - 4 
of disease activity (Likert scale) 
Patients assessment of disease 3.4 ± 0.8 2-4
activity (Likert scale) 
28 tender joint count 5.6 ± 3.8 1 -12 
28 swollen joint count 6.8 ±3.6 1 - 15 
ESR (mm/hr) 50.5 ± 36.2 11 -124 
CRP mg/L 37.5 ± 24.7 5.3 - 73.7 
HAQ 1.7 ± 0.8 0.125-3 
Local activity index 12.6 ± 3.9 6- 19
Disease activity score 5.1±0.9 3.9- 7 
3.4.3 Correlation between measures of disease activity and basal kinin levels 
The basal levels of kinins in the synovial fluid were correlated with the measures of 
disease activity. There was a significant negative correlation between SF basal kin ns and 
the CRP (r = -0.537, p < 0.05) (Fig.3.17), and the disease activity score (r= -0.458� p < 













Figure 3.17 Correlation between the CRP and basal kinins in 
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Figure 3.18 Correlation between the disease activity score and basal 
kinins in the SF in RA patients 
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3.4.4 Correlation between measures of disease activity and generated kinin levels 
The relationship between the measures of disease activity and the levels of generated 
kinins in the SF was determined using the Pearsons' correlation co-efficient. There was a 
significant correlation between the generated kinin levels and the 28 tender and swollen 
joint counts, ESR, CRP, HAQ and the disease activity score (Table 3. 7 and Figs. 3 .19 -
3.23). 
Table 3.7 Correlation between measures of disease activity and 
generated kinin levels in synovial fluid from the 20 patients with RA 
Index Pearson's correlation p value 
r 
Tender joint count 0.536 <0.05 
Swollen joint count 0.509 <0.05 
ESR 0.598 <0.01 
CRP 0.725 <0.01 
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Figure 3.19: Correlation between the 28 tender joint count and 
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Figure 3.20 Correlation between 28 swollen joint count and the level 
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Figure 3.21 Correlation between the ESR and the level 
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Figure 3.22 Correlation between CRP and SF generated kinins 
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Figure 3.23: Correlation between the disease activity score and SF 
generated kinins in RA patients. 
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3.5 CYTOKINE STUDY : SYNOVIAL FLUID 
Interleukin I J3 and tumour necrosis factor are proinflammatory cytokines, and are thought 
to play a central role in the immune response observed in RA (Brennan et al. 1992a). IL 
I J3 has the ability to recruit cells to the site of inflammation, stimulate the production of 
other cytokines, augment lymphocyte production, induce endothelial cell proliferation, 
activate neutrophils to synthesize and release prostaglandins, and induce hepatic 
production of acute phase proteins. The bone resorption and cartilage destruction in RA is 
thought to be mediated via IL 1 J3 induced stimulation of prostaglandins and 
metalloproteinases. Similarly, TNF a is also a potent stimulator of the inflammatory 
response. The pro-inflammatory actions of TNF a are mediated either directly or through 
the stimulation of other cytokines and secondary mediators such as prostaglandins, 
leucotrienes and oxygen free radicals. In RA, TNF a stimulates bone resorption, enzyme 
release from synovial cells and release of acute phase proteins. 
High levels of IL-1 J3 and TNF a have been reported in the synovial fluid obtained from RA 
patients (Arend and Dayer, 1995; Manicourt et al. 1993). In the present study, both IL 1 J3 
and TNF a were measured in the synovial fluid of 20 RA patients, and the levels of IL 1 J3 
and TNF a correlated with markers of disease activity. 
3.5.1 Interleukin 1 J3 
A quantitative sandwich enzyme immunoassay technique using a commercial ELISA kit 
(Quantikine HS, R&D Systems) was used to measure IL I J3 levels in the SF. A standard 
curve was plotted using the absorbance of the standards versus the concentration of the 
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Figure 3.24 IL 1 f3 Standard curve 
The mean IL 1 f3 level was 8.42 ± 9.67 pg/ml with a range from 0.27 to 29.04 pg/ml. 
Correlation with disease activity 
There was a significant correlation between the SF levels of IL 1 f3 and pain (VAS), 
physician's global assessment of disease activity, 28 tender joint count and CRP (Table 3.8 
and Figs. 3.25 - 3.28). Although there appeared to be a correlation between IL lf3 and 
disease activity score, the relationship was not significant (Fig. 3 .29). 
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Table 3.8 Correlation between measures of disease activity and IL 1J3 
levels in synovial fluid from 20 patients with RA 
Measure of disease activity Pearson's correlation p value 
r 
28 tender joint count 0.472 <0.05 
Pain (VAS) 0.462 <0.05 
Physician's global 0.549 <0.05 
assessment of disease activity 
CRP 0.536 <0.05 
DAS 0.412 =0.07 
40 
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Figure 3.25 Correlation between SF levels of IL 1 P and 
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Figure 3.27 Correlation between SF levels of IL 1(3 and physician's 
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Figure 3.28 Correlation between SF levels of IL 1 '3 and CRP 
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Figure 3.29 Correlation between the SF levels of IL-1 '3 and 
the disease activity score in RA patients. 
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3.5.2 Tumour necrosis factor a 
A quantitative sandwich enzyme immunoassay technique using a commercial ELISA kit 
(Quantikine HS, R&D Systems) was used to measure TNF a levels in the SF. A standard 
curve was plotted using the absorbance of the standards versus the concentration of the 
standards (Fig. 3.30) and the concentrations of the concentration of TNF a in the SF 
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Figure 3.30 TNF a Standard curve 
40 
The mean level of TNF a in the synovial fluid from 20 patients with RA was 15. 71 ± 10. 5 7 
pg/ml with a range of 4. 41 to 41. 42 pg/ml. 
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Correlation with disease activity 
There was a significant correlation between the levels of synovial fluid TNF a and the 28 
tender joint count and CRP {Table 3.9 and Figs. 3.31 & 3.32). 
Table 3.9 Correlation between indices of disease activity and 
TNF a levels in synovial fluid from 20 patients with RA 
Index Pearson's correlation p value 
r 
Tender joint count 0.458 <0.05 
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Figure 3.31 Correlation between SF levels of TNF a and the 28 
tender joint count in RA patients 
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Figure 3.32 Correlation between SF levels of TNF a and CRP in RA 
patients 
3.5.3 Correlation between TNF a and IL-1 f3 
Synovial fluid levels of both TNF a and IL-I f3 were available in 16 patients with RA. 
There was a significant correlation between the TNF a and IL-I f3 levels (r-0.591; p < 
0.05) (Fig. 3.33). 
- 50
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Figure 3.33 Correlation between SF levels of TNF a and IL 1 f3 in RA 
patients 
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3.6 CORRELATION BE1WEEN THE KININ AND CYTOKINE CASCADES 
To determine the relationship between the kinin and cytokine cascades in RA. the levels of 
TK and basal and generated kinins in the synovial fluid were compared to the levels of IL -
IP and TNF a.. 
3.6.1 Correlation between SF levels of IL-1(3 and enzymic TK 
Although there was a trend towards a negative correlation between the SF levels of 
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Figure 3.34 Correlation between the SF levels of IL-1 J3 and 
enzymic TK in RA patients 
3.6.2 Correlation between SF levels of IL-1(3 and generated kinins 
There appeared to be no direct correlation between the SF levels of IL-1 P and generated 
kinins (Fig. 3.35). 
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Figure 3.35 Correlation between SF levels of IL-1 f3 and generated 
kinins in RA patients 
However, when the relationship was further analyzed, there was a biphasic correlation, 
namely a positive correlation with low to moderate levels of IL-IJ3 (r = 0.51; p <0.05) and 
a negative correlation with high levels oflL-lJ3 (r = -0.50; p <0.05) (Figs. 3.36 & 3.37). 
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Figure 3.36 Correlation between low to moderate levels of IL-1 f3 and 
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Figure 3.37 Correlation between high levels of lL-1(3 and generated 
kinins in the SF of RA patients 
3.6.3 Correlation between SF levels of TNF a and the kinin cascade. 
There was no correlation between the levels of TNF a and either enzymic TK or generated 
kinin levels in the SF. 
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3. 7 CIRCULATING AND SYNOVIAL FLUID NEUTROPIIILS 
The kinin moiety, within the kininogen molecule, and the kinin B2 receptor has been 
identified on the surface and TK within the granules of normal circulating neutrophils 
(Figueroa et al. 1992; Haasemann et al. 1994; Figueroa et al. 1989). Since there is an 
efflux of neutrophils into the SF in the inflamed joints, the SF and circulating neutrophils 
of RA patients were harvested and studied to determine the status of the kinin cascade on 
neutrophils in RA. 
The air-dried neutrophil slides (see section 2.5.1) were first stained with May Groenwald 
Giemsa stain to confirm the presence of neutrophils (Fig. 3.38). Thereafter, slides of 
synovial fluid and circulating neutrophils from 8 patients with RA and circulating 
neutrophils from 8 healthy volunteers were immunostained to detect (i) the presence or 
absence of the kinin moiety within the kininogen molecule, (ii) TK and the (iii) kinin B 1 
and B2 receptors. The slides were viewed under a confocal microscope. For each subject, 
images were generated from 10 neutrophils, and the intensity of immunotluorescence 
image quantified and expressed as pixels x 102 /µm2 per subject. 
The mean intensity of staining for the kinin moiety, TK, kinin B 1 and B2 receptors in the 
control neutrophils was then compared to that present on the circulating and SF neutrophils 
harvested from RA patients. Further, the intensity of labeling for these antigens was 
correlated with measures of disease activity (see section 2.3). 
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Figure 3.38 May Groenwald Giemsa stain showing the presence 
of neutrophils (N). Magnification x 40. 
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3.7.1 Immunolocalisation of immunoreactive tissue kallikrein 
Tissue kallikrein specifically localizes in the duct cells of the submandibular salivary 
gland. Human salivary gland was therefore used as positive control tissue for TK labeling 
during each immunocytochemistry run (Fig. 3.39). 
The TK labeling in the circulating neutrophils from healthy volunteers and the circulating 
and synovial fluid neutrophils from the RA patients is shown in Fig. 3.40. The mean 
intensity for immunoreactive TK on the circulating neutrophils from the healthy volunteers 
was 19.5 pixels x 102/µm2 with a median of 18 pixels x 102/µm
2 (Fig 3.41 and 3.42 and 
Table 3. 10). For the circulating and SF neutrophils from the RA patients, the mean 
intensity for TK was 15.5 pixels x 102/µm2 and 12.3 pixels x 102/µm2 respectively, with 
corresponding medians of 11 pixels x I 02/µm2 and 9.5 pixels x I 02/µm2. 
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Figure 3.39 Confocal micrograph positive labeling for TK in 
the duct cells of normal human salivary gland. 
The intensity of immunofluorescence is shown on the colour strip: red 
to white: maximum, green to yellow = moderate, light blue = low and 
purple to blue = zero 
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Figure 3.40 Immunovisualisation of tissue kallikrein in neutrophils 
Immunolabelling of tissue kallikrein on circulating neutrophils of (A) 
volunteers, and (B) circulating neutrophils and (C) synovial fluid neutrophils 
of RA patients. The intensity of irnmunofluorescence is shown on the colour 
strip: red to white: maximum, green to yellow = moderate, light blue = low 
and purple to blue = zero. The corresponding phase contrast images are 
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Figure 3.42 Histogram of immunoreactive TK in neutrophils showing 
mean values for the intensity of labeling of TK (in pixels 
x 102/µm2on the neutrophil membrane 
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When comparing the mean intensity of TK labeling in the circulating neutrophils from 
healthy volunteers (n=8) and the circulating and synovial fluid neutrophils of the RA 
patients n=8), there was no statisticaJ difference (p >0.05). However, when the intensity of 
labeling of the SF neutrophils (n=80) from the RA patients was compared to the circulating 
neutrophils (n=80) of healthy volunteers, there was a significant loss of TK labeling in the 
SF neutrophils of the RA patients (1-Way ANOVA, p < 0.01). The details for each subject 
are presented in Table 3.10. 
Correlation with indices of disease activity 
There was no significant correlation between the immunoreactivity of TK on the 
circulating neutrophils from the RA patients and the measures of disease activity. 
Table 3.10 Values for the intensity of immunolabelling for tissue kallikrein 
No (i) Circulating neutrophils (ii) Circulating neutrophils (iii) SF neutrophils
healthy volunteers RA patient RA patient
l 13 15 0 
2 36 36 13 
3 19 8 0 
26 9 0 
5 17 10 
6 23 8 36 
7 15 5 20 
8 9 37 20 
Mean 19.5 15.5 12.3 
Median 18 9.5 11 
Kruskal (i) vs. (ii) : > 0.05 (i) vs. (iii) : > 0.05
-Wallis
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3.7.2 Immunolocalisation of the kinin moiety 
The kinin moiety has been previously localized on normal human neutrophils (Bhoola et
al. 1992). Loss of immunolabelling following preadsorption with an excess of the 
monoclonal mouse antibradykinin antibody and replacement of the primary antibody with 
PBS served as the negative method control at each labeling run. 
On the circulating neutrophils from the healthy volunteers, irnmunolabelling was observed 
as a peripheral rim (Fig. 3 .43A). The mean intensity of immunolabelling was 20.8 pixels x 
I 02/µm
2 
with a median of 20 pixels x 102/µm2 (Figs. 3.44 & 3.45 and Table 3.11). In the 
RA patients, there was a loss of the kinin moiety from both the SF and circulating 
neutrophils (Fig. 3.38B and C). The mean and median intensities for the kinin moiety on 
the SF neutrophils were 11 pixels x 102/µm2 and 11.5 pixels x 102/µm2 respectively 
(Fig.3.44 & 3.45 and Table 3.11). On the circulating neutrophils, the mean intensity was 
3.8 pixels x 10
2
/µm




Figure 3.43 Immunovisualisation of the kin in moiety on the 
neutrophil membrane 
Irnmunolabelling of the kinin moiety on circulating neutrophils of 
volunteers (A), and the circulating (B) and synovial fluid (C) neutrophils of 
RA patients. The intensity of irnmunoflourescence is shown on the colour 
strip: red to white = maximum, green to yellow = moderate, light blue = low 
and purple to blue = zero. The corresponding phase contrast images are 
illustrated in the second panel. 
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The Kruskal Wallis test was used to compare the intensity of the kinin moiety on the 
circulating neutrophils of the control subjects to that on the circulating and SF neutrophils 
of the RA patients. The loss of the kinin moiety was statistically significant different 
between the circulating neutrophils from the controls and RA patients (p < 0.01), as well as 
between the circulating neutrophils from the controls and the SF neutrophils from the RA 
patients (p < 0.05). Although there appeared to be a greater loss of intensity on the 
circulating neutrophils compared to the SF neutrophils in the RA patients, this finding was 
not statistically significant (p > 0.05) 





No (i) Circulating neutrophils (ii) Circulating neutrophils (iii) SF neutrophils
healthy volunteers RA patient RA patient
1 9 17 4 
2 22 9 12 
3 27 1 11 
4 18 2 19 
5 37 0 11 
6 13 0 15 
7 15 1 14 
8 37 0 2 
Mean 20.8 3.8 11 
Median 20 1 11.5 
Kruskal- (i) vs. (ii) : < 0.05 (i) vs. (iii) : < 0.01
Wallis 
There was no correlation between the kinin moiety immunoreactivity and measures of 
disease activity. 
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3.7.3 Immunolocalisation of the kinin Bl receptor 
The kinin B 1 receptors have been demonstrated in the neurons of the substantia gelatinosa 
in the spinal cord (Raidoo and Bhoola, 1997). Sections of the human spinal cord were 
therefore used as positive control tissue during the labeling runs (Fig. 3.46). 
Kinin B 1 receptors were immunolocalised on the circulating neutrophils from healthy 
volunteers and the circulating and SF neutrophils of RA patients (Fig. 3.47). The mean 
intensity for kinin B 1 receptor on the circulating neutrophils from the healthy volunteers 
was 8.1 pixels x 102/µm2 with a median of 5.5 pixels x 102/µm
2 (Fig 3.48 & 49 and Table 3. 
12). For the circulating and SF neutrophils from the RA patients, the mean intensity for the 
Bl receptor was 14.5 pixels x 102/µm2 and 16.8 pixels x 102/µm2 respectively, with 
corresponding medians of 13.3 pixels x 102/µm
2 and 15.6 pixels x 102/µm2.
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Figure 3.46 Confocal images of kinin Bl receptor labeling on control 
spinal cord 
Positive labeling for B 1 kinin receptor 1s shown on the neurons of the 
substantia gelatinosa of the spinal cord (A). There is an absence of labeling 
m the negative method control (B). The intensity of the 
immunofluorescence is shown on the colour strip: red to white: maximum, 
green to yellow: moderate, light blue = low and purple to blue = zero. 
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Figure 3.47 Immunovisualisation of the kinin Bl receptors on the neutrophil 
membrane 
Immunolabelling of kinin BI receptors on circulating neutrophils of volunteers (A), 
and the circulating (B) and synovial fluid neutrophils (C) of RA patients. The 
intensity of the immunoflourescence is shown on the colour strip: red to white =
maximum, green to yellow = moderate, light blue = low and purple to blue = zero. 
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Figure 3.49 Histogram of immunoreactive kinin Bl receptor on neutrophils 
showing mean values for the intensity of labeling of the kinin Bl 
receptor (in pixels x 102/µm2) on the neutrophil membrane 
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Although there was a clear increase in the intensity of labeling of the kinin B 1 receptor on 
the SF neutrophils from RA patients ( n=8), when compared to the circulating neutrophils 
from healthy volunteers (n=8), the mean values did not reach significance (Kruskal Wallis; 
p > 0.05). However, a significant increase in B 1 receptor labeling was observed on both 
the circulating and SF neutrophils of the RA patients (n=80) when compared to circulating 
neutrophils of the healthy volunteers (n=80) (1 Way ANOV A, p < 0.01 and < 0.05 
respectively). Details of the intensity of labeling for each of the subjects are shown in Fig. 
3.48 and Table 3.12 
Table 3.12 Intensity of immunolabelling for the kinio Bl receptor 
No (i) Circulating neutrophils (ii) Circulating neutrophils
healthy volunteers RA patient 
1 7 12 
2 4 29.2 
3 2 3.6 
4 2 2 
5 21 25.9 
12 14.5 
7 14 18.9 
8 3 9.8 
Mean 8.1 14.5 













Kruskal- (i) vs. (ii) : > 0.05 (i) vs. (iii) : > 0.05
Wallis 
Correlation with disease activity 
There was a positive correlation between the immunoreactivity for the B 1 kinin receptor 
on the circulating neutrophils from the RA patients and the local activity index (r = 0.783; 
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Figure 3.50 Correlation between immunoreactive kinin Bl receptor 
on circulating oeutrophils from RA patients and the local 
activity index 
3. 7.4 Immunolocalisation of the kinin B2 receptor
Kinin B2 receptors have been localized on the collecting ducts and tubules of normal 
kidneys (Naidoo et al. 1996a). During each labeling experiment, normal human kidney 
tissue was used as the positive controls. For the method control, loss of labeling following 
preadsorption with an excess of the rabbit anti-human B2 receptor antibody and 
replacement of the primary antibody with PBS was demonstrated (Fig. 3.51 ). 
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Figure 3.51 Confocal image of control human kidney 
Positive labeling for the kinin B2 receptor is present on the 
collecting ducts and tubules of normal human kidney. The 
intensity of the immunoflourescence is shown on the colour strip: 
red to white = maximum; green to yellow = moderate; light blue= 
low and purple to blue = zero 
The immunolabelling for the kinin B2 receptor on the circulating neutrophils from healthy 
volunteers and the circulating and SF neutrophils from RA patients is shown in Fig. 3.52. 
The mean intensity for the kinin B2 receptor on the circulating neutrophils from the 
healthy volunteers was 4.6 pixels x 102/µm2 with a median of 5 pixels x 102/µm2 (Fig 3.53 
& 3.54 and Table 3.13). For the circulating and SF neutrophils from the RA patients, the 
mean intensity for B2 receptor was 22.4 pixels x 102/µm2 and 16.1 pixels x 102/µm2
respectively, with corresponding medians of 15.5 pixels x 102/µm2 and 12 pixels x 
102/µm2 _ 
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Figure 3.52 Immunovisualisation of the kinin B2 receptor on the neutrophil 
membrane 
Immunolabelling of kinin B2 receptor on circulating neutrophils of (A) volunteers, and 
(B) circulating neutrophils and (C) synovial fluid neutrophils of RA patients. The
intensity of immunofluorescence is shown on the colour strip: red to white: maximum, 
green to yellow = moderate, light blue = low and purple to blue = zero. The 
corresponding phase contrast images are illustrated in the second panel. 
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Figure 3.54 Histogram of immunoreactive kinin B2 receptors on 
neutrophils showing mean values for the intensity of 
labeling of the kinin B2 receptor (in pixels x 1«>2/µm2) on 
the neutrophil membrane 
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Although there was a clear increase of the kin n 82 receptor on the circulating and SF 
neutrophils from the RA patients compared to circulating neutrophils from healthy 
volunteers, this was only significant for the circulating neutrophils from the RA patients (p 
= 0.05). Details for each patient are shown in Fig. 3.53 and Table 3.13. 
There was no correlation between the measures of disease activity and the intensity of 
labeling for the kinin 82 receptor on the neutrophils from the RA patients. 
Table 3.13 Intensity of immuoolabelling for the kinin B2 receptor 
No (i) Circulating neutrophils (ii) Circulating neutrophils
healthy volunteers RA patients 
1 3 7 
2 8 14 
3 1 17 
4 5 10 
5 5 2 
6 2 18 
7 5 63 
8 8 48 
Mean 4.6 22.4 
Median 5 15.5 








































Clinical characteristics of the patients with rheumatoid arthritis 
Natne Age (yrs) Sex Duration Nodules RF
No . ACR 
DMARD 
criteria 
SM 46 Female 4 Pos 5 No 
DB 52 Female 6 Pos 6 3 
CA 65 Female 14 Pos 6 5 
SM 50 Male 20 present Pos 7 3 
MP 53 Male 12 Pos 6 2 
KN 40 Female 1.6 Pos 6 2 
IB 47 Female 17 Pos 6 4 
MN 56 Female 1.6 present Neg 6 No 
MT 49 Female 6 Neg 5 2 
CD 60 Female 14 Pos 6 2 
MS 50 Female 15 Neg 5 No 
MM 44 Female 5 Pos 4 2 
RS 46 Female 15 Neg 5 2 
LP 46 Female 20 Neg 4 3 
MG 50 Female 2.5 Pos 5 No 
EC 50 Female 15 Pos 6 2 
KM 50 Female 10 Neg 5 1 
PC 40 Female 11 :Jeg 5 2 
GN 60 Female 7 Neg 4 2 





5 mg HT 
7.5 mg HT 
10 mg 





10 mg HT 
nil 
7.5 mg HT 
nil 







Appendix 3.1 Clinical characteristics of the patients with rheumatoid arthritis 
Lab. no Name Age (yrs) Sex Duration Nodules RF 
No. ACR 
DMARD Prednisone dose 
Co-morbid 
criteria diseases 
21 255 PK 37 Female 4 Pos 6 No nil 
22 256 AA 65 Female 10 present Pos 7 1 nil 
HT;DM; 
Hypothyroid 
23 262 MG 54 Female 36 Pos 5 3 5 mg DM 
24 263 MS 56 Male 14 present Pos 7 5 nil 
25 277 RS 72 Female 14 Pos 6 No nil 
26 276 KG 42 Female 3 Pos 6 No 5 mg Hypothyroid 
27 295 CMA 42 Male 3 Pos 6 2 10 mg 
28 363 CD 43 Male 5 Neg 5 No nil 
29 364 IJ 56 Female 17 Neg 5 1 nil 
36 370 HBF 41 Female 6 Pos 5 1 5mg 
37 373 PS 43 Male 20 Neg 5 No nil 
36 373 ZM 21 Female 2 Pos 5 No nil 
37 374 AF 48 Female 4 Pos 6 No 7.5 mg 
36 375 AM 40 Female 16 Pos 6 No nil 
37 379 JZ 52 Female l Pos 5 No nil HT;DM 
36 360 GK 38 Female 1.8 Neg 4 No nil 
37 361 AM 64 Female 0.8 Pos 6 No nil HT;DM 





Appendix 3.1 Clinical characteristics of the patients with rheumatoid arthritis 




DMARD Prednisone dose 
s criteria 
39 376 RS 52 Female 3 Pos 5 No nil 
40 361 MM 52 Male 3 Pos 6 1 nil 
41 362 SB 59 Female 17 Pos 6 2 5 mg 
42 363 AM 37 Female 5 Pos 6 2 nil 
43 365 BG 52 Female 2 Neg 5 No nil 
44 366 BY 37 Female 6 Pos 6 2 nil 
45 361 PK 37 Female 2.5 Pos 6 1 7.5 mg 
46 375 MN 59 Female 1 Neg 5 No 5 mg 
47 394 MM 63 Male 3 Neg 5 No nil 
48 395 EN 52 Female 3 Neg 6 1 nil 
49 398 AR 64 Female 17 Pos 6 4 nil 
50 408 GR 53 Female 9 Neg 5 5 5 mg 




Appendix 3.2 Demographic details of the RA patients and healthy volunteers 
RHEUMATOID 
HEAL THY VOLUNTEERS 
ARTHRITIS 
Lab 
Name Age Sex 
Lab 
Name Age Sex 
No No 
191 SM 46 Female 259 PR 46 Female 
192 DB 52 Female 390 DS 52 Female 
195 CA 65 Female 506 FC 64 Female 
193 SM 50 Male SIS SD 48 Male 
196 MP 53 Male 456 PR 52 Male 
197 KN 40 Female 463 pp 40 Female 
200 m 47 Female 451 SN 47 Female 
206 MN 56 Female 579 NN 58 Female 
214 MT 49 Female S48 MS 48 Female 
216 CD 60 Female 448 CM 59 Female 
220 MS 50 Female 450 KS 50 Female 
222 MM 44 Female 452 MM 45 Female 
226 RS 46 Female 385 SN 47 Female 
228 LP 46 Female 574 ZM 45 Female 
236 MG 50 Female 461 RB 50 Female 
236 EC 50 Female 570 MR 49 Female 
237 KM 50 Female 578 PK 50 Female 
238 PC 40 Female 455 MK 39 Female 
237 GN 60 Female 505 HF 58 Female 
247 ZE 45 Female S42 MG 43 Female 
255 PK 37 Female 449 PN 37 Female 
256 AA 65 Female 445 ss 68 Female 
262 MG 54 Female 562 MR 54 Female 
263 MS 56 Male 577 SC 54 Female 
277 RS 72 Female 444 AM 74 Female 
276 KG 42 Female S36 WV 44 Female 
295 CMA 42 Male 251 UGL 42 Male 
363 CD 43 Male 453 N 40 Male 
364 u 56 Female 563 SG 55 Female 
370 HBF 41 Female 462 CV 42 Female 
373 PS 43 Male 454 GD 43 Female 
373 ZM 21 Female 571 NM 22 Female 
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RHEUMATOID ARTHRITIS HEALTHY VOLUNTEERS 
374 AF 48 Female 573 cw 49 Female 
375 AM 40 Female 460 LP 42 Female 
379 JZ 52 Female 567 JR 53 Female 
360 GK 38 Female Sl5 RN 39 Female 
361 AM 64 Female 564 MG 60 Female 
369 VR 55 Female 562 SN 55 Female 
376 RS 52 Female 561 MM 53 Female 
361 MM 52 Male 464 YA 50 Female 
362 SB 59 Female 569 BC 59 Female 
363 AM 37 Female 386 AN 38 Female 
365 BG 52 Female 565 JM 52 Female 
366 BV 37 Female 250 JM 36 Female 
361 PK 37 Female Sl2 PO 36 Female 
375 MN 59 Female 575 GK 59 Female 
394 MM 63 Male 457 GS 64 Female 
395 EN 52 Female 576 B 52 Female 
398 AR 64 Female 572 M 64 Female 











Demographics of patients with RA from whom syoovial 
tissue samples were obtained at arthroscopy 
Swollen 
ESR CRP Prednisone DMARD 
joint count 
7 13 21 No No 
21 35 74 No No 
10 1 0 5 mg MTX 
2 18 n/a No No 
5 25 20 No No 
2 n/a n/a No No 
Abbreviations: ESR, erythrocyte sedimentation rate; CRP, C reactive protein; MTX. 














Demographics of patients from whom synovial 
tissue samples were obtained at autopsy 
Sex Cause of death 
Male Blunt injuries to chest and neck 
Male Stab chest 
Male Myocardial infarction 
Male Suicide by hanging 
Male Suicide by hanging 
Male Gun shot chest 
Female Stab chest 
Male Stab chest 
Male Gun shot chest 
Male Stab chest 
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Appendix 3.5 Twenty eight tender and swollen joint count 
Joint Right 













IP thumb D 
knee D 
swollen joint count D 
















Scale: 0 = no pain/tenderness or swelling 
1 = pain/tenderness or swelling 
Left 































Appendix 3.6 Modified Health Assessment Questionnaire 
We are interested in learning how your illness affects your ability to function in daily 
life. Please feel free to add any comments on the back of this page. 
PLEASE TICK THE ONE RESPONSE WIDCH BEST DESCRIBES YOUR 
USUAL ABILITIES OVER THE PAST WEEK: 
Without ANY With SOME 
difficulty 
1. Dressing and Grooming
Are you able to
Dress yourself, including tying 
shoelaces and doing buttons ? 
Shampoo your hair? 
2. Rising
Are you able to :
Stand up from an annless 
straight chair ? 
Get in and out of bed ? 
3. Eating
Are you able to :
Cut your meat ? 
Lift a full cup or glass to 
your mouth? 
Open a new carton of milk 




With MUCH UNABLE 






Are you able to
Walk outdoors on flat ground ? 
Climb up five steps ? 
PLEASE TICK ANY AIDS OR DEVICES TBA T YOU USUALLY USE 
FOR ANY OF THESE ACTMTIES : 
•.••..•••••.••.••••• Cane ••.•••.•.•..• Devices used for dressing (button hook) 
•••••••••.•.•.....•• Walking frame ..........••. Zipper pull, long handles shoe horn, etc 
.................... Crutches ...••..•..... Built-up or special utensils 
.................... Wheelchair .... Special or built-up chair 
... ... ... ... ... .. Other (specify) •.......•...•.••..•••..••.•••...••.••....•.....••••.••.•..... 
PLEASE TICK ANY CATEGORIES FOR WIDCH YOU USUALLY NEED 
HELP FROM ANOTHER PERSON : 
..............•....•. Dressing and Grooming ......................... Eating 
.................... . Rising . . . . . . . . . . . . . . . . . . . . . . . .. Walking 
PLEASE TICK mE ONE RESPONSE wmcH BEST DESCRIBES YOUR 
USUAL ABILITIES OVER THE PAST WEEK : 
Without ANY With SOME With MUCH UNABLE 
difficulty difficulty difficulty to do 
Hygiene 
Are you able to 
Wash and dry your entire 
body? ......... ········· .•.•.••.. ......... 
Take a bath? ......... .•..•...• ...••..•. ......... 
Get on and off the toilet ......... ....•.•.. ......... ......... 
Walk outdoors on flat 
ground? ......... ..••..... •...•...• . ........ 
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Without ANY With SOME With MUCH UNABLE
difficulty difficulty difficulty to do 
6. Reach
Are you able to :
Reach and get down a 
5 lb object( e.g. a bag of 
potatoes) from just 
above your head ? •........ ......... ......... . ........ 
Bend down to pick up 
Clothing from the floor ? ........• ......... ......... . ........ 
7. Grip
Are you able to
Open car doors ? ...•.•... ....•.... .•.....•. . ........ 
Open jars, which have been 
previously opened ? ••.•..... ..•....•. ...•..•.• .......•. 
Tum taps on and off? ......•.. ....•..•. ········· .......•. 
8. Activities
Are you able to :
Run errands and shop ? ......... ......... ......... ......... 
Get in and out of a car ? ......... •...••..• ....••.•. ......... 
Do chores such as vacuuming, 
housework or light 
gardening? ......... ......... .•.•..•.• ......... 
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PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE 
FOR ANY OF THESE ACTIVITIES : 
....••.••.••••• Raised toilet seat ............. Bath rail 
............... Bath seat .............. .. Long handled appliances for reach 
............... Jar opener (for jars previously opened) 
............... Other (Specify) 
PLEASE TICK ANY CATEGORIES FOR WIDCH YOU USUALLY NEED 
HELP FROM ANOTHER PERSON : 
............ Hygiene 
Reach 
Gripping and opening things 
Errands and housework 
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Appendix 3. 7 Measures of disease activity and synovial fluid basal and generated kinin levels in 20 patients with RA 
Disability Pain Physician's Patient's T28 S28 ESR CRP HAQ LAI DAS basal generated 
VAS VAS GA GA kinin kinin 
1 82 83 2 3 3 6 76 60.9 1.75 19 5.22 3.01 170.67 
2 38 37 3 3 6 9 19 24.3 1.5 9 4.77 8.78 50.3 
3 15 89 1 2 1 4 40 5.37 0.25 6 4.16 6.88 46.8 
4 43 80 3 4 1 4 36 36.6 3 18 3.94 8.36 101.79 
5 71.5 85.5 3 4 3 3 50 21.8 1.625 17 4.69 12.28 43.29 
6 18 16 3 4 1 10 68 40.6 1.625 12 4.91 1.56 84.5 
7 80 90 4 2 12 15 108 19.6 2.5 17 6.97 4.95 137.69 
8 91 73 3 4 8 9 11 17.8 3 14 4.60 3.03 123.09 
9 87 64 4 4 8 3 60 52.8 2.25 15 5.49 1.9 85.3 
10 14 9 3 4 2 11 25 15.5 0.125 8 4.45 13.77 37.63 
11 54 54 2 4 4 2 26 6.59 2.125 14 4.26 26.17 24.53 
12 22 25 2 2 7 1 12 20.5 1.625 9 3.94 3.1 12.5 
13 98 72 3 4 7 9 124 72.7 2.875 12 6.37 1.68 94.84 
14 56 56 3 4 3 6 20 13.1 1 15 4.21 6.05 50.88 
15 36 63 3 3 6 5 56 7.89 0.75 16 5.36 3.52 37.01 
16 52 57 3 3 3 6 28 23.8 1.125 9 4.47 3.83 29.08 
17 48 36 3 4 11 9 78 72 2.5 12 6.37 0.83 144.65 
18 41 46 3 3 10 10 74 73.7 1.75 8 6.28 0.97 109.94 
19 36 36 2 3 4 4 27 11.8 0.5 10 4.47 2.85 18.67 
20 0 37 3 4 11 9 78 72 2.5 12 6.37 0.43 216.02 
Abbreviations: RA, rheumatoid arthritis; VAS, visual analogue scale; GA, global assessment; T28, twenty eight tender joint count, S28, 
twenty eight swollen joint count; ESR, erythrocyte sedimentation rate, CRP, C reactive protein; HAQ, health assessment questionnaire, LAI, 




4.1 PATHOPHYSIOLOGY OF RHEUMATOID ARTHRITIS 
Rheumatoid arthritis is an autoimmune disease of unknown aetiology characterized by a 
chronic synovitis, which manifests as joint pain and swelling, and often progresses to bone 
and joint destruction. If effective therapy is not instituted, the progressive joint destruction 
results in a significant loss of function and disability and an increased mortality. 
The exact aetiology of RA is unknown and the current hypothesis is that the inflammation 
and tissue destruction result from complex cell-cell interactions. The initial step is thought 
to be the interaction between the antigen presenting cells and CD4+ T cells in a genetically 
susceptible host. This results in macrophage activation and pro-inflammatory cytokine 
release and kinin peptide formation. These mediators stimulate synovial fibroblasts and 
chondrocytes to secrete enzymes that degrade proteoglycans and collagen, leading to tissue 
destruction. 
The disease is characterized by five stages. In the first stage, the immune system is 
triggered by exposure to an unknown antigen. In stage 2, the B and T celJs are activated, 
in stage 3, synovial proliferation occurs, and a large number of PMN cells accumulate in 
the synovial fluid. The fourth stage is characterized by the presence of an invasive pannus 
associated with bony erosions and degradation of the cartilage. In stage 5, the pannus 
invades the cartilage and there is joint space narrowing. 
Clinically, RA presents predominantly as a symmetrical polyarthritis with variable extra­
articular systemic involvement. The activity of the disease is reflected clinically by the 
duration of morning stillness, presence of pain, and the number of swollen and tender 
joints, and biochemically by a raised erythrocyte sedimentation rate (ESR) and C reactive 
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protein (CRP). With severe or chronic inflammation, radiographic evidence of bone and 
joint destruction becomes apparent. Early radiographic changes include periarticular 
osteoporosis and bony erosions. With advanced disease, there is joint space narrowing and 
extensive bony destruction. 
The histopathological changes in the synovium include hyperplasia with an increase in the 
thickness of the synovial lining layer, infiltration of the sublining layer with mononuclear 
cells, T and B lymphocytes, macrophages and plasma cells and proliferation of new blood 
vessels within the synoviwn (angiogenesis). A variety of inflammatory cells is implicated 
in the pathogenesis of the inflammatory process. These include the B and T lymphocytes, 
macrophages, neutrophils and synovial fibroblasts. A complex interaction of these cells 
with inflammatory mediators such as the proinflammatory cytokines, kinins, and 
metalloproteinases is responsible for the pathological findings in RA. In addition, there is 
an exudation of fluid into the joint space. Unlike the normal joint, the synovial fluid in RA 
contains a large nwnber of inflammatory cells, including neutrophils, T cells, macrophages 
and plasma cells, which provide a continuing local immune response in the joint. 
The pro-inflammatory cytokines, IL-113 and TNFa are important mediators of 
inflammation, tissue injury and immunologic reactions. Several studies have demonstrated 
elevated levels ofIL-113 in the synovial fluid and serwn of patients with RA (Odeh, 1997), 
and a correlation between the degree of inflammation and IL-113 levels (Kahle, et al. 1992). 
Interleukin- I 13 is a potent mediator of bone resorption and cartilage destruction (Pettipher 
et al. 1985) and stimulates the production of other pro-inflammatory and angiogenic 
cytokines. The systemic features of RA, such as malaise, fatigue, fever, anaemia and 
elevation of acute phase proteins (APP) are also due to IL-I 13 (Dinarello, 1984). The role 
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of IL- IP in RA is supported by the decrease in the number of tender joints and APPs in 
clinical trials of IL- I receptor antagonist in patients with RA (Bresnihan and Cunnane, 
1998). Abundant evidence exists for a significant role for TNFa in the pathogenesis of RA 
(Brennan et al. 1992a). Tumour necrosis factor a also stimulates bone resorption, cartilage 
destruction and release of other cytokines (Odeh, 1997). High concentrations of TNFa are 
present in the serum and synovial fluid of RA patients and in the synovial lining cells and 
macrophages (Tetta et al. 1990, Manicourt et al. 1993). In addition, treatment with 
monoclonal antibodies to TNFa results in significant clinical and biochemical 
improvement (Keystone, 1999). 
Considerable evidence also exists for the role of kinins as primary mediators in RA. 
Kinins are vasoactive peptides that induce the cardinal manifestations of inflammation, 
namely pain, vasodilatation and oedema. In addition, they stimulate the release of IL- IP 
and TNFa (Tiffany and Burch, 1989), several other second-generation mediators of 
inflammation (Bhoola el al. 1992), and enhance bone resorption via prostaglandin 
formation. High levels of kinins and kallikreins have been reported in the synovial fluid of 
RA patients (Hargreaves et al. 1988; Volpe Junior et al. 1996; Selwyn et al. 1989). Kinin 
receptors have been localized on synovial fibroblasts (Bathon et al. 1992a) and the kinin 
receptor antagonist has been shown to suppress joint swelling in experimental models of 
arthritis (Cruwys et al. 1994; Sharma and Wirth, 1996). 
The principal aims of treatment in RA are to control inflammation and to prevent joint 
destruction. Current treatment with first and second line drugs is inadequate in that they 
only partially control established RA, and the side effect profile limits their use especially 
for prolonged periods. The traditional disease modifying antirheumatic drugs have been 
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shown to provide symptomatic and clinical improvement but do not significantly alter long 
term outcome. The development of targeted biological agents such as TNF a receptor 
blockade is a recent advance. However, this therapeutic measure has been found not to be 
universally effective. In view of the overall poor prognosis of RA with current therapeutic 
regimens, there is a need for new approaches to the treatment and a better understanding of 
its pathogenesis. 
4.2 TISSUE KALLIKREIN IN SYNOVIAL TISSUE. 
Considerable experimental evidence has linked the kallikrein-kinin (KK) cascade to 
inflammation. The presence of the KK cascade in synovial tissue was first suggested by 
the ability of bradykinin to increase intracellular cyclic AMP release from cultured 
synovial fibroblasts (Fahey et al. 1977), and to increase vascular permeability of canine 
synovial tissue (Grennan et al. 1977). Later, TK was implicated in neutrophil diapedesis 
(Figueroa el al. 1989), and in the processing in vitro of a variety of promolecules that 
include matrix metalloproproteinases (Tschesche el al. 1989), procollagenase (Eeckhout 
and Vaes, 1977) and progelatinase (Menashi el al. 1994 ). The potential activation of these 
proproteinases by TK, suggests that TK either directly or through the formation of kinins 
may promote endothelial cell migration, leucocyte aggregation and tissue remodeling. A 
pathogenic role for TK in inflammatory synovitis is supported by the identification of TK 
in both the synovial fluid (Worthy et al. 1990; Bhoola and Dieppe, 1991) and the granules 
of synovial fluid neutrophils of RA patients (Figueroa et al; 1989, Rahman el al. 1994). 
Reduced TK immunoreactivity has been shown on the SF neutrophils in RA (Williams el
al. 1997), suggesting that TK is released from the granules of neutrophils during 
inflammation. 
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To strengthen further the view that TK is linked to joint inflammation, one aim of this 
study was to examine the presence of TK in control and inflamed synovial tissue by 
immunolabelling experiments using recombinant TK as the primary antigen. TK was 
expressed on the synovial lining cells, subintimal macrophages and the endothelial cells of 
blood vessels in both the control and inflamed synovium (Cassim et al. unpublished). 
There was a significant increase in the intensity of labeling in the endothelial cells of 
rheumatoid tissue compared to controls. This finding suggested that TK might play a role 
in the pathological changes associated with R A The localiz.ation of TK in the endothelial 
cells suggests that it may modulate endothelial function, thereby contributing to the 
increase protein and fluid leakage into the tissues and synovial space, leucocyte 
aggregation and angiogenesis which are dominant features in inflamed synovium. This 
concept is supported by the intense expression of TK in angiogenic endothelial cells 
(Plendl et al. 2000). In addition, there are a large number of activated macrophages in the 
rheumatoid synovium (Burmester et al. 1997). These macrophages produce prostaglandins 
and proinflammatory cytokines (Seitz and Hunstein, 1985; Firestein et al. 1990). Kinins 
are potent stimulators of IL-1 p and TNFa release from macrophages (Tiffany and Burch, 
1989) and conversely IL-1 p and TNFa induce the effects of kinins (Bathon et al. 1989). 
The presence of TK in macrophages thus provides further evidence for role of kinins in 
regulating the production and release of cytokines from the macrophages. Tissue 
kallikrein has also been identified normal and in inflamed colon and specifically in 
macrophages forming granulomas in experimental colitis (Stadnicki et al. 1998). 
However, he TK concentrations were markedly reduced in the inflamed caecum compared 
with normal caecum. The authors postulate that the pro-inflammatory effects of TK in the 
intestine are due to macrophage production and secretion. A similar mechanism may apply 
in the inflamed synovium. Kinins cleaved from the kininogen molecule via the enzymatic 
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action of kallikreins exert their vasoactive properties by activation of specific kinin 
receptors. Alternatively TK has been shown to activate the kinin receptors directly, 
independent of BK release (Hecquet et al. 2000). 
4.3 KININ Bl RECEPTORS IN SYNOVIAL TISSUE. 
The actions of the vasoactive peptides, BK and kallidin are mediated via the kinin B 1 and 
B2 receptors. The Bl receptors are not present normally, and appear to be induced in 
experimental inflammation, by noxious stimuli and cytokines (Bhoola et al. 1992). Minute 
amounts of kinin B 1 receptor binding sites were identified in healthy porcine vascular 
tissues by autoradiography. In contrast, there was a three-fold increase in the number of 
binding sites in inflamed or septic tissue (Schremmer-Danniger et al. 1996, 1998). The 
role of B 1 receptors in inflam ation is further suggested by the upregulation of B 1 
expression by the pro-inflammatory cytokines, IL-1 J3, IL-8 and TNF ex (Haddad et al.
2000; Bastian et al. 1998). 
In rats, intra-articular injection of the B 1 agonist, desArg
9 
BK into normal knees induced 
significant plasma extravasation that was inhibited by desArg9 (Leu8) BK, a B 1 receptor
antagonist (Cruwys et al. 1994). In another study, IL-1J3 and TNF ex increased Bl agonist 
induced paw oedema (Campos et al. 1998). However, reports on the role of Bl 
antagonism as a therapeutic modality are conflicting. In a porcine model of LPS induced 
endotoxic shock, treatment with a B 1 antagonist had no beneficial effect (Siebeck et al.
1996), and the authors suggest that the upregulation of BI receptors during LPS shock may 
be an important mechanism of host defense. Further, in the peptidoglycan-polysaccharide 
induced model of arthritis in the Lewis rat, administration of a B2 receptor antagonist 
blocked the systemic effects of inflammation. However, inhibition of the B 1 receptor 
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prevented an anti-inflammatory response (Uknis et al. 2001). In contrast, Bl antagonism 
has been shown to reduce B 1 agonist induced paw oedema (Campos et al. 1998). 
Although B 1 receptors have been identified on animal models of inflammation and sepsis, 
they have not been previously reported on human synovial tissue. Immunolabelling 
experiments were performed to localize the expression of B 1 receptors in control and 
inflamed synovial tissue. In control synovial tissue, labeling of Bl receptors was 
visualized in the synovial lining cells, macrophages and endothelial cells (Cassim et al.
unpublished). In the inflamed synovial tissue, there was a significant increase in the 
intensity of labeling in the synovial lining cells compared to control tissue. In contrast, no 
immunolabelling for Bl receptors was seen in synovial tissue obtained at arthroplasty, 
namely from patients with long standing chronic arthritis (Cassim et al. 1997). These 
:findings suggest that B 1 receptor expression is upregulated during acute inflammation. 
The increased expression of IL- Ip and TNF a in inflammation may contribute to the 
enhanced expression of the kinin Bl receptors. The role of the kinin Bl receptor in 
inflammation remains speculative. Preliminary studies in animal models suggest a 
therapeutic effect of Bl antagonists. 
4.4 KININ B2 RECEPTORS IN SYNOVIAL TISSUE 
The B2 receptor is ubiquitous, and mediates most of the actions of BK and kallidin 
(Bhoola et al. 1992). B2 receptors have been localized on the plasma membrane of normal 
human neutrophils (Haasemann et al. 1994). In the normal human kidney, B2 receptors 
are thought to be responsible for most of the physiological effects of BK (Naicker et al.
1999). In contrast, in RA, an upreguJation of the B2 receptor on circuJating and synovial 
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fluid neutrophils was noted (Cassi.In et al. 1996). Additionally, a higher density of B2 
receptors was observed in RA synovial tissue compared to OA (Bathon et al. 1992a), and 
IL-P enhanced the number of B2 receptor binding sites suggesting a functional role for B2 
receptors in inflammatory synovitis. This is supported by the reports that the B2 receptor 
antagonist, HOE 140, reduced BK induced plasma extravasation in rat arthritic joints 
(Cruwys et al. 1994), and suppressed knee swelling in adjuvant-induced arthritis in rats 
(Sharma and Wirth, 1996). 
In the current study, kinin B2 receptor expression was quantified in the synovial lining 
cells, fibroblasts, macrophages and the endothelial cells. The kinin B2 receptor was 
present in both the control and inflamed synovium and was expressed on the synovial 
lining cells, fibroblasts, macrophages and endothelial cells in both control and inflamed 
tissue (Cassim et al. unpublished). In RA, there is an increase in the thickness of the 
synovial lining layer, proliferation of fibroblasts, macrophage infiltration and new vessel 
formation. Therefore, there is likely to be an increase in the density of kinin B2 receptors 
compared to controls. Most of the vasoactive properties of kinins are mediated via the B2 
receptors and their increased expression in the in.flamed synovium supports a role for 
kinins as mediators of inflammation. Activation of the receptors in the synovial lining 
layer may contribute to the invasion of adjacent bone and cartilage and subsequent tissue 
destruction. As a G-protein coupled receptor, the kinin B2 receptor promotes several 
signal transduction events at the cellular level (Bhoola et al. 1992). These include 
activation of phospholipase A2 (PLA2) and stimulation of adenyl cyclase. Following 
activation of PLA2 arachidonic acid is cleaved from membrane phospholipids and 
metabolized to produce prostaglandins and leucotrienes. The prostaglandins increase 
vascular permeability and induce osteoclastic bone resorption. The leucotrienes attract 
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leucocytes to the site of inflammation, promote adherence of leucocytes to endothelial cells 
and activate the secretion of reactive oxygen species and degradative enzymes from 
neutrophils. Thus, kinins may promote the inflammatory process either directly or via 
second messenger systems. 
4.5 TISSUE KALLIKREIN IN THE SYNOVIAL FLUID 
The kallikreins, tissue kallikrein (TK) and plasma kallikrein (PK), by their enzymatic 
action cleave the vasoactive peptides, kinins, from kininogens. Augmented activity of both 
TK and PK has been reported in the synovial fluid compared to plasma in patients with 
inflammatory arthritis (Volpe-Junior et al 1996). However, of the 10 patients studied only 
three had RA 
Plasma kallikrein cleaves bradykinin from HK and from LK in the presence of neutrophil 
elastase (Sato and Nagasawa, 1988). Both active and total PK have been identified in the 
synovial fluid obtained from patients with arthritis (Rahman et al. 1995). Most of the PK 
in the synovial fluid appears to be in the proenzyme form and approximately half of the 
active form is bound to the protease inhibitor a2 macroglobulin (Nagase et al. 1982). 
Other inhibitors include Cl esterase, a 1 antitrypsin and antithrombin III. Once the PK­
inhibitor complexes are formed, they are rapidly cleared by the circulation. The PK found 
in synovial fluid may be due to transudation from plasma, an increased activation of 
plasma pre-kallikrein, or increased entry on migrating neutrophils. 
Tissue kallikrein cleaves the decapeptide lys-bradykinin (kallidin) from both HK and LK. 
Kallidin, like BK appears to enhance bone resorption via prostaglandin formation (Lerner 
et al. 1987; Gustafson et al. 1998). Tissue kallikrein has previously been identified in 
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synovial fluid from arthritic joints (Worthy et al. 1990; Bhoola and Dieppe, 1991), and 
active enzyme levels were reported to be higher in patients with RA compared to OA 
(Selwyn et al. 1989). However, the relationship between TK activity and measures of 
disease activity was not studied. The presence of TK in the synovial fluid from inflamed 
joints suggests that kinins are released into the joint, where they may exhibit their 
vasoactive properties. Since neutrophils are abundant in the synovial fluid, the kininogen 
substrate is readily available to be cleaved by TK. In addition, TK may directly activate 
the kinin receptors present on the adjacent synovial tissue and neutrophils (Hecquet et al.
2000) 
This is the first study to correlate comprehensively synovial fluid levels of TK with clinical 
and biochemical measures of disease activity. A negative correlation was observed 
between the active enzyme levels and the 28 swollen joint count in the RA patients. The 
swollen joint count is a validated method to assess disease activity, and is more reliable 
than the tender joint count as tenderness does not always correlate with inflammation. In 
the 28 swollen joint count joint, 14-paired joints, which are commonly involved in RA, 
were examined. The decrease in TK levels with an increasing swollen joint count probably 
reflected sequestration or complexing of TK by kallistatin type inhibitors in patients with 
active disease. This view is supported by the reports of high levels of a 1 anti-trypsin, the 
normal endogenous inhibitor of TK, in the synovial fluid obtained from patients with RA 
(Brackertz et al. 1975; Robinson et al. 1981; Rahman et al. 1994)). It is postulated the 
kinins released from the kininogen molecule by both kallikreins activate the kinin receptors 
and other second messenger systems, thereby increasing vascular permeability and 
exudation of fluid into the synovial joint. 
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4.6 BASAL AND GENERA TED KININ LEVELS IN SYNOVIAL FLUID. 
Kinins are thought to play an important role in the pathogenesis of inflammation. They are 
potent vasoactive peptides that stimulate nociceptive C fibres, extravasation of vascular 
fluid, release of neurotransmitters and other second messengers including cytokines, 
prostaglandins and leucotrienes. 
A pain producing substance, resembling BK was first isolated in synovial fluid of patients 
with RA (Armstrong et al. 1957), and subsequently in acute gouty arthritis (Eisen, 1966, 
Mehnon et al. 1967). The ability of a serine protease inhibitor of PK to block the 
formation of BK in vitro in a rat model and to produce analgesia provided further evidence 
for the role of kinins in inflammation and pain (Hargreaves et al. 1988). This was 
supported by a recent study in which a new specific PK inhibitor significantly reduced 
joint swelling in peptidoglycan-induced arthritis in the Lewis rat (De La Cadena et al.
1995). In addition, both BK and kallidin enhance bone resorption via prostaglandin 
formation (Lerner et al. 1987; Gustafson et al. 1998). These studies support the role of 
kinins as mediators of the inflammatory response and joint damage in inflammatory 
arthritis and raise the possibility of new and novel treatment for inflammatory arthritis. 
Measurement of basal kinins in the synovial fluid is difficult because of their short half-life 
and rapid degradation by kininases. To overcome this problem an assay to measure the 
capacity of synovial fluid to generate kinins was developed. Although the capacity of 
synovial fluid to generate kinins has been demonstrated (Bond et al. 1997), correlation 
with disease activity has not been reported previously. 
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In the 20 RA patients studied, the mean basal kinin level in the synovial fluid was 5.6 
ng/ml (range: 0.43 - 27.17 ng/ml), and the mean level of generated kinins was 80.6 ng/ml 
(range: 12.5 - 216.02 ng/ml). The low levels of basal kinins in the synovial fluid confirm 
previous reports that in vivo kinin concentrations are very low in biological fluids (Bond et 
al. 1997). This is presumably due to the presence of kininases in the synovial fluid. 
Further, greater kininase activity has been demonstrated in the inflamed joint compared to 
that in the non-inflamed joint (Chercuiffe et al; 1987; Sheikh and Kaplan, 1987). The 
negative correlation between the basal and generated kinin levels suggests that there is a 
greater kininase activity in synovial fluid with high generating capacity in order to 
maintain low kinin levels in vivo. In addition, we have shown a negative correlation 
between the SF levels of basal kinins and the C reactive protein (CRP) and disease activity 
score. 
Since kinins are vasoactive peptides that evoke the cardinal signs of inflammation, it is 
expected that the synovial fluid of patients with greater disease activity will have a higher 
kinin generating capacity. This is the first report of correlation between the generated 
kinin levels in the synovial fluid and clinical and biochemical measures of disease activity. 
The 28 tender and swollen joint counts were used to assess disease activity clinically since 
they are easier to use than the traditional joint counts using a larger number of joints and 
have been previously validated (Fuchs et al. 1989). There was a significant correlation 
between the level of generated kinins and the 28 swollen and tender joint count reflecting 
an increase in the kinin generating capacity of the synovial fluid with increased disease 
activity. 
The kinin generating capacity 1s a complex and dynamic cascade involving the 
bioregulation of all the components of the kallikrein-kinin system, and therefore 
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correlation with disease activity may not be restricted as with a single component of the 
cascade. Thus, the correlation between disease activity and kinin generating capacity may 
be due to increased kallikrein, increased kininogen or decreased kallistatin. 
The association between kinin generating capacity and inflammation was further 
strengthened by the correlation with the biochemical indices of the acute phase response, 
namely the ESR and CRP. The ESR is an indirect measure of the acute phase response 
while the CRP is the most accurate measure of the acute phase response that accompanies 
tissue inflammation. Both the ESR and CRP predominantly reflect the hepatic production 
of APPs, however APPs may also be produced locally at the site of inflammation (Van 
Leeuwen and Van Rijswijk, 1992). The ESR and CPR are widely used to assess disease 
activity and response to therapy. The relationship between the kallikrein-kinin cascade and 
the acute phase response has not been investigated previously. We postulate that kinins 
may stimulate the production of either hepatic or local production of APPs directly, or via 
the stimulation of IL-1 �- Since evaluation of disease activity by single variables leads to 
methodological problems, several indices consisting of more than one variable have been 
developed. We used the previously validated modified disease activity score that includes 
the ESR, CRP and the 28 swollen and tender joint counts (Prevoo el al. 1995). The 
significant correlation between the SF levels of generated kinins and the disease activity 
score confirms that generated kinin levels are a true reflection of the degree of 
inflammation. These findings have important implications for not only the pathogenesis of 
inflammatory synovitis, but also may have therapeutic implications. Current therapeutic 
regimens for RA are not directed against the kallikrein-kinin cascade and this may explain 
the lack of a universal response even when biologic agents are used. Initial studies have 
reported the efficacy of kinin receptor antagonists in animal models of arthritis. The 
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further development of kinin receptor antagonists may introduce a novel therapeutic 
modality for inflammatory arthritis. 
4. 7 SYNOVIAL FLUID CYTOKINES 
Cytokines are low molecular weight proteins responsible for direct cell-to-cell 
communication and play a pivotal role in inflammation. They are not commonly detected 
in the circulation, but act in a local or immediate microenvironment where they act on 
adjacent cells in a paracrine fashion or on the same cells that produce them in an autocrine 
fashion. While IL- J p, IL-6, IL-8 and TNF a are pro-inflammatory cytokines, IL-4, IL-10 
and TGFP appear to have anti-inflammatory properties and modulate the inflammatory 
response. In addition, there are natural inhibitors and binding proteins that neutralize the 
activity oflL-IP and TNF a (Weckmann and Alcocer-Varela, 1996) which down regulate 
the inflammatory response. In the RA joint there appears to be disequilibrium between the 
cytokine production and anti-cytokine homeostatic response resulting in an inflammatory 
reaction (Maini, 1996). 
4.7.1 Interleukin tp 
Interleukin 1 p is secreted by macrophages, fibroblasts, endothelial cells, synovial lining 
cells and T and B-lymphocytes during antigen presentation and has both systemic and local 
effects (Dinarello, I 994). These include the ability to recruit inflammatory cells to the site 
of inflammation, stimulate the production of other proinflammatory (IL-6 and TNFa) and 
angiogenic cytokines (IL-8), mediate bone resorption and cartilage destruction and induce 
the hepatic synthesis of acute phase proteins, all of which are cardinal features of 
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inflammatory synovitis. IL-113 can also induce the proliferation of synovial fibroblasts and 
other mediators of inflammation such as prostaglandins and proteases. 
Increased levels of IL-113 have been demonstrated in the serum and synovial fluid from 
patients with inflammatory arthritis (DeMarco and Zurier, 1997). Increased expression of 
the pro-IL-I 13 gene in synovial cells of OA and RA patients further supports a role for IL-
113 in the initiation and/or progression of arthritis (DeMarco and Zurier, 1997). Of note, is 
that a wide variation in the expression and production of IL-113 has been reported in 
patients with RA (Ulfgren et al. 2000). This may explain the variation in response 
different modes of therapy. 
The concentration of IL-113 in the SF from 20 patients with RA was measured using an 
ELISA method. The mean concentration of IL-I 13 was 8.42 ± 9.67 pg/ml with a range of 
0.27 - 29.04 pg/
m
l. The correlation between IL-113 concentrations and measures of disease 
activity was then determined using the Pearson's correlation coefficient. There was a 
positive correlation between IL-113 levels and clinical measures of disease activity, namely 
the 28 tender joint count, pain as measured on the VAS and the physician's global 
assessment of disease activity. The 28 tender joint count and the physician's global 
assessment of disease activity reflect the degree of inflammation. Their correlation with 
IL-113 is therefore not surprising, as IL-113 has been shown to induce inflammation. Pain is 
a consequence of the inflammatory process, and therefore may correlate with IL-113 levels. 
An alternative explanation for the correlation of pain and IL-113 may be that the pain is 
mediated via an IL-113 stimulation of kinin release. Kinins are potent pain producing 
substances. Intramuscular injections of BK has been shown to produce significantly 
increased pain compared to an infusion of saline (Babenko et al. 2000). This algesic effect 
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may be due to kinin-induced release of thromboxanes and prostaglandin or to the direct 
sensitization of afferent neurons. In addition, IL- Ip has been shown to increase the kinin­
induced release of prostaglandins from human synovial cells (O' Neill and Lewis, 1989). 
The prostaglandins are potent mediators of inflammation, pain and bone resorption, and 
prostaglandin inhibitors are widely used as analgesic and anti-inflammatory agents. 
4.7.2 Tumour necrosis factor a 
TNFa is thought to be the key mediator in the cytokine network and to induce the 
synthesis and release of a number of other proinflammatory cytokines (Brennan et al.
1992a). Other cellular actions ofTNFa include modulation of PMN function (Kowanko et
al. 1990), a prostaglandin-dependent stimulation of bone resorption (Lorenzo et al. 1991 ), 
inhibition of collagen synthesis, and cartilage destruction (Canalis, 1987). High levels of 
1NFa have been reported in the synoviaJ fluid from patients with RA (Cope et al. 1992) 
and a correlation between the TNFa level in the SF and the SF leucocyte count and ESR 
has been documented (Saxne et al. 1998). Monoclonal antibodies against TNF have been 
shown to be effective in controlling disease activity in RA (Keystone, 1999), however their 
effect is not universal. This may be due to the presence of other pro-inflammatory 
mediators in the synovial fluid. 
The synovial fluid concentration of TNFa was measured in 20 patients with RA, using the 
ELISA method. The mean TNFa level was 15.71 ± 10.57 pg/rnJ with a range of 4.41 -
41.42 pg/rnJ. There was a correlation between the TNFa concentration and the 28 tender 
joint count and CRP. However, there was no correlation between the TNFa level and 
other markers of disease activity, namely the 28 swollen joint count, pain, physician's 
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global assessment of disease activity, ESR and the disease activity score. This was 
surprising since, treatment with 1NFa antagonists has been associated with a significant 
reduction in these parameters ((Weinblatt et al. 1999). One explanation may be that the 
measurement of the concentration of 1NFa was influenced by the presence of peptidases 
or the induction of anti-inflammatory cytok.ines. High levels of prostaglandin E2, a potent 
inflammatory mediator has been shown to down regulate 1NFa production (Maini, 1996). 
In addition, 1NFa binding proteins, soluble fragments of the 1NFa receptor released 
during proteolytic cleavage of the receptor molecules, act as natural inhibitors of 1NFa. 
The anti-inflammatory cytok.ines, IL-4, 10 and interferon y, which may also be present in 
the synovial fluid, down regulate the production of1NFa. 
4.7.3 Correlation between synovial fluid concentrations ofIL-1(3 and TNFa. 
IL-1 p and TNFa are both proinflammatory cytok.ines. 1NFa has the ability to increase the 
production of IL-I (Brennan et al. 1992a), and conversely, IL-1 stimulates TNFa 
synthesis. Therefore the relationship between synovial fluid concentrations of IL-1 P and 
1NFa in 16 patients with RA was studied. There was a significant correlation between the 
IL-Ip and TNFa levels. This confirms the relationship between IL-IP and TNFa and 
suggests a synergistic role for these cytok.ines in inflammatory synovitis. 
4.8 FUNCTIONAL INTERACTION BETWEEN THE CYTOKINE AND KININ 
CASCADES 
Sufficient evidence exists for a role for both the cytok.ine and k.inin cascades in 
inflammation. In this study, we report the expression of components of the kinin cascade 
in inflamed synovium and the correlation between the k.inin generating capacity and 
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disease activity. In addition, we have also shown a correlation between IL-I f3 and TNFa 
with disease activity. It was therefore postulated that there is a functional inter-relationship 
between the cytokine and kinin cascades. Bradykinin is a potent stimulator of IL-I and 
1NF release from the macrophages (Tiffany and Burch, 1989), and conversely IL-I has 
been shown to up regulate the number of kinin receptors on human synovial tissue (Bathon 
et al. I 992a). Interleukin-] has also been shown to potentate BO and TNFa-induced 
release of prostaglandins (O'Neill and Lewis, 1989). We therefore attempted to determine 
the relationship between the synovial fluid TK and generated kinin concentrations and the 
concentrations oflL-I f3 and 1NFa. 
Although there was a trend towards a negative correlation between the SF levels of 
enzymic TK and IL-1 f3 a, this was not significant. One obvious explanation is the wide 
variance in the IL-I f3 concentrations. However, in th.is study a negative correlation 
between the concentration of enzymic TK and disease activity and a positive correlation 
between the concentrations of IL-I f3 and disease activity was shown, it therefore follows 
that the concentration of enzymic TK would decrease as that of IL-I f3 increases. Despite 
expectations, no correlation was noted between the concentration of enzymic TK and that 
of TNFa. Larger studies are required to confirm the hypothesis of a causal relationship 
between the cytokines and kinins. 
The basal and generated kinin levels in the SF were then compared to the cytokine 
concentrations. There was no correlation between basal kinin levels and either IL-1 f3 or 
1NFa. When the concentration of SF generated kinins were correlated with IL-1 f3 in the 
20 RA patients studied, there appeared to be no direct correlation between the two values. 
However, on further analysis, a positive correlation was found between low to moderate 
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levels of SF IL-IP and the SF generated kin.in concentrations. In contrast, there was a 
negative correlation between the higher values of SF IL-1 f3 and the SF generated kin.in 
concentrations. T
h
is may be explained by the previously reported wide variation in 
expression and production of IL-1 p by synovial tissue (Ulfgren et al. 2000). A number of 
factors influence the concentration of IL-Ip in biological fluids. These include the 
capacity to produce cytokines, the short half-life of cytokines in biological fluids and the 
presence of natural inhibitors such as the IL-1 receptor antagonist and anti-inflammatory 
cytokines namely, IL-IO and transforming growth factor p (TGF f3). In addition, an 
increase in intracellular c AMP and prostaglandin E2 (PGE2) suppress IL-1 p production by 
activated macrophages. Kinins have been shown to stimulate the release of IL-1 P from 
macrophages (Tiffany and Burch, 1989). However, kinins, via activation of the G-protein 
coupled receptors promote the activation of phospholipase A2 resulting in the formation of 
prostaglandins and stimulate adenyl cyclase thereby increasing cAMP, and may therefore 
subsequently down regulated the production of IL-1 p. This suggests that there is a 
complex relationship between the kin.in system and IL-1 p, which may explain the lack of a 
direct correlation between the levels of generated kin.ins and IL-1 P in the synovial fluid. In 
addition, there may be a biphasic relationship between IL-1 P and the kinin system, in that 
at higher levels IL-1 p suppresses kinin generation in an attempt to down regulate the 
inflammatory process. No correlation was found between the concentrations of TNFa and
generated kin.in concentrations in the synovial fluid. 
4.9 TISSUE KALLIKREIN IN NEUTROPHILS 
Tissue kallikrein has previously been localized in the granules of normal human 
neutrophils (Figueroa et al. 1989). Since neutrophils are abundant in the SF, this study was
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undertaken to determine the changes in TK expression m the circulating and SF 
neutrophils from RA patients. There was no significant difference between the mean 
values for the intensity of TK labeling in the circulating and SF neutrophils from RA 
patients compared to that in circulating neutrophils from healthy volunteers. To overcome 
this problem, we compared the intensity of labeling for TK on each neutrophil, there was a 
significant loss of TK labeling in the SF neutrophils from the RA patients. This finding 
confirms a previous report (Williams et al. 1997), and suggests that TK is released from 
the neutrophil granules during inflammation and is therefore able to cleave the kinin 
moiety from the kininogen molecule. TK has also been implicated in neutrophil diapedesis 
(Figueroa et al. 1989), and may contribute to the efflux of neutrophils into the SF in RA 
thus potentiating the inflammatory response. In addition, the TK released may also 
directly activate the kinin receptors (Ulfgren et al. 2000). 
4.10 KININ MOIETY ON THE SURFACE OF NEUTROPHILS 
The kininogen molecule has been previously localized on the surface on normal human 
neutrophils (Figueroa et al. 1992). The kinin moiety is interleafed between the two 
polypeptide domains (3 and 5) of the kininogen molecule, and is cleaved from the 
kininogen molecule by kallikreins. Loss of the kinin moiety from neutrophils has been 
previously reported in sepsis (Naidoo et al. 1996b) and in RA (Cassim et al. 1996). The 
release of kinins into the SF in RA patients is supported by the capacity of the SF to 
generate kinins (Bond et al. 1997). In this study, we compared the intensity oflabeling for 
the kinin moiety on circulating and SF neutrophils from RA patients to that on circulating 
neutrophils from healthy volunteers. There was a significant loss of labeling for the kinin 
moiety on the circulating and SF neutrophils from RA patients, confirming that the kinin 
moiety is released during inflammation from circulating and SF neutrophils from RA 
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patients. This finding suggests that kinins may be implicated in both the local and 
systemic features of RA. 
4.11 KININ Bl RECEPTORS ON NEUTROPHILS 
The kinin BI receptors are not present normally but have been induced in experimental 
models of inflammation and sepsis. There are no previous studies looking at kinin BI 
receptor expression on neutrophils. This study is the first report showing the presence of 
kinin BI receptors on circulating neutrophils from normal volunteers and on circulating and 
SF neutrophils obtained from RA patients. There was a lower intensity of labeling for the 
BI receptors on the circulating neutrophils from the healthy volunteers, with a mean of 8.1 
pixels x 102/µm2. On the circulating and SF neutrophils from the RA patients, there was an 
upregulation of the Bl receptors with a mean intensity of 14.5 pixels x 102/µm2 and 16.8 
pixels x 102/µm2 respectively. This suggests that the BI receptor is induced in 
inflammation. The correlation between the intensity of BI labeling and the local activity 
index supports a role for B 1 receptors at the site of inflammation. The local activity index 
was used as a measure of inflammation of the knee joint from which the SF neutrophils 
were obtained. There was no correlation between the intensity of Bl labeling and the ESR, 
CRP, 28 tender and swollen joints, patients and physician's assessment of disease activity 
and the disease activity score. It can be argued that these measures reflect global disease 
activity, whereas the local activity index reflects the degree of local inflammation. The 
exact role for the BI receptor in inflammation is unknown. While in some models of 
experimental inflammation or sepsis, the upregulation of Bl receptors may be a defense 
mechanism in the inflamed joint BI receptors may play a pathogenetic role. With the 
development of specific B 1 receptor antagonists, the role of B 1 receptors may be further 
elucidated. 
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4.12 KININ B2 RECEPTORS ON NEUTROPHILS 
The vasoactive properties of k.inins are mediated primarily via the activation of kinin B2 
receptors. Since Kinin B2 receptors have been previously identified on the surface of 
normal neutrophils and there is an efflux of neutrophils into the inflamed, joint we 
compared the intensity of labeling for B2 receptors on circulating neutrophils from healthy 
volunteers to that on circulating and SF neutrophils obtained from RA patients. There was 
a clear increase in the intensity of labeling in the neutrophils from RA patients compared to 
those from healthy volunteers. This suggests that kinins may be responsible for the 
systemic and local features of RA. 
B2 receptor activation is thought to increase vascular permeability. This may account for 
the efflux of neutrophils in the inflamed joint. Further B2 receptor antagonists have been 
shown to inhibit PMN elastase release, reduce LPS induced increase in vascular 
permeability, inhibit BK-induced release of arachidonic acid, IL-6 and IL-8 and to have an 
analgesic effect. The further development of more specific B2 receptor antagonists may be 
improve not only the understanding of the pathogenesis of inflammatory arthritis but also 
provide a novel therapeutic modality. 
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4.13 CONCLUSIONS 
This is the first comprehensive study of the kallikrein-kinin cascade in synovial tissue, 
synovial fluid and neutrophils in RA, and of the relationship between the KK and cytokine 
cascades and clinical markers of disease activity. 
i) Tissue kallikrein and the kinin BI and B2 receptors have been localized m
control and rheumatoid synovial tissue.
ii) A correlation between tissue kallikrein activity and the kinin generating
capacity in synovial obtained from RA patients and validated markers of
disease activity was demonstrated.
iii) A loss of labeling of the immunoreactive tissue kallikrein and the kinin moiety,
and the upregulation of the kinin BI and B2 receptors was observed in the
neutrophils obtained from RA patients.
iv) Although no direct correlation was demonstrated between the kaUikrein-kinin
cascades, our results suggest a complex and dynamic relationship between these
systems.
These findings provide convincing evidence for the role for the kallikrein-kinin system in 
the pathogenesis of rheumatoid arthritis and have important implications for the 
development of novel therapeutic modalities. 
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